vanderbilt university medical center years ended june 30

Ernst & Young LLP

C O N S O L I D A T E D F I N A N C I A L S T A T E M E N T S A N D

S U P P L E M E N T A R Y I N F O R M A T I O N , I N C L U D I N G

U N I F O R M G U I D A N C E R E P O R T S A N D S C H E D U L E

Vanderbilt University Medical Center Years Ended June 30, 2019 and 2018 With Report of Independent Auditors

Vanderbilt University Medical Center Index to Consolidated Financial Statements June 30, 2019 and 2018

Page

Report of Independent Auditors ............................................................................................................... 1

Consolidated Financial Statements

Consolidated Balance Sheets ...................................................................................................................... 3 Consolidated Statements of Operations ...................................................................................................... 4 Consolidated Statements of Changes in Net Assets ................................................................................... 5 Consolidated Statements of Cash Flows ..................................................................................................... 6 Notes to Consolidated Financial Statements ............................................................................................... 7

Supplementary Information

Schedule of Expenditures of Federal Awards and State Financial Assistance ......................................... 40 Notes to Schedule of Expenditures of Federal Awards and State Financial Assistance ........................... 73

Uniform Guidance Reports and Schedule

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with Government Auditing Standards ................................................................................. 74

Report of Independent auditors on Compliance for Each Major Federal Program and Report on Internal Control Over Compliance Required by the Uniform Guidance ................................. 76

Schedule of Findings and Questioned Costs ............................................................................................. 79

A member firm of Ernst & Young Global Limited

1

Ernst & Young LLP Suite 2100 222 2nd Avenue South Nashville, TN 37201

Tel: +1 615 252 2000 ey.com

Report of Independent Auditors

The Board of Directors Vanderbilt University Medical Center

We have audited the accompanying consolidated financial statements of Vanderbilt University Medical Center, which comprise the consolidated balance sheet as of June 30, 2019 and 2018, and the related consolidated statements of operations and changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements.

Management’s Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in conformity with U.S. generally accepted accounting principles; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free of material misstatement, whether due to fraud or error.

Auditor’s Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity’s preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity’s internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the consolidated financial position of Vanderbilt University Medical Center as of June 30, 2019 and 2018, and the consolidated results of its operations and its cash flows for the year then ended in conformity with U.S. generally accepted accounting principles.


2

Adoption of New Accounting Standards

As discussed in Note 2 to the consolidated financial statements, Vanderbilt University Medical Center changed its method for recognizing revenue as a result of the adoption of Accounting Standards Update (ASU) No. 2014-09, Revenue from Contracts with Customers (Topic 606), effective July 1, 2018, and changed its consolidated financial statement presentation as a result of the adoption of ASU 2016-14, Presentation of Financial Statements for Not-For-Profit Entities, during the year ended June 30, 2019. Our opinion is not modified with respect to these matters.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The schedule of expenditures of federal awards and state financial assistance, as required by Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards and the Audit Manual issued by the State of Tennessee Department of Audit, is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audit of the consolidated financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States. In our opinion, the information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other Reporting Required by Government Auditing Standards

In accordance with Government Auditing Standards, we also have issued our report dated November 12, 2019, on our consideration of Vanderbilt University Medical Center’s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Vanderbilt University Medical Center’s internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with Government Auditing Standards in considering Vanderbilt University Medical Center’s internal control over financial reporting and compliance.

ey November 12, 2019

Vanderbilt University Medical Center Consolidated Balance Sheets June 30, 2019 and 2018

The accompanying notes are an integral part of these consolidated financial statements.

3

($ in thousands) 2019 2018

AssetsCurrent assets:

Cash and cash equivalents 574,748$ 500,908$ Current investments 115,941 134,467Patient accounts receivable, net of allowance for bad debts of $179.1 million as of June 30, 2018 482,485 474,385Grants and contracts receivable 58,750 57,748Inventories 75,407 72,636Other current assets 89,311 85,843

Total current assets 1,396,642 1,325,987

Restricted cash 11,938 77,257Noncurrent investments 491,047 350,750Noncurrent investments limited as to use 103,609 95,681Property, plant, and equipment, net 1,395,095 1,306,639Other noncurrent assets 48,067 35,877

Total assets 3,446,398$ 3,192,191$

Liabilities and Net AssetsCurrent liabilities:

Current installments of long-term debt 8,568$ 5,774$ Accounts payable and other accrued expenses 304,188 268,087Estimated payables under third-party programs 24,877 72,947Accrued compensation and benefits 214,382 197,945Current portion of deferred revenue 14,965 37,303Current portion of medical malpractice self-insurance reserves 12,012 16,558

Total current liabilities 578,992 598,614

Long-term debt, net of current installments 1,506,877 1,512,698Fair value of interest rate exchange agreements 67,901 54,206Noncurrent portion of medical malpractice self-insurance reserves 44,328 57,520Noncurrent portion of deferred revenue 7,773 18,719Other noncurrent liabilities 26,345 22,804

Total liabilities 2,232,216 2,264,561

Net assetsNet assets without donor restrictions controlled by Vanderbilt University Medical Center 1,050,509 807,481Net assets without donor restrictions related to noncontrolling interests 7,776 5,724

Total net assets without donor restrictions 1,058,285 813,205

Net assets with donor restrictions 155,897 114,425

Total net assets 1,214,182 927,630

Total liabilities and net assets 3,446,398$ 3,192,191$

Vanderbilt University Medical Center Consolidated Statements of Operations Years Ended June 30, 2019 and 2018


4


Operating revenuesNet patient service revenue 3,820,871$ 3,578,525$ Provision for bad debt - (135,748)

Net patient service revenue 3,820,871 3,442,777Academic and research revenue 519,447 495,306Other operating revenue 157,011 148,316

Total operating revenues 4,497,329 4,086,399

Operating expensesSalaries, wages, and benefits 2,290,910 2,179,647Supplies and drugs 892,211 770,459Facilities and equipment 268,974 256,938Services and other 701,079 659,455Depreciation and amortization 106,524 105,654Interest 56,529 58,078

Total operating expenses 4,316,227 4,030,231

Income from operations 181,102 56,168

Nonoperating revenues and expensesIncome from investments 30,106 24,021Gift income 14,416 11,945Earnings of unconsolidated organizations 4,031 3,696Unrealized (loss) gain on interest rate exchange agreements,

net of cash settlements (17,480) 6,379

Total nonoperating revenues and expenses 31,073 46,041

Excess of revenues over expenses 212,175 102,209

Excess of revenues over expenses attributable

to noncontrolling interests (4,075) (4,068)

Excess of revenues over expenses attributable to VUMC 208,100 98,141

Other changes in net assets without donor restrictionsChange in noncontrolling interest's net assets 2,052 (167)Net asset reclassification (182) (89)Net assets released from restriction for capital 35,110 1,292Other changes - 49

Total changes in net assets without donor restrictions 245,080$ 99,226$

Vanderbilt University Medical Center Consolidated Statements of Changes in Net Assets Years Ended June 30, 2019 and 2018


5


Net assets without donor restrictionsNet assets without donor restrictions at the beginning of the period 813,205$ 713,979$

Excess of revenues over expenses 208,100 98,141Change in noncontrolling interest's net assets 2,052 (167)Net asset reclassification (182) (89)Net assets released from restriction for capital 35,110 1,292Other changes - 49

Change in net assets without donor restrictions 245,080 99,226Net assets without donor restrictions at the end of the period 1,058,285$ 813,205$

Net assets with donor restrictionsNet assets with donor restrictions at the beginning of the period 114,425$ 86,923$

Contributions 85,331 34,988Restricted investment income 1,665 899Net assets released from restrictions for operations (10,596) (7,182)Net asset reclassification 182 89Net assets released from restriction for capital (35,110) (1,292)

Change in net assets with donor restrictions 41,472 27,502Net assets with donor restrictions at the end of the period 155,897$ 114,425$

Total net assetsBeginning of the period 927,630$ 800,902$

Change in total net assets 286,552 126,728

End of the period 1,214,182$ 927,630$

Vanderbilt University Medical Center Consolidated Statements of Cash Flows Years Ended June 30, 2019 and 2018


6


Cash flows from operating activitiesChange in total net assets 286,552$ 126,728$ Adjustments to reconcile change in total net assets to net cash provided by operating activities:

Depreciation and amortization 106,524 105,654Amortization of debt issuance costs, and original issue premium

and discount 26 518Loss (gain) on disposal of assets 485 (7,686)Undistributed equity in earnings of equity method affiliates 343 (1,807)Net realized and unrealized gain on investments (10,721) (10,954)Purchases of trading securities (231,753) (348,124)Sales of trading securities 220,535 332,330Change in split-interest trusts 194 (230)Unrealized loss (gain) on interest rate exchange agreements 13,695 (10,997)Restricted contributions for endowments and property, plant,

and equipment (25,683) (24,326)(Decrease) increase in cash due to changes in:

Patient accounts receivable (8,100) (99,699)Accounts payable and other accrued expenses 38,073 478Other assets and other liabilities, net (95,548) 58,536

Net cash provided by operating activities 294,622 120,421

Cash flows from investing activitiesPurchase of property, plant, and equipment (195,197) (198,562)Purchases of long-term securities (340,184) (291,235)Sales and maturities of long-term securities 232,230 135,927Proceeds on sale of property, plant, and equipment 220 20,394

Net cash used in investing activities (302,931) (333,476)

Cash flows from financing activitiesProceeds from issuance of long-term debt - 329,719Debt issuance costs - (3,035)Repayment of long-term debt (5,000) (108,100)Principal payments under capital lease obligations (1,831) (1,191)Restricted contributions for endowments and property, plant, and equipment 25,683 24,326Distributions to noncontrolling interests (2,022) (4,234)

Net cash provided by financing activities 16,830 237,485

Net change in cash, cash equivalents, and restricted cash 8,521 24,430

Cash, cash equivalents, and restricted cashBeginning of the period 578,165 553,735

End of the period 586,686$ 578,165$

Vanderbilt University Medical Center Notes to Consolidated Financial Statements June 30, 2019 and 2018

7

1. Description of Organization

Vanderbilt University Medical Center (“VUMC”) is a Tennessee not-for-profit corporation incorporated in March 2015 to operate an academic medical center, including a comprehensive research, teaching, and patient care health system (the “Medical Center”). Until April 29, 2016, the Medical Center operated as a unit within Vanderbilt University (“the University” or “VU”), as a part of the University’s administrative structure, with the same governing board, legal, financial, and other shared services.

VUMC began operations effective April 30, 2016, following the closing of the sale of the Medical Center by the University (the “Acquisition”). VUMC owns and operates three hospitals located on the main campus of the University in Nashville, Tennessee: Vanderbilt University Adult Hospital (“VUAH”), Monroe Carell Junior Children’s Hospital at Vanderbilt (“MCJCHV”), and Vanderbilt Psychiatric Hospital (“VPH”). In addition, VUMC partially owns Vanderbilt Stallworth Rehabilitation Hospital (“VSRH”), also located on the main campus of the University, through a joint venture with Encompass Health Corp. (formerly called HealthSouth Corp.) in which VUMC holds a 50% interest, which includes a 1% interest held by Vanderbilt Health Services, LLC, (“VHS”), a VUMC wholly owned subsidiary. VUAH, MCJCHV, and VPH are licensed for 1,072 beds, and VSRH is licensed for 80 beds.

VUMC consists of two major operating divisions and an administrative overhead division. The operating divisions include the Clinical Enterprise and Academic Enterprise divisions. The administrative overhead division is referred to as Medical Center Administration (“MCA”).

The Clinical Enterprise division includes the professional clinical practice revenues and related expenses of Vanderbilt Medical Group (“VMG”), and technical revenues and associated expenses for the operation of VUMC’s hospitals and clinic facilities, including VUAH, MCJCHV, and VPH. The Clinical Enterprise also includes VHS.

VUAH is a quaternary care teaching hospital licensed for 692 acute care and specialty beds. VUAH, a Level I trauma center, provides advanced patient care and serves as a key site for medical education and clinical research conducted by physician faculty. VUAH includes a comprehensive burn center, the Vanderbilt Transplant Center, the Vanderbilt Heart and Vascular Institute, and the Vanderbilt Ingram Cancer Center.

MCJCHV is a pediatric quaternary care teaching hospital licensed for 142 acute and specialty beds, 50 pediatric intensive care beds, and 96 neonatal intensive care beds. MCJCHV is the region’s only full-service pediatric hospital, with over 30 pediatric specialties. MCJCHV serves as a site for medical education and clinical research conducted by pediatric physician faculty, houses the only Level IV neonatal intensive care center and the only Level 1 pediatric trauma center within the region, and is a regional referral center for extracorporeal membrane oxygenation (heart and lung failure).

VPH is a psychiatric hospital licensed for 92 beds and provides both inpatient and outpatient partial hospitalization psychiatric services to both adult and adolescent patients. Also, VPH provides psychiatric assessment services and neuromodulation procedures through electroconvulsive therapy and transcranial magnetic stimulation.

VMG is the practice group of physicians and advanced practice nurses employed by VUMC, most of whom have faculty appointments from the University, who perform billable professional medical services. VMG is not a separate legal entity. VMG has a board which consists of the VUMC clinical service chiefs, who also serve as clinical department chairs. Under the oversight


8

of VUMC executive leadership, VMG sets professional practice standards, bylaws, policies, and procedures. VUMC bills for services rendered by VMG clinicians in both inpatient and outpatient locations. Collected fees derive a component of each VMG clinician’s compensation. VMG includes nationally recognized physicians whose expertise spans the spectrum from primary care to the most specialized quaternary discipline. The entire clinical faculty is “board certified” or eligible for board certification. All staff members are re-credentialed every two years by the National Committee for Quality Assurance standards. All specialties and subspecialties currently recognized by the various national specialty boards are represented on the clinical faculty.

VHS serves as a holding company for 16 health care related subsidiaries and joint ventures owned with various entities, including, but not limited to, VSRH and the Vanderbilt Health Affiliated Network (“VHAN”). VHS operations primarily consist of community physician practices, walk-in and retail health clinics, imaging services, outpatient surgery centers, radiation oncology centers, a home health care agency, a home infusion and respiratory service, an affiliated health network, accountable care organizations, and a rehabilitation hospital. These subsidiaries include clinics managed in multiple outpatient locations throughout middle Tennessee and southwestern Kentucky.

VUMC also has a holding company that includes five limited liability subsidiaries which support various business to business activities in order to improve the quality, affordability, and availability of health care services. These subsidiaries include businesses focused on pharmacy and supply chain.

The Academic Enterprise division includes all clinically-related research, research-support activities, and faculty endeavors supporting post-graduate training programs. A significant funding source for VUMC’s research has historically been the federal government. Federal funding is received from the Department of Health and Human Services, the National Institutes of Health, the Department of Defense, NASA, and other federal agencies. Sponsored research awards, including multiple-year grants and contracts from government sources, foundations, associations, and corporations signify future research commitments. Also, core activities supporting research, including advanced computing and grant administration, are included in this division.

The terms “Company,” “VUMC,” “we,” “our”, or “us” as used herein and unless otherwise stated or indicated by context refer to Vanderbilt University Medical Center and its affiliates. The terms “facilities” or “hospitals” refer to entities owned and operated by VUMC and its affiliates, and the term “employees” refers to employees of VUMC and its affiliates.

VUMC operates on a fiscal year which ends on June 30. The term “Fiscal” preceding a year refers to a particular VUMC fiscal year.

2. Summary of Significant Accounting Policies

Basis of Presentation The accompanying consolidated financial statements have been prepared on the accrual basis in accordance with accounting principles generally accepted in the U.S. (“GAAP”). Based on the existence or absence of donor-imposed restrictions, VUMC classifies resources into two categories: net assets without donor restrictions and net assets with donor restrictions. In addition, these statements follow GAAP applicable to the not-for-profit industry as described in the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification (“ASC”) Topic 958.


9

Principles of Consolidation The consolidated financial statements include the accounts of VUMC and its wholly owned, majority-owned, and controlled organizations. Noncontrolling interests in less-than-wholly owned consolidated subsidiaries of VUMC are presented as a component of net assets to distinguish between the interests of VUMC and the interests of the noncontrolling owners. All material intercompany transactions and account balances among the various entities have been eliminated.

VUMC uses the equity method to account for its interests in unconsolidated partnerships, joint ventures, and limited liability entities over which it exercises significant influence. Investment carrying amounts are adjusted for VUMC’s share of investee earnings or losses based on percentage of ownership. Distributions received from unconsolidated entities that represent returns on VUMC’s investment (i.e., dividends) are reported as cash flows from operating activities in VUMC’s statement of cash flows.

Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. These estimates affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated balance sheets and the reported amounts of revenues and expenses during the reporting periods. Actual results ultimately could differ from those estimates.

Cash and Cash Equivalents Cash and cash equivalents are liquid assets with minimal interest rate risk and maturities of three months or less when purchased. VUMC invests operating assets in a diversified manner. At times, VUMC may have cash and cash equivalents at a financial institution in excess of federally insured limits, and therefore, bear a risk of loss.

Liquidity and Availability VUMC has $1,670.5 million of financial assets available within one year of June 30, 2019 to meet cash needs for general expenditures consisting of cash and cash equivalents of $574.7 million, patient accounts receivable of $482.5 million, pledges receivable of $6.3 million, and unrestricted investments of $607.0 million. None of these financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditure within one year of the balance sheet date. Pledges receivable are subject to implied time restrictions but are expected to be collected within one year.

VUMC has a policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, as part of its liquidity management, VUMC invests cash in excess of daily requirements in various short-term investments, including certificate deposits and short-term treasury instruments.

As more fully described in Note 11 Long-Term Debt, VUMC also has a committed line of credit in the amount of $100.0 million, which it could draw upon in the event of an unanticipated liquidity need.

Revenue Recognition—Patient Services VUMC recognizes revenue from patient services at the amount that reflects the consideration to which VUMC expects to be paid for providing such services. These amounts, representing transaction price, are due from patients, third-party payors (including health insurers and government programs), and others and include variable consideration for retroactive revenue adjustments due to settlements of audits, reviews, and investigations. Patient service revenue is


10

recognized as performance obligations based on the nature of the services provided by VUMC are satisfied.

Performance obligations satisfied over time relate to admitted patients in VUMC hospitals receiving inpatient acute care services from admission to the point when services are no longer required, which is generally at the time of discharge. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected or actual charges. Outpatient services are performance obligations satisfied at a point in time with the related revenue being recognized when goods or services are provided.

VUMC has elected to apply the optional exemption provided in FASB (ASC) 606-10-50-14 as substantially all of its performance obligations relate to contracts with a duration of less than one year. Therefore, VUMC is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially satisfied at the end of the reporting period. Unsatisfied or partially satisfied performance obligations are primarily related to in-house patients at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which is typically within a week.

VUMC uses a portfolio approach consisting of major payor classes to account for categories of patient contracts as a collective group rather than recognizing revenue on an individual contract basis. Based on historical collection trends and other analysis, VUMC believes that revenue recognized by utilizing the portfolio approach approximates the revenue that would have been recognized if an individual contract approach were used.

VUMC determines the transaction price, which involves estimates and judgment, based on standard charges for goods and services provided, reduced by explicit and implicit price concessions, including contractual adjustments provided to third-party payors, discounts provided to uninsured and underinsured patients in accordance with VUMC policy, and historical collection experience. VUMC analyzes its history and identifies trends for each of its major revenue categories to estimate the appropriate price concessions. Management regularly reviews data about these major revenue categories in evaluating the reasonableness of the transaction price, taking into consideration recent experience by payor category, payor agreement rate changes, and other factors.

In addition to patient payments, VUMC earns revenue and reimbursements from certain services provided under federal healthcare programs and other contracts with third-party payors. These compensation arrangements are complex programs which extend over multiple accounting periods and are subject to the interpretation of federal and state-specific reimbursement rates, new or changing legislation, and final cost report settlements. Estimated settlements under these programs are recorded in the period the related services are performed and are subsequently adjusted, as needed, based on new information.

VUMC provides care to patients who meet the criteria for charity care under its financial assistance policy for no payment or at payment amounts less than its established charge rates. VUMC does not recognize the charges that qualify as charity care as revenue because VUMC does not pursue collection of these amounts.

Revenue Recognition— Non-Patient Services Revenue for non-patient services is recognized at an amount that reflects the consideration VUMC expects to be entitled in exchange for providing goods or services. The amounts recognized reflect considerations due from customers, the U.S. government, and others, and is recognized as performance obligations are satisfied. Primary categories of non-patient revenue include academic


11

and research revenue as well as other miscellaneous activities as further described in Note 8 Other Relevant Financial Information.

VUMC receives funding through grants and contracts issued by departments and agencies of the U.S. government, industry, and other foundation sponsors who restrict the use of such funds to academic and research purposes. VUMC recognizes revenue from these grants and contracts in accordance with contract terms, as defined in the agreements governing that funding. VUMC recognizes facilities and administrative (“F&A”) costs recovery as revenue when the allowable expenditure is incurred on the associated grant or contract. This activity represents reimbursement, primarily from the federal government, of F&A costs on sponsored activities.

Grants and contracts receivable include amounts due from these sponsors of externally funded research. These amounts have been billed or are billable to the sponsor and are recorded at the amount that reflects the consideration VUMC expects to receive.

Deferred Revenue Deferred revenue is recorded for funds received in advance. The related revenue is recognized when the performance obligations have been met.

Gift Income and Pledges VUMC recognizes unconditional promises to give cash and other assets, referred to as pledges, as gift income at fair value when the pledge is received. Conditional promises to give are recognized as pledges once the conditions are substantially met. Pledges are recognized as net assets with or without donor restrictions. Gifts received with donor stipulations limiting the use of the donated assets are reported as net assets with donor restrictions. Donor-restricted contributions whose restrictions are met within the same year as received are reported as gift income in the accompanying consolidated statements of operations. Gift income is recognized when a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished. Gifts of cash or other assets that must be used to acquire long-lived assets are reported as net assets with donor restrictions until the assets are placed in service, at which point they are reclassified to net assets without donor restrictions.

Pledges receivable are reported net of allowances for uncollectible amounts based on an analysis of past collection experience and other judgmental factors. Pledges receivable are included in other current or other noncurrent assets in the consolidated balance sheets based on the expected timing of cash flows. VUMC discounts the noncurrent portion of pledges receivables at a rate commensurate with the scheduled timing of receipt. VUMC applied annual discount rates ranging from 0.5% to 1.5% to amounts outstanding as of June 30, 2019 and 2018.

Concentrations of Credit Risk VUMC grants unsecured credit to its patients, primarily residing in Nashville, Tennessee and the surrounding areas of middle Tennessee, most of whom are insured under commercial, Medicare, or TennCare agreements. Medicare, Blue Cross Blue Shield (“BCBS”), and TennCare (which includes BCBS, United, and Amerigroup) represent VUMC’s significant concentrations of credit risk from payors.

Inventories VUMC reports inventories at the lower of cost or market, with cost being determined on the first-in, first-out method. Inventories consist primarily of medical supplies, surgical implants, and pharmaceuticals.


12

Restricted Cash VUMC reports cash whose use is restricted at cost, which approximates fair value. The cash is primarily restricted for use in purchasing and constructing property, plant, and equipment.

Investments VUMC reports investments held at fair value in the consolidated balance sheets. VUMC records purchases and sales of securities on the trade dates, and realized gains and losses are determined based on the average historical cost of the securities sold. VUMC reports net receivables and payables arising from unsettled trades as a component of investments.

Property, Plant, and Equipment, Net VUMC records purchases of property, plant, and equipment at cost and expenses repairs and maintenance costs as incurred. VUMC capitalizes interest cost incurred on borrowed funds during the period of construction of capital assets as a component of the cost of acquiring those assets. VUMC capitalizes donated assets at fair value on the date of donation.

Capitalized software for internal use is recorded during the application development stage. These costs include fees paid to third parties for direct costs of materials and services consumed in developing or obtaining the software; payroll related costs and capitalized interest costs. Costs for training and application maintenance in the post-implementation operation stage are expensed as incurred.

VUMC computes depreciation using the straight-line method over the estimated useful life of land improvements (3 to 18 years), buildings and leasehold improvements (2 to 37 years), and equipment (1 to 20 years). Equipment costs also include capitalized internal use software costs, which are expensed over the expected useful life, which is generally 1.5 to 12 years. VUMC assigns useful lives in accordance with American Hospital Association guidelines.

Software for internal use is amortized on a straight-line basis over its estimated useful life. In determining the estimated useful life, management considers the effects of obsolescence, technology, competition, other economic factors, and rapid changes that may be occurring in the development of software products, operating systems, and computer hardware. Amortization begins once the software is ready for its intended use.

Impairment of Long-Lived Assets VUMC reviews long-lived assets, such as property, plant, and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. VUMC measures the recoverability of assets to be held and used by comparing the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, VUMC recognizes an impairment charge to the extent the carrying amount of the asset exceeds its fair value.

Conditional Asset Retirement Costs and Obligations VUMC recognizes the estimated fair value of liabilities for existing legal obligations to perform certain activities, primarily asbestos removal, in connection with the retirement, disposal, or abandonment of assets. These liabilities are included in other noncurrent liabilities on the consolidated balance sheets and total $6.3 million and $6.1 million as of June 30, 2019 and 2018, respectively. VUMC measures these liabilities using estimated cash flows with an inflation rate applied of 3.0% as of June 30, 2019 and 2018. VUMC discounts those cash flow estimates at a credit-adjusted, risk-free rate, which ranged from 2.9% to 4.2% as of June 30, 2019 and 2018, and adjusts these liabilities for accretion costs and revisions in estimated cash flows.


13

Long-Term Debt The carrying value of VUMC’s debt is the par amount adjusted for the net unamortized amount of debt issuance costs, and bond premiums and discounts.

Interest Rate Exchange Agreements VUMC reports interest rate exchange agreements at fair value, which is determined to be the present value of future net cash settlements that reflect market yields as of the measurement date and estimated amounts that VUMC would pay, or receive, to terminate the contracts as of the report date. VUMC considers current interest rates and creditworthiness of the interest rate exchange counterparties when estimating termination settlements.

Self-Insurance Reserves VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability coverage via an irrevocable self-insurance trust. The maximum annual self-insurance retention was $5.5 million per occurrence, up to $43.0 million in the aggregate for both Fiscal 2019 and 2018. Actuarial firms assist management in estimating expected losses on an annual basis, at which time VUMC records medical malpractice, professional, and general liability expense within the limits of the program. These liabilities are classified as current or noncurrent based on the expected timing of cash flows and are measured at the net present value of those cash flows using a discount rate of 2.5% as of June 30, 2019 and 2018. For both Fiscal 2019 and 2018, VUMC obtained excess medical malpractice, professional, and general liability coverage from commercial insurance carriers for claims in excess of $5.5 million per occurrence, up to $125.0 million. These policies would also provide coverage up to $125.0 million if any claims in the aggregate exceed $43.0 million.

VUMC also elects to self-insure for employee health and workers’ compensation expenses. Actuarial firms assist management in estimating expected losses on an annual basis. The maximum retention for workers’ compensation was $0.8 million per occurrence for both Fiscal 2019 and 2018. There is no stop loss insurance on health plan claims.

Income Taxes VUMC is a tax-exempt organization as described in Section 501(c)(3) of the Internal Revenue Code (the “Code”) and is generally exempt from federal income taxes under Section 501(a) of the Code.

The Tax Cuts and Jobs Act (the “Act”) was enacted on December 22, 2017. The Act reduces the U.S. federal corporate tax rate from 35% to 21%, requires companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred, and creates new taxes on certain foreign sourced earnings. For tax-exempt entities, the Act also requires organizations to categorize certain fringe benefit expenses as a source of unrelated business income, pay an excise tax on remuneration above certain thresholds that is paid to executives by the organization, and report income or loss from unrelated business activities on an activity-by-activity basis, among other provisions. At June 30, 2019, the Company made a reasonable estimate of the tax effects of the enactment of the Act. The Company will continue to revise and refine the calculations as additional IRS guidance is issued.

Excess of Revenues Over Expenses The consolidated statements of operations include excess of revenues over expenses as a performance indicator. Excess of revenues over expenses includes all changes in net assets without donor restrictions, except for changes in noncontrolling interest holders’ share of consolidated entities, net assets released from restrictions used for capital, and certain other items.


14

Statement of Cash FlowsFor VUMC’s consolidated statements of cash flows, cash, cash equivalents, and restricted cash isdefined as those amounts included in the cash and cash equivalents caption and restricted cashcaption on the consolidated balance sheets.

Conforming ReclassificationsCertain amounts in the Fiscal 2018 consolidated financial statements have been reclassified to conform to their Fiscal 2019 presentation.

Recent Accounting PronouncementsPeriodically, the FASB issues Accounting Standards Updates (“ASUs”) that may impact therecognition, measurement, and presentation of balances and activity in VUMC’s consolidatedfinancial statements or the disclosures contained within those statements. As part of preparingconsolidated financial statements, VUMC evaluates the effects of the ASUs and applies theupdated guidance within the required effective dates.

Adopted

In May 2014, the FASB issued ASU 2014-09, Revenue from Contracts with Customers (Topic606). The ASU converged and replaced existing GAAP revenue recognition guidance andrequires an entity to recognize revenue to depict the transfer of promised goods or services tocustomers in an amount that reflects the consideration to which the entity expects to be entitledin exchange for those goods or services. On July 1, 2018, this ASU was adopted on a modifiedretrospective basis. The most significant change was related to the presentation of ourconsolidated statement of operations, where we no longer present the “Provision for bad debts”as a separate line item and our “Patient service revenues” are presented net of estimatedimplicit price concessions. We have also eliminated the related presentation of “allowance forbad debts” on our consolidated balance sheet. The adoption of the ASU resulted in no mater-ial impact to operating income or excess of revenues over expenses on VUMC’s con-solidated financial statements.

In August 2016, the FASB issued ASU 2016-14, Presentation of Financial Statements forNot-for-Profit Entities, which, among other things, replaces the existing three-categoryclassification of net assets (i.e., unrestricted, temporarily restricted, and permanently restricted)with a model that combines temporarily restricted and permanently restricted into a singlecategory called “net assets with donor restrictions.” Differences in the nature of donorrestrictions are disclosed in the notes, with an emphasis on how and when the resources canbe used. ASU 2016-14 also provides guidance for classifying deficiencies in endowment funds,accounting for the lapsing of restrictions on gifts to acquire property, plant, and equipment, andproviding information about how the nature of expenses relates to programs and supportingactivities. During Fiscal 2019, this standard was adopted. The prior period consolidatedfinancial statements presented were adjusted to reflect these changes. The adoption of theASU resulted in no material impact to VUMC’s consolidated financial statements.

In June 2019, the FASB issued ASU 2018-08, Not-For-Profit Entities (Topic 958): Clarifying theScope and the Accounting Guidance for Contributions received and Contributions made. Theamendments in this ASU clarify guidance for when a transaction should be accounted for as acontribution under Not-for-Profit Entities – Revenue Recognition (Subtopic 958-605) or as anexchange transaction accounted for under Revenue from Contracts with Customers (Topic606). VUMC adopted ASU 2018-08 effective July 1, 2018. The most significant change relatesto the presentation of academic and research revenue paid in advance that meet the definitionof a contribution. These amounts are now presented within net assets as net assets with donor


15

restrictions as opposed to deferred revenue. The impact of this adoption was not material to the consolidated financial statements.

In November 2016, the FASB issued ASU 2016-08, Statement of Cash Flows (Topic 230): Restricted Cash. The amendments in this ASU require that a statement of cash flows explain the change during the period in the total cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. Amounts generally described as restricted cash and restricted cash equivalents should be included with cash and cash equivalents when reconciling the beginning-of-period and end-of-period total amounts shown on the statement of cash flows. VUMC adopted ASU 2016-08 effective July 1, 2018 on a retrospective basis. The prior period consolidated financial statements presented were adjusted to reflect this change. The adoption of the ASU resulted in no material impact to VUMC’s consolidated financial statements.

Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases, which requires lessees to recognize assets and liabilities for most leases. ASU 2016-02’s transition provisions will be applied to the most recent period presented in the financial statements. For VUMC, the amendments in ASU 2016-02 are effective July 1, 2019, although early adoption is permitted. VUMC expects the primary effect of adopting the new standard to be a requirement to record assets and offsetting obligations for current operating leases. VUMC is still evaluating the impact on the consolidated financial statements.

3. Related Parties

On April 29, 2016, VUMC acquired the assets, liabilities, rights, and obligations of the clinical enterprise, postgraduate medical training programs, and clinically related research of the University’s owned and operated Medical Center, “the Acquisition”.

The assets acquired and liabilities assumed from the Acquisition were detailed in a Master Transfer and Separation Agreement (“MTSA”). The MTSA contains the framework for the ongoing economic relationship between VUMC and the University. The relationship is memorialized in the form of an Academic Affiliation Agreement (“AAA”), a Trademark License Agreement (“TMLA”), a Ground Lease, and a Reciprocal Master Services Agreement (“MSA”). The agreements are described below.

The AAA outlines the ongoing academic, research, and clinical affiliation between the University and VUMC for all of the University’s degree-granting, certificate, and research programs. The AAA allocates responsibility between the University and VUMC for jointly administered research and academic programs and is an exclusive agreement between VUMC and VU requiring VUMC to be organized, governed, and operated in a manner that supports VU’s academic and research mission. The agreement provides that VU will be the exclusive academic affiliate of VUMC, and VUMC will be the exclusive clinical affiliate of VU.

The AAA requires VUMC to pay VU an annual fee in equal monthly payments adjusted annually for inflation based upon the Biomedical Research and Development Price Index (“BRDPI”) in perpetuity under certain mutually agreed-upon termination or default clauses. During Fiscal 2019 and 2018, VUMC recorded operating expense totaling $74.9 million and $73.1 million, respectively, in connection with fees due under the AAA.


16

Under the TMLA, the University grants, subject to certain consents and approvals, a perpetuallicense to use various University-owned licensed marks in connection with VUMC’sfundamental activities after the Acquisition date. The licensed marks, which VUMC continuesto use as its primary brands, include virtually all those previously in use by VUMC. Thisagreement requires VUMC to pay VU a monthly royalty payment equal to 1.0% of all operatingrevenue of VUMC and a percentage of net income from operations (5% in Fiscal 2018, 10% inFiscal 2019, and 15% in Fiscal 2020 and beyond). During Fiscal 2019 and 2018, VUMCrecorded operating expense totaling $63.8 million and $44.2 million, respectively, in connectionwith royalty fees due under the TMLA. Also, VUMC is required to pay in equal monthlyinstallments an annual TMLA base fee, which increases 3% annually, but is also reduced bythe amount of principal payments made under a subordinate note discussed in Note 11 Long-Term Debt (the “Fixed TMLA Royalty Payment”). During Fiscal 2019 and 2018, VUMCrecorded operating expense totaling $60.6 million and $58.7 million, respectively, in connectionwith this base fee. In July of 2018, VU sold its rights to future base fee payments to a thirdparty. The TMLA is in force in perpetuity under certain mutually agreed-upon termination ordefault clauses.

The Ground Lease is an agreement between VU and VUMC that allows VUMC to use the landon which VUMC’s campus and related buildings are located. The initial term of the GroundLease ends June 30, 2115, with the option to extend the lease for two additional terms of up to50 to 99 years each with agreement between VU and VUMC. The lease covers 1.7 millionsquare feet or 38.75 acres of space, payable monthly and CPI adjusted annually. During Fiscal2019 and 2018, VUMC recorded operating expense totaling $19.0 million and $18.5 million,respectively, in connection with fees due under the Ground Lease.

The University and VUMC provide services to one another for agreed-upon consideration asoutlined in the MSA. VU provides services to VUMC, such as information technologyinfrastructure support, utilities, and law enforcement staffing. VUMC provides variousoperational services for the University, such as a student health clinic and animal care.Additionally, the MSA encompasses an Employee Matters Agreement (“EMA”) and specificEmployee Service Agreements (“ESAs”). The EMA and ESAs govern employee transitions andongoing sharing between VU and VUMC in various capacities, such as research, teaching,clinical, and other administrative services. Services under the MSA can be terminated by eitherparty subject to predetermined cancellation notification periods. In connection with the MSA,during Fiscal 2019 and 2018, VUMC recognized revenue totaling $45.1 million and $50.9million, respectively, and recorded operating expense totaling $122.8 million and $124.2million, respectively.

Also, as part of the Acquisition, VUMC issued to VU a $100.0 million subordinate promissorynote payable, which is further described in Note 11 Long-Term Debt, with a balance of$84.6 million as of June 30, 2019, and $89.6 million as of June 30, 2018. In July of 2018, VU sold its rights to future principal and interest payments on this note to a third party.


17

The impact of these agreements in the consolidated statements of operations during Fiscal 2019 and 2018 is as follows:


Academic and research revenue 14,401$ 12,239$ Other operating revenue 30,745 38,647

Total operating revenues 45,146$ 50,886$

Operating expensesSalaries, wages, and benefits 7,725$ 6,973$ Facilities and equipment 58,872 57,385Services and other 274,512 254,370Interest 2,823 2,985

Total operating expenses 343,932$ 321,713$

Other current assets include amounts receivable from VU, which totaled $4.9 million as of June 30, 2019, and $7.0 million as of June 30, 2018. Accounts payable and other accrued expenses include amounts payable to related parties, which totaled $47.7 million as of June 30, 2019, and $31.8 million as of June 30, 2018.

In the normal course of business, members of VUMC’s Board of Directors or VUMC employees may be directly or indirectly associated with companies engaged in business activities with VUMC. VUMC has a written conflict of interest policy that requires, among other things, that members of the VUMC community (including trustees) may not review, approve, or administratively control contracts or business relationships when (i) the contract or business relationship is between VUMC and a business in which the individual or a family member has a material financial interest, or (ii) the individual or a family member is an employee of the business and is directly involved with activities pertaining to VUMC.

Furthermore, VUMC’s conflict of interest policy extends beyond the foregoing business activities in that disclosure is required for any situation in which an applicable individual’s financial, professional, or other personal activities may directly or indirectly affect, or have the appearance of affecting, an individual’s professional judgment in exercising any VUMC duty or responsibility, including the conduct or reporting of research.

The policy extends to all members of the VUMC community (including trustees, faculty, staff, and their immediate family members). Each applicable person is required to certify compliance with the conflict of interest policy on an annual basis. This certification includes specifically disclosing whether VUMC conducts business with an entity in which he or she (or an immediate family member) has a material financial interest, as well as any other situation that could appear to present a conflict with VUMC’s best interests.

When situations exist relative to the conflict of interest policy, VUMC takes active measures to appropriately manage the actual or perceived conflict in the best interests of VUMC, including periodic reporting of measures taken to the Audit Committee of the Board of Directors.


18

4. Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements

Management has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by the major classes of payors. The sources of net patient service revenue by payor for Fiscal 2019 are as follows:

2019

Other third-party payors, primarily commercial carriers 2,355,860$ Medicare/Managed Medicare 896,843TennCare/Medicaid 529,785Uninsured (self-pay) 38,383

3,820,871$

The sources of patient service revenue, net of contractual adjustments and provision for bad debts, by payor for Fiscal 2018 are as follows:

2018

Other third-party payors, primarily commercial carriers 2,179,809$ Medicare/Managed Medicare 792,186TennCare/Medicaid 428,530Uninsured (self-pay) 42,252

3,442,777$

Patient accounts receivable, net of explicit and implicit price concessions, comprise amounts due from the following sources as of June 30, 2019:

($ in thousands) 2019

Medicare 77,122$ TennCare/Medicaid 67,917Blue Cross 112,779Other third-party payors, primarily commercial carriers 163,132Patient responsibility(1)

61,535

Patient accounts receivable 482,485$

(1) Includes self-pay after insurance.


19

Patient accounts receivable, net of related contractual adjustments, discounts, and bad debt allowances, comprise amounts due from the following sources as of June 30, 2018:

($ in thousands) 2018

Medicare 71,405$ TennCare/Medicaid 77,158Blue Cross 95,986Other third-party payors, primarily commercial carriers 174,397Patient responsibility(1)

55,439

Patient accounts receivable, net 474,385$

(1) Includes self-pay after insurance.

Estimated third-party settlements by major payor category as of June 30, 2019 and 2018, are as follows:


Receivables under third-party programsTricare/Champus(1)

8,536$ 8,875$

Total receivables under third-party programs 8,536$ 8,875$

Payables under third-party programsTennCare/Medicaid 18,896$ 53,162$

Medicare(1)14,517 28,660

Total payables under third-party programs 33,413$ 81,822$

(1) These two federal healthcare programs are combined for presentation purposes on the face of the

consolidated balance sheets and are reflected as an obligation in Fiscal 2019 and Fiscal 2018.

Certain contracts require pay for performance or episode of care settlements whereby VUMC receives additional payment or pays a penalty based on its ability to achieve certain clinical measures or manage the cost of care for patients within various thresholds. VUMC estimates and accrues these adjustments in the period the related services are rendered and adjusts these estimates in future periods as settlements are finalized. The aggregate liability associated with pay for performance and episode of care settlements at June 30, 2019 and 2018, was $1.0 million and $0.9 million, respectively, with the ultimate resolution of such financial arrangements not expected to have a material impact on the operating results of VUMC.

Medicare Amounts received under Medicare are subject to review and final determination by program intermediaries or their agents. Final settlements have been reached for program periods ended June 30, 2014. Final settlements have not been reached for subsequent years due to audit delays experienced with the Medicare Administrative Contractor, and thus, those periods remain subject to audit by program representatives.


20

TennCare TennCare is a Medicaid managed care program implemented by the state of Tennessee to provide healthcare coverage to those patients eligible for Medicaid through the Federal 1115 Waiver Program. VUMC contracts with each of the three TennCare managed care organizations (“MCOs”), which offer health maintenance organization (“HMO”) and Medicare Special Needs Products for Dual Eligible Enrollees. VUMC receives inpatient reimbursement through payments that are primarily based on the Medicare severity diagnostic related group system (“MS-DRG”) for these plans. VUMC receives outpatient payments generally based on an ambulatory payment classification system (“APC”), and/or a payor-developed fee schedule.

In accordance with the Tennessee Hospital Assessment Act, VUMC receives a payment of a portion of its unreimbursed TennCare costs based upon VUMC’s share of uninsured TennCare costs for all of the covered hospitals.

There is no assurance that this program will be continued in its current structure or will not be materially modified in the future, however, we anticipate funding will remain relatively stable over the coming year.

The change in our payables under third-party programs is due to a change in estimate relating to the settlement of prior years’ third-party payor liability of approximately $46.0 million and increased net patient service revenue during the year-ended June 30, 2019.

In Fiscal 2019 and 2018, net patient service revenue includes the following supplemental amounts received in each respective period from TennCare and the associated reserves for those payments, changes in estimates effecting reserves are excluded:


Essential access -$ 14,609$ Disproportionate share 10,965 11,511Trauma fund 1,600 1,900Graduate medical education 14,603 14,158Provision for disproportionate share audit (10,965) (11,511)Charity pool 12,246 -Provision for virtual disproportionate share audit (2,682) -

Total supplemental TennCare revenue,net of audit provision 25,767$ 30,667$

5. Charity Care Assistance, Community Benefits, and Other Unrecovered Costs

VUMC maintains a policy which sets forth the criteria under which health care services are provided to patients who have minimal financial resources to pay for medical care. Additionally, VUMC provides other services that benefit the economically disadvantaged for which little or no payment is expected.

Charity care is determined by examining patient and family income relative to the federal poverty guidelines. VUMC provides additional discounts based on the income level of the patient household using a sliding scale for those patients with a major catastrophic medical event not qualifying for full charity assistance. Tennessee law mandates that all uninsured patients receive a discount from billed charges for medically necessary services. These amounts are classified as charity care if the patient meets charity care criteria, for which no revenue is recorded, or is


21

included as a part of price concessions in Fiscal 2019 and in discounts and contractual adjustments in Fiscal 2018.

VUMC maintains records to identify and monitor the level of charity care provided, and these records include gross charges and patient deductibles, coinsurance and copayments foregone for services furnished under its charity care policy, and the estimated cost of those services. VUMC calculates a ratio of total costs to gross charges and then multiplies the ratio by foregone charity care charges in determining the estimated cost of charity care. The gross amount of foregone charity care revenue in Fiscal 2019 and 2018 totals $341.5 million and $323.9 million, respectively. The estimated cost of providing care to charity patients in Fiscal 2019 and 2018 totals $89.9 million and $93.2 million, respectively.

In addition to the charity care services described above, TennCare/Medicaid and state indigent programs do not cover the full cost of providing care to beneficiaries of those programs. As a result, in addition to direct charity care costs, VUMC provided services related to TennCare/Medicaid and state indigent programs and was reimbursed substantially below the cost of rendering such services. VUMC also provides public health education and training for new health professionals and provides, without charge, services to the community at large for many patients with special needs.

6. Academic and Research Revenue, and Grants and Contracts Receivable

Academic and research revenue comprises the following for Fiscal 2019 and 2018:


Grants and contracts revenueFederally funded 297,758$ 288,535$ Non-federally funded 113,423 102,239

411,181 390,774

Facilities and administrative costs recovery 108,266 104,532

Academic and research revenue 519,447$ 495,306$

Grants and contracts receivable comprises the following as of June 30, 2019 and 2018:


Federally funded 28,171$ 29,370$ Non-federally funded 30,579 28,378

Total grants and contracts receivable 58,750$ 57,748$


22

7. Pledges Receivable, Net

Pledges receivable, net of applied discounts and allowance for uncollectible pledges, as of June 30, 2019 and 2018, were as follows:


Amounts dueWithin one year 8,072$ 9,569$ In one to five years 25,027 11,141

Total pledges receivable 33,099 20,710

Unamortized discount (1,296) (453)

31,803 20,257

Allowance for uncollectible pledges (3,317) (2,068)

Net pledges receivable 28,486$ 18,189$

Net pledges receivable classified asCurrent 6,327$ 8,070$ Noncurrent 22,159 10,119

28,486$ 18,189$

In addition to pledges reported as pledges receivable, VUMC had cumulative bequest intentions and conditional promises to give totaling $65.8 million as of June 30, 2019, and $58.1 million as of June 30, 2018. Due to their conditional nature, VUMC does not recognize intentions to give as assets.

8. Other Relevant Financial Information

Other current assets comprise the following as of June 30, 2019 and 2018:


Prepaid expenses 39,610$ 29,263$ Other receivables 31,261 30,635Amounts due from VU (see Note 3 Related Parties) 4,929 7,038Current pledges receivable, net (see Note 7 Pledges Receivable, Net) 6,327 8,070

Expected recoveries from commercial insurance excess

coverage 3,345 5,457Other 3,839 5,380

Total other current assets 89,311$ 85,843$


23

Other noncurrent assets comprise the following as of June 30, 2019 and 2018:


Equity in unconsolidated organizations $ 21,480 $ 21,822Noncurrent pledges receivable (see Note 7 Pledges Receivable, Net) 22,159 10,119Other 4,428 3,936

Total other noncurrent assets $ 48,067 $ 35,877

Other operating revenue comprises the following for Fiscal 2019 and 2018:


Amounts recognized under MSA with VU (see Note 3 Related Parties) $ 30,745 $ 38,647Clinical contracts 40,952 37,366VHS other revenue 23,622 19,632Nonclinical contracts 8,442 7,631Resident and house staff rotations 11,507 6,972Parking fees 7,116 6,967Cafeteria 6,452 6,191VHPS other revenue 5,087 -Other 23,088 24,910

Total other operating revenue $ 157,011 $ 148,316

9. Investments

VUMC investments are made up of current investments, restricted cash, noncurrent investments, and noncurrent investments limited as to use on the face of the consolidated balance sheets. VUMC investments include assets limited as to use related to the following specified purposes as of June 30, 2019 and 2018:


Self-insured malpractice program 52,069$ 65,383$ Donor endowments 38,443 22,721Split-interest trusts 7,383 7,577Supplemental employee retirement program assets 5,714 -

103,609$ 95,681$

VUMC’s endowment does not include gift annuities, interests in trusts held by others, contributions pending donor designation, or contributions receivable.

Self-insured malpractice program – VUMC elects to self-insure a portion of its medical malpractice, professional, and general liability via an irrevocable self-insurance trust.

Donor endowments – Donor-restricted gifts where the principal amount is to be held in perpetuity. Distributions of earnings are restricted for use according to the donor’s intent, as specified in a gift

fickja

Line

fickja

Line


24

agreement. Donor endowments typically benefit specific programs in clinical departments of theMedical Center, for either general program support, a directorship, or research.

Split-interest trusts – Trusts established by donors where VUMC is named as beneficiary.Depending on the terms of the trust, VUMC may receive periodic distributions, and potentially aprincipal amount at some point in the future. Like donor endowments, split-interest trusts typicallybenefit specific programs as defined in the terms of the trust.

Supplemental employee retirement program assets – Assets set aside to fulfill obligations as they come due according to the terms of the retirement program.

The Board of Directors’ interpretation of its fiduciary responsibilities for donor-restrictedendowments under the Uniform Prudent Management of Institutional Funds Act (“UPMIFA”)requirements is to preserve intergenerational equity, barring the existence of any donor-specificprovisions. Under this broad guideline, future endowment beneficiaries should receive at least thesame level of real economic support as the current generation. The overarching objective is topreserve and enhance the real (inflation-adjusted) purchasing power of the endowment inperpetuity. VUMC invests assets to provide a relatively predictable and stable stream of earnings tomeet spending needs and attain long-term return objectives without the assumption of undue risks.

Investments were as follows as of June 30, 2019 and 2018:


Corporate bonds $ 153,940 $ 122,639Equity mutual funds 128,287 135,885Cash and cash equivalents 9,436 75,972Split-interest trusts 7,383 7,577Hedged equity mutual funds 61,401 41,275Fixed income mutual funds 167,079 97,946Certificates of deposit 25,897 48,243Asset-backed securities 29,506 33,547Real estate mutual funds 18,969 14,098Commercial paper 10,916 10,284Government bonds 10,604 1,899Hedged debt mutual funds 86,678 63,295Commodities and managed futures mutual funds 6,895 5,495Target date mutual funds 5,544 -

Total investments, at fair value $ 722,535 $ 658,155

fickja

Stamp

fickja

Line


25

Investment returns comprise the following elements for Fiscal 2019 and 2018:


Interest and dividend income 19,749$ 13,415$ Net realized gains on sales of securities 10,847 14,713

Realized investment gains, before fees 30,596 28,128

Unrealized investment losses, net (126) (3,759)

Total investment returns before fees 30,470 24,369

Investment manager and trustee fees and other (364) (348)

Total income from investments, net 30,106$ 24,021$

VUMC has exposure to risks, including liquidity, interest rate, counterparty, basis, regulatory, market, and credit risks, for marketable securities. Due to the level of risk exposure, it is possible that material near-term valuation changes for investment securities may occur.

VUMC manages all investments, including endowments, as an investment pool.

10. Property, Plant, and Equipment, Net

Property, plant, and equipment comprise the following as of June 30, 2019 and 2018:


Land and land improvements 33,404$ 20,132$ Buildings and improvements 1,087,686 971,393Equipment and software 441,091 391,745Construction in progress 145,380 131,838

Property, plant, and equipment at cost 1,707,561 1,515,108

Accumulated depreciation and amortization (312,466) (208,469)

Property, plant, and equipment, net 1,395,095$ 1,306,639$

As part of the MTSA, VUMC acquired land and land improvements and buildings and improvements which are not allowed to be repurposed without the express consent of VU.

During Fiscal 2019, VUMC placed in service phases of the MCJCHV expansion as well as completed phases of the VUAH bed expansion and clinical relocation, which are included in buildings and improvements. We expect the remaining construction in progress includes all ongoing construction costs incurred and primarily represents the ongoing MCJCHV and VUAH construction to be completed in Fiscal 2020.

In Fiscal 2019 and 2018, VUMC capitalized interest of $6.0 million and $2.0 million, respectively, related to long-term capital projects, primarily the MCJCHV expansion and the VUAH bed expansion.


26

Property, plant, and equipment balances above include the following amounts related to capitalized internal use software:


Equipment and software 158,189$ 150,568$

Construction in progress 2,976 1,137

161,165 151,705

Accumulated amortization (26,063) (12,019)

Internal use software, carrying value 135,102$ 139,686$

Depreciation and amortization comprised the following amounts in Fiscal 2019 and 2018:


Depreciation of tangible assets 82,236$ 87,538$ Amortization of capital leases, leasehold improvements, and internal use software 24,288 18,116

Total depreciation and amortization 106,524$ 105,654$


27

11. Long-Term Debt

Long-term debt comprises the following as of June 30, 2019 and 2018:

2019 2018Effective Fiscal

Carrying Carrying Interest Year

($ in thousands) Amount Amount Rate (2)of Maturity

Series debtFixed-rate debt

Series 2016A 476,930$ 476,930$ 4.1 % 2047Series 2016B 300,000 300,000 4.1 % 2027Series 2017A 121,270 121,270 4.1 % 2049Series 2017 Taxable 100,000 100,000 4.2 % 2038

Total fixed-rate debt 998,200 998,200 4.1 %

Variable-rate debtSeries 2016D 100,000 100,000 4.9 % 2047Series 2016E 128,070 128,070 4.1 % 2047Series 2016F 21,900 21,900 3.5 % 2025Series 2017B 50,000 50,000 3.5 % 2047Series 2018 Tax-exempt 53,385 53,385 2.5 % 2050

Total variable-rate debt 353,355 353,355 4.0 %

Total series debt 1,351,555 1,351,555

Other long-term debtSubordinated note 84,583 89,583 3.2 % 2036Product financing arrangement 31,508 28,929 4.0 % 2027Capital leases 1,730 1,156 4.0 % Various

Subtotal(1)1,469,376 1,471,223 4.1 %

Net unamortized premiums 58,424 60,521Net unamortized issuance costs (12,355) (13,272)

Total long-term debt 1,515,445 1,518,472

Current portion (8,568) (5,774)

Long-term debt, net 1,506,877$ 1,512,698$

(1) The effective interest rate of 4.1% as of June 30, 2019, is presented exclusive of interest rate exchange

agreements discussed in Note 12 Interest Rate Exchange Agreements. Inclusive of these agreements, the overall portfolio effective interest rate was 4.3%.

(2) The effective interest rate for each debt instrument is calculated by dividing each instrument’s interest expense by the weighted average debt outstanding, and where applicable, interest expense is reduced by premium amortization and increased by original issue discount amortization. Interest rates per the agreements are detailed in the accompanying notes.

On April 29, 2016, VUMC issued the Series 2016 A, B, C, D, E, and F bonds (“2016 Series Debt”) and notes aggregating $1.3 billion of proceeds for the purpose of financing the Medical Center Acquisition and paying a portion of the costs of issuance associated with the 2016 Series Debt.


28

The bonds and notes comprising the 2016 Series Debt were issued by the Health and Educational Facilities Board of The Metropolitan Government of Nashville and Davidson County, Tennessee (“HEFB”). As a conduit issuer, the HEFB loaned the debt proceeds to VUMC. VUMC’s debt service requirements under these loan agreements coincide with required debt service of the actual HEFB bonds.

The Series 2016A tax-exempt fixed-rate revenue bonds were issued in the par amount of $476.9 million and include an original issue premium of $59.6 million. The Series 2016A bonds have a final maturity date of July 1, 2046, and can be optionally redeemed at par on or after July 1, 2026. The 2016A bonds were structured as serial bonds with maturities from Fiscal 2030 through 2032, as well as three term bonds maturing Fiscal 2036 through 2047, which are subject to mandatory sinking fund redemption in lots. The Series 2016A bonds bear interest at 5% per annum and pay interest semiannually on July 1 and January 1.

The Series 2016B taxable fixed-rate revenue bonds were issued in the par amount of $300.0 million, bearing interest at 4.1% per annum. Interest is paid semiannually on July 1 and January 1, and has a bullet maturity of July 1, 2026. VUMC is entitled, at its option, to redeem all or a portion of the Series 2016B bonds before April 1, 2026, at a make-whole redemption price, which equals the greater of (i) 100% of the remaining outstanding principal and (ii) the net present value of the remaining scheduled principal and interest payments to the original maturity date, using a discount rate of 35 basis points above rates for U.S. Treasury securities with comparable maturities.

The Series 2016D taxable variable-rate revenue notes (“floating rate notes”) were issued in the par amount of $100.0 million and bear interest initially at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2021, and a final maturity of July 1, 2046. Beginning six months prior to the mandatory tender date of July 1, 2021, the bonds have an optional redemption feature. If the Series 2016D bonds are successfully remarketed at the mandatory tender date, they are subject to mandatory redemption in lots commencing on July 1, 2021, and each July thereafter until final maturity.

The Series 2016E taxable term loan revenue notes were issued in the par amount of $128.1 million and were placed privately with a bank. The notes bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.4% through the initial mandatory tender date of July 1, 2022, and a final maturity of July 1, 2046. During Fiscal 2018, VUMC renegotiated the interest to a variable-rate mode at a fixed spread to one-month LIBOR of 1.8%. In addition to optional redemption of all or a portion of the notes at any time, subject to notice, the Series 2016E notes are subject to principal amortization commencing on July 1, 2022, as defined in the Series 2016E loan agreement between VUMC and the lender.

The Series 2016F taxable variable-rate revenue bonds were issued in the par amount of $75.0 million and were placed privately with a bank. The bonds bear interest in a variable-rate mode at a fixed spread to one-month LIBOR of 2.5% through the initial mandatory tender date of July 1, 2022. During Fiscal 2018, $53.1 million of the Series 2016F bonds were extinguished using proceeds from the 2018 tax-exempt fixed-rate revenue bonds, discussed further below. The renegotiated interest rate on the remaining $21.9 million of principal outstanding is a variable-rate mode at a fixed spread to one-month LIBOR of 1.2%. The remaining principal has a mandatory tender date of July 1, 2024. Prior to that, VUMC must pay $2.1 million of principal on July 1, 2022, and $2.2 million of principal on July 1, 2023. The remaining $17.6 million of principal is due on July 1, 2024.


29

On July 26, 2017, the Series 2017A Tax-Exempt and Series 2017 Taxable Corporate Bonds were issued, and on August 1, 2017, the Series 2017B Taxable Revenue Bonds were issued (“2017 Series Debt”), aggregating $271.3 million of proceeds for the purpose of refinancing existing debt, funding capital projects related to the MCJCHV expansion and the VUAH bed expansion/clinical relocation, which is a phased project, and paying a portion of the costs of issuance associated with the 2017 Series Debt.

The Series 2017A Tax-Exempt Revenue Bonds and the Series 2017B Taxable Term Loan Revenue Note were issued by the HEFB. The Series 2017 Taxable Bonds were a corporate issue with VUMC as the issuer.

The Series 2017A tax-exempt fixed-rate revenue bonds were issued in the par amount of $121.3 million and include an original issue premium of $5.1 million. The final maturity date is July 1, 2048, and optional redemption at par can occur on or after July 1, 2027. The Series 2017A bonds bear interest at 4.4% per annum and pay interest semiannually on July 1 and January 1.

The Series 2017 taxable fixed-rate corporate bonds were issued in the par amount of $100.0 million, bearing interest at 4.2% per annum. Interest is paid semiannually on July 1 and January 1, and the bonds have a final maturity date of July 1, 2037. There is a bullet payable beginning July 1, 2026, that allows VUMC to call the debt.

The Series 2017B taxable variable-rate term loan notes were issued in the par amount of $50 million and placed privately with a bank. The notes bear interest initially at a fixed-spread to one-month LIBOR of 1.2%. The notes have a final maturity date of July 1, 2046, and a tender date of August 1, 2024. Proceeds from the issuance of the Series 2017B notes were used to extinguish the Series 2016C R-FLOATs, initially issued on April 29, 2016.

On April 20, 2018, the Series 2018 Tax-Exempt Revenue Bonds (“2018 Series Debt”) aggregating $53.4 million of proceeds were issued for the purpose of refinancing existing debt and paying a portion of the costs of issuance associated with the 2018 Series Debt. The Series 2018 Tax-Exempt Revenue Bonds were issued by the HEFB, were placed privately with a bank, and bear interest at a fixed spread to 81% of one-month LIBOR of 0.6%. The bonds have a final maturity date of July 1, 2049, and can be optionally redeemed on or after July 1, 2025. Proceeds from the issuance of the Series 2018 bonds were used to extinguish a portion of the Series 2016F taxable variable-rate bonds.

Each of the bonds and notes comprising the 2016, 2017, and 2018 Series Debt represent separate obligations under a Master Trust Indenture (“MTI”) structure. The MTI provides the flexibility for multiple parties to participate in debt issuances as part of an obligated group; presently, VUMC has no other third-party members participating in the obligated group. All debt issued under the MTI is a general obligation of the obligated group. Under the provisions of the Leasehold Deed of Trust, Security Agreement, Assignment of Rents and Leases, and Fixture Filing (the “Security Agreement”) within the MTI, gross receivables of the obligated group are pledged as collateral. Additionally, the Security Agreement established a mortgage lien on (i) the leasehold interest of the land subject to the Ground Lease; (ii) the buildings, structures, improvements, and fixtures now or hereafter located on the land subject to the Ground Lease; and (iii) certain other collateral.

Trust indentures for certain bond issues contain covenants and restrictions, the most material of which include limitations on the issuance of additional debt, maintenance of a specified debt service coverage ratio, and a minimum amount of days cash on hand. VUMC complied with such covenants and restrictions as of June 30, 2019 and 2018.


30

On April 29, 2016, VUMC delivered a secured subordinated promissory note in the amount of$100.0 million to the University to finance the Acquisition (the “subordinated note”). In July of 2018, VU sold its rights to future principal and interest payments on this note to a third party. The note was issued at a fixed rate of 3.25% with monthly principal payments totaling $5.0 mil-lion annually commencing on May 31, 2016, for a period of 20 years ending on April 30, 2036. VUMC may, at any time and from time to time, without premium or penalty, prepay all or any por-tion of the unpaid principal amount of the subordinated note. This note is secured by the gross receivables and mortgaged property described in the Security Agreement subject to the requirements of the 2016 Series Debt and the MTI.

As part of the Acquisition, VUMC assumed a 10-year, unsecured, noninterest-bearing productfinancing arrangement with a vendor for the purchase and implementation of internal use software.As part of this agreement, VUMC has committed to an annual payment of $0.5 million payable inmonthly installments through November 2019. These payments will be considered imputedinterest. During Fiscal 2020, the annual payment increases to $4.9 million payable in monthlyinstallments. These payments are considered principal and imputed interest and continue throughFiscal 2027. The balance due under the Product Financing Arrangement is $31.5 million and$28.9 million as of June 30, 2019 and 2018, respectively. At June 30, 2019 and 2018, $1.9 millionand $0 was included in the current installments of long-term debt caption, with the remainingbalance in the long-term debt, net of current installments caption.

In Fiscal 2019 and 2018, noncash investing and financing activities totaled $2.4 million and $5.8million, respectively, related to property, plant, and equipment expenditures financed through theproduct financing arrangement and capital leases.

Interest paid on all obligations, net of amounts capitalized, was $59.7 million and $54.7 million inFiscal 2019 and 2018, respectively.

Principal retirements and scheduled sinking fund requirements based on nominal maturityschedules for long-term debt due in subsequent fiscal years ending June 30 are as follows:

($ in thousands)

2020 8,568$ 2021 9,1832022 109,2812023 139,6342024 11,840Thereafter 1,190,870

1,469,376$

VUMC has entered into an agreement with a bank to provide a general use line of credit with a maximum available commitment totaling $100.0 million. The line of credit, which may be drawn upon for general operating purposes, expires on April 24, 2020, and can be renewed. Interest on each advance under this line of credit accrues at a rate of 0.65% plus LIBOR, and a commitment fee of 0.15% per annum accrues on any unused portion of the line of credit. Commitment fees for the line of credit totaled $0.2 million in Fiscal 2019 and 2018. No amounts were drawn under this credit facility as of June 30, 2019 or 2018.


31

12. Interest Rate Exchange Agreements

On April 29, 2016, the University transferred an interest rate exchange agreement to VUMC with a total notional amount of $150.0 million and an original termination date of May 1, 2040. VUMC split the transferred notional amount into two agreements, with key features summarized below:

MandatoryNotional Amount Pay Fixed Rate Receive Variable Rate Termination Date

$75.0 million 4.12% 68% of one-month LIBOR April 29, 2021$75.0 million 4.18% 68% of one-month LIBOR April 29, 2023

VUMC incorporated these interest rate exchange agreements into its debt portfolio management strategy. Collateral pledging requirements were removed from the novated agreements, and the agreements were modified to either be negotiated, extended or terminated automatically on April 29, 2021 and 2023, at which point the exchange agreements will be settled at fair value.

VUMC recorded the following activity related to the interest rate exchange agreements during Fiscal 2019 and 2018:


Mark-to-market adjustments (13,695)$ 10,997$ Cash settlements (3,785) (4,618)

Unrealized (loss) gain on interest rate exchange agreements, net of cash settlements (17,480)$ 6,379$

13. Operating Leases

VUMC has entered into certain long-term agreements with respect to facilities and equipment, both as a lessee and a lessor, which VUMC classifies as operating leases. Rental expense and rental income in Fiscal 2019 and 2018 are as follows:

Location in Consolidated($ in thousands) 2019 2018 Statements of Operations

Operating lease rental expense 124,810$ 112,712$ Operating expenses—

Facilities and equipmentOperating lease rental income, including related- party income 8,046 7,843 Operating revenues—

Other operating revenue


32

The following is a schedule by fiscal year of future minimum rentals on noncancelable operating leases as of June 30, 2019:

Ground($ in thousands) Equipment Property Lease Total

2020 35,233$ 53,466$ 19,020$ 107,719$ 2021 24,580 48,634 19,020 92,2342022 15,116 41,437 19,020 75,5732023 6,891 38,481 19,020 64,3922024 2,927 36,436 19,020 58,383Thereafter - 186,035 1,730,820 1,916,855

Total minimum rentals 84,747$ 404,489$ 1,825,920$ 2,315,156$

Essential provisions of leases considered by management to be material are as follows:

On April 29, 2016, VUMC entered into a Ground Lease with VU for approximately 1.7 million square feet of land for an initial term ending June 30, 2115, and an option to extend for up to two additional terms of 50 to 99 years each upon agreement by VU and VUMC. The initial annual base rent of $19.0 million is payable monthly, and is CPI adjusted annually. The Ground Lease allows VUMC to use the land on which its campus and related buildings are located. The $1.8 billion in ground lease payments in the table above represents future minimum rentals based on current payments.

In July 2007, VU entered into an agreement to lease approximately 50% of the space in the 850,000 square foot One Hundred Oaks shopping center located approximately five miles from the main campus (“100 Oaks Lease”). VU redeveloped this leased space primarily for medical and office uses. This operating lease commenced during Fiscal 2009 with an initial lease term of 12 years. In October 2014, VU agreed to an amendment which extends the original lease term by an additional 15 years, with an option to renew the lease further for four additional 10-year periods. As part of the lease agreement, the lessee also has first rights on leasing additional space in the shopping center and first rights on purchasing if the landlord desires to sell. On April 29, 2016, the 100 Oaks Lease was assigned to VUMC. As a condition of the assignment, amendments to the 100 Oaks Lease were added which required VUMC to provide the landlord a $25.0 million irrevocable standby letter of credit, pay a $13.2 million refinancing penalty payable to the landlord, and pay $7.8 million of the landlord’s closing costs, financing fees, and prepayment penalties associated with a refinancing of the landlord’s debt. The prepayment penalty and closing costs were recorded as part of the Acquisition. The irrevocable standby letter of credit must remain in place through April 29, 2026. The amounts related to this standby letter of credit are recorded as facilities and equipment expense and totaled $0.2 million in Fiscal 2019 and $0.3 million in Fiscal 2018. VUMC included minimum property rental payments totaling $125.6 million related to this space in the above future minimum property rentals.

On April 29, 2016, VU assigned to VUMC a lease for approximately 231,000 square feet of office space at 2525 West End Avenue with expiration dates ranging from 2026 through 2030, with options to renew for two additional five-year periods. VUMC included minimum property rental payments totaling $75.0 million related to this space in the above future minimum property rentals.


33

On April 29, 2016, VUMC and VU entered into certain lease agreements for the use of space in buildings owned by both entities. As of June 30, 2019, VUMC’s estimated future minimum property lease payments to VU totaled $24.1 million. Estimated future lease receipts from VU for the fiscal year ended June 30, 2020, are $7.2 million, subject to annual renewal.

14. Net Assets

Net asset restrictions relate to the following purposes as of June 30, 2019 and 2018:


Donor-restricted - time or purposeProperty, plant, and equipment 11,023$ 38,404$ Research and education 88,084 38,331Operations 3,841 2,761

Total donor-restricted - time or purpose 102,948$ 79,496$

Donor restricted - perpetuityResearch and education 52,949$ 34,929$

Net assets without donor restrictions are free of donor-imposed restrictions. This classificationincludes all revenues, gains, and losses not restricted by donors. VUMC reports all expenditures innet assets without donor restrictions since the use of restricted contributions in accordance withdonors’ stipulations results in the release of the restriction.

Donor restricted – time or purpose contain donor-imposed stipulations that expire with thepassage of time or that can be satisfied by the action of VUMC. These net assets may includeunconditional pledges, split-interest agreements, interests in trusts held by others, andaccumulated appreciation on donor-restricted endowments not yet appropriated by the Board ofDirectors for distribution. Donor gifts that are restricted for funding capital projects are consideredreleased from restriction once related capital expenditures have been made and the asset is placedin service.

Donor restricted – perpetuity contains amounts held in perpetuity as requested by donors. These net assets may include unconditional pledges, donor-restricted endowments, split-interest agreements, and interests in trusts held by others. Generally, the donors of these as-sets permit VUMC to use a portion of the income earned on related investments for specific pur-poses.

UPMIFA specifies that unless stated otherwise in a gift instrument, donor-restricted assets in anendowment fund are restricted assets until appropriated for expenditure. Barring the existence ofspecific instructions in gift agreements for donor-restricted endowments, VUMC reports thehistorical value of such endowments as donor restricted – perpetuity and the net accumulatedappreciation as donor restricted – time or purpose. In this context, the historical value representsthe original value of initial contributions restricted as permanent endowments plus the original valueof subsequent contributions and, if applicable, the value of accumulations made in accordance withthe direction of specific donor gift agreements.


34

15. Fair Value Measurements

Fair value measurements represent the amount at which the instrument could be exchanged in an orderly transaction between market participants at the measurement date. VUMC utilizes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value into three levels:

Level 1 Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that VUMC has the ability to access.

Level 2 Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in inactive markets, inputs other than quoted prices that are observable for the assets or liabilities, and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 Inputs to the valuation methodology are unobservable and significant to the fair value measurement. Unobservable inputs reflect VUMC’s assumptions about the inputs market participants would use in pricing the asset or liability, including assumptions about risk. Unobservable inputs are developed based on the best information available in the circumstances and may include VUMC’s own data.

VUMC’s principal assets and liabilities are cash and cash equivalents, investments, patient accounts receivable, estimated receivables and payables under third-party programs, grants and contracts receivable, pledges receivable, accounts payable and other accrued expenses, self-insurance reserves, long-term debt, and interest rate exchange agreements. Except for long-term debt, the carrying amount of these assets and liabilities approximates fair value.

As of June 30, 2019, the carrying value and estimated fair value of total long-term debt totaled $1.515 billion and $1.588 billion, respectively. As of June 30, 2018, the carrying value and estimated fair value of total long-term debt totaled $1.518 billion and $1.534 billion, respectively. VUMC bases estimated fair value of long-term debt on market conditions prevailing at fiscal year-end reporting dates. Besides potentially volatile market conditions, fair value estimates typically reflect limited secondary market trading. The fair values of the fixed-rate Series Debt, as defined in Note 11 Long-Term Debt, were based on a Level 2 computation using quoted prices for similar liabilities in inactive markets as of June 30, 2019 and 2018, as applicable. The carrying amounts related to VUMC’s variable-rate Series Debt and other long-term debt obligations approximate their fair values as of June 30, 2019 and 2018. As of June 30, 2019 and 2018, the fair values of the promissory note payable and the product financing arrangement were based on a Level 2 discounted cash flow approach applying a risk-adjusted spread for issuers of similar credit quality to U.S. Treasury yields for securities with comparable maturities.


35

For financial instruments measured at fair value on a recurring basis, the following tables summarize valuation hierarchy levels as of June 30, 2019 and 2018, determined by the nature of the financial instrument and the least observable input significant to the fair value measurement:

TotalCarrying

($ in thousands) Level 1 Level 2 Level 3 Amount

AssetsCorporate bonds 2,657$ 151,283$ -$ 153,940$ Equity mutual funds 31,873 96,414 - 128,287Cash and cash equivalents 9,436 - - 9,436Beneficial interests in split-interest trusts 7,383 - - 7,383Hedged equity mutual funds - 61,401 - 61,401Fixed-income mutual funds 46,146 120,933 - 167,079Certificates of deposit - 25,897 - 25,897Asset-backed securities 81 29,425 - 29,506Real estate mutual funds - 18,969 - 18,969Commercial paper - 10,916 - 10,916Government bonds - 10,604 - 10,604Hedged debt mutual funds - 86,678 - 86,678Commodities and managed futures mutual funds - 6,895 - 6,895Target date mutual funds - 5,544 - 5,544

Total assets reported at fair value 97,576$ 624,959$ -$ 722,535$

Liabilities

Interest rate exchange agreements -$ 67,901$ -$ 67,901$

Total liabilities reported at fair value -$ 67,901$ -$ 67,901$

Fair Value Measurements as of June 30, 2019


36

TotalCarrying

($ in thousands) Level 1 Level 2 Level 3 Amount

AssetsCorporate bonds 9,507$ 113,132$ -$ 122,639$ Equity mutual funds 36,269 99,616 - 135,885Cash and cash equivalents 75,972 - - 75,972Beneficial interests in split-interest trusts 7,577 - - 7,577Hedged equity mutual funds - 41,275 - 41,275Fixed-income mutual funds 21,079 76,867 - 97,946Certificates of deposit - 48,243 - 48,243Asset-backed securities - 33,547 - 33,547Real estate mutual funds - 14,098 - 14,098Commercial paper - 10,284 - 10,284Government bonds - 1,899 - 1,899Hedged debt mutual funds - 63,295 - 63,295Commodities and managed futures mutual funds - 5,495 - 5,495

Total assets reported at fair value 150,404$ 507,751$ -$ 658,155$

Liabilities

Interest rate exchange agreements -$ 54,206$ -$ 54,206$

Total liabilities reported at fair value -$ 54,206$ -$ 54,206$

Fair Value Measurements as of June 30, 2018

VUMC employs derivatives, primarily interest rate exchange agreements, to help manage interest rate risks associated with variable-rate debt. In addition to the credit risk of the counterparty owing a balance, VUMC calculates the fair value of interest rate exchange agreements based on the present value of future net cash settlements that reflect market yields as of the measurement date.

Parties to interest rate exchange agreements are subject to risk for changes in interest rates, as well as the risk of credit loss in the event of nonperformance by the counterparty. VUMC deals only with high-quality counterparties that meet rating criteria for financial stability and credit-worthiness.

16. Retirement Plan

VUMC’s full-time employees participate in a 403(b) defined contribution retirement plan administered by a third party. For eligible employees with one year of continuous service, this plan requires employer matching of employee contributions up to 5% of eligible compensation. The employee immediately vests in these contributions.

VUMC funds the obligations under this plan through monthly transfers to the respective retirement plan administrator with the corresponding expense recognized in the year incurred. During Fiscal 2019 and 2018, VUMC recognized $64.1 million and $60.7 million, respectively, of expense in connection with this plan.


37

17. Functional Expenses

VUMC provides general health care services primarily to residents within its geographic location and supports research and education programs. Total operating expenses by nature and function for Fiscal 2019 and 2018 were as follows:

($ in thousands)

Healthcare Services

Academic Research and

EducationAdministrative

and Other Total

Salaries, wages, and benefits 1,613,439$ 490,280$ 187,191$ 2,290,910$ Supplies and drugs 831,059 47,418 13,734 892,211Facilities and equipment 156,210 38,257 74,507 268,974Services and other 517,935 95,339 87,805 701,079Depreciation and amortization 83,922 992 21,610 106,524Interest 43,082 12,241 1,206 56,529

Total operating expenses 3,245,647$ 684,527$ 386,053$ 4,316,227$

For the year ended June 30, 2019

($ in thousands)

Healthcare Services

Academic Research and

EducationAdministrative

and Other Total

Salaries, wages, and benefits 1,535,710$ 460,973$ 182,964$ 2,179,647$ Supplies and drugs 717,164 48,882 4,413 770,459Facilities and equipment 145,207 39,885 71,846 256,938Services and other 463,798 82,605 113,052 659,455Depreciation and amortization 81,252 622 23,780 105,654Interest 47,395 9,603 1,080 58,078

Total operating expenses 2,990,526$ 642,570$ 397,135$ 4,030,231$

For the year ended June 30, 2018

Certain expense categories are attributable to more than one function. Therefore, these expenses require an allocation on a reasonable basis that is consistently applied. The expenses that are allocated include salaries, wages, and benefits, and services and other.

18. Commitments and Contingencies

Management has policies, procedures, and an organizational structure to enforce and monitor compliance with government statutes and regulations. VUMC’s compliance with such laws and regulations is subject to future government review and interpretations, as well as regulatory actions unknown or unasserted at this time.

Litigation. VUMC is a defendant in certain lawsuits alleging medical malpractice and civil action.

On August 16, 2016, VUMC received written notice from VU of a third-party claim which could, if determined adversely to VU, require indemnification by VUMC pursuant to the provisions of the MTSA, dated as of April 29, 2016. The third-party claim is a lawsuit (Cassell v. Vanderbilt University, et al., No. 3:16-cv-02086 (U.S.D.C. M.D. TN)) brought by current and former employees of VU which alleges claims relating to administration of the Vanderbilt University Retirement Plan and New Faculty Plan. A proposed settlement has been reached, the terms of


38

which are subject to review and approval by an independent court-appointed fiduciary and, assuming a favorable review, to final approval by the District Court. VUMC has established a liability reserve which reflects its estimated liability under the proposed settlement, assuming final approval is received for the terms as proposed.

In January 2018, VUMC received a subpoena from the United States Department of Health and Human Services, Office of Inspector General (“OIG”) dated January 18, 2018, requesting medical and billing records for 62 patients who received certain cardiac diagnostic testing services at VUMC. VUMC completed its production of records responsive to the subpoena in April 2018. In October 2018 OIG notified VUMC the matter was closed, and no further action has been taken in the matter by OIG.

In late Fiscal 2018, VUMC identified that standing orders used in certain VUMC clinical departments may not have been documented and entered appropriately. Upon further review, VUMC determined that medical record documentation required to support the medical necessity for the services rendered pursuant to certain of such orders was insufficient and that certain reimbursement amounts received for the services so ordered must consequently be repaid. VUMC has established a liability equal to the amount of the estimated repayment associated with such orders. Through the operation of its compliance program, VUMC from time to time initiates the review of billing for clinical services provided by VUMC and its affiliated providers. VUMC has established a liability reserve relating to certain matters under review as of June 30, 2019, which is not material to VUMC’s overall financial position.

Regulations. VUMC’s compliance with regulations and laws is subject to future governmentreviews and interpretations, as well as regulatory actions unknown at this time. VUMC believesthat the liability, if any, from such reviews will not have a significant effect on VUMC’sconsolidated financial position.

Medical Malpractice Liability Insurance. The consolidated balance sheets include reserves formedical malpractice, professional, and general liability coverage totaling $56.3 million as ofJune 30, 2019, and $74.1 million as of June 30, 2018. These liabilities are measured at the netpresent value of those cash flows using a discount rate of 2.5% at both dates and are classifiedas current or noncurrent based on the expected timing of cash flows. Other current assetsinclude expected recoveries from commercial insurance carriers under excess coveragearrangements totaling $3.3 million as of June 30, 2019, and $5.5 million as of June 30, 2018.During Fiscal 2019 and 2018, VUMC recorded expenses for medical malpractice liabilityinsurance of $23.5 million and $20.5 million, respectively.

Employee Health and Workers’ Compensation Insurance. Accrued compensation and benefitsincluded actuarially determined liabilities for employee health and workers’ compensationclaims totaling $17.3 million and $6.6 million, respectively, as of June 30, 2019, and$17.0 million and $7.5 million, respectively, as of June 30, 2018. During Fiscal 2019 and 2018,VUMC recorded expenses for self-insured employee health benefit plans, net of employeepremiums, totaling $177.2 million and $160.4 million, respectively. During Fiscal 2019 and2018, VUMC recorded expenses for self-insured workers’ compensation plans of $2.8 millionand $3.7 million, respectively.

Federal and State Contracts and Other Requirements. Expenditures related to federal andstate grants and contracts are subject to adjustment based upon review by the grantingagencies. Amounts of expenditures that granting agencies might disallow cannot bedetermined at this time. These amounts affect government grants and contracts revenue, as


39

well as facilities and administrative costs recovery. VUMC does not expect these costs to influence the consolidated financial position by material amounts.

Health Care Services. In Fiscal 2019 and 2018, 85% and 84%, respectively, of VUMC’s operating revenue was generated by providing health care services, where revenue is affected by reimbursement arrangements with federal and state healthcare programs, commercial insurance, and other managed care payors. If reimbursement rates from third-party payors decrease or if contract terms become less favorable in future periods, VUMC’s operating revenues may decline. See Note 4 Patient Service Revenue, Patient Accounts Receivable, and Estimated Third-Party Settlements, for further information regarding healthcare revenues and related receivables.

HIPAA Compliance. Under the Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), the federal government has authority to complete fraud and abuse investigations. HIPAA has established substantial fines and penalties for offenders. VUMC maintains policies, procedures, and organizational structures to enforce and monitor compliance with HIPAA, as well as other applicable local, state, and federal statutes and regulations.

Construction. VUMC had contractual commitments under major construction and equipment contracts totaling $113.7 million and $119.5 million as of June 30, 2019 and 2018, respectively.

Letter of Credit. As a requirement of the assignment of the 100 Oaks Lease described in Note 13 Operating Leases, VUMC provided an irrevocable standby letter of credit of $25.0 million to the landlord of the property dated June 10, 2016.

19. Subsequent Events

Management evaluated events after June 30, 2019 through November 12, 2019, the date on which the consolidated financial statements were issued. During this period, there were no subsequent events requiring recognition or disclosure in the consolidated financial statements that have not been recorded or disclosed.

Effective August 1, 2019, VUMC acquired Tennova Healthcare – Lebanon, now known as Vanderbilt Wilson County Hospital (“VWCH”), from Community Healthcare Systems, Inc. VWCH is a two-campus facility licensed for 245 beds and is a substantial provider of both inpatient and outpatient medical services in Lebanon, Tennessee.

On October 22, 2019, VUMC issued a $128.6 million 35 year note with a 30 year average life at a rate of 3.87% to replace the Series 2016E taxable term loan revenue notes.

Additional Identifying NumberFederal Award Name of Funder Assigned By Funder Total Amount FederalCFDA Identification Pass‐Through Pass‐Through Provided to Federal Program Cluster Cluster

Federal Awarding Agency/Program Title Number (Optional) Entity Entity Sub‐Recipients Expenditures Total Name Total

DEPARTMENT OF AGRICULTUREAGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH 10.001 59‐0210‐6‐004 CRDF 59‐0210‐6‐004 $31,138 $32,755 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGRICULTURAL RESEARCH_BASIC AND APPLIED RESEARCH 10.001 59‐0210‐6‐004 CRDF 59‐0210‐6‐004 $1,617 $32,755 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

AGRICULTURE AND FOOD RESEARCH INITIATIVE (AFRI) 10.310 2017‐68001‐26352 $94,539 $480,132 $480,132 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TOTAL DEPARTMENT OF AGRICULTURE $94,539 $512,887

DEPARTMENT OF DEFENSECOLLABORATIVE RESEARCH AND DEVELOPMENT 12.114 W912HQ‐16‐C‐0033 PITTSBURGH W912HQ‐16‐C‐0033 $178,087 $178,087 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

DEPARTMENT OF DEFENSE HIV/AIDS PREVENTION PROGRAM 12.350 N32398‐17‐RCA‐0012 $7,418 $7,418 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BASIC SCIENTIFIC RESEARCH ‐ COMBATING WEAPONS OF MASS DESTRUCTION 12.351 HDTRA1‐13‐1‐0034 $30,588 $30,588 $10,750 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BASIC SCIENTIFIC RESEARCH ‐ COMBATING WEAPONS OF MASS DESTRUCTION 12.351 HDTRA1‐13‐1‐0034 ‐$19,838 $10,750 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐10‐2‐0133 $204,878 $254,802 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐12‐1‐0159 $320,533 $377,620 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐12‐1‐0335 $37,931 $37,931 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐12‐1‐0335 ‐$5,160 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐1‐0110 $15,480 $15,480 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐1‐0110 ‐$3,634 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐1‐0259 $159,871 $171,818 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐1‐0328 $101,933 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐1‐0559 $249,577 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐1‐0622 $76,229 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐1‐0605 $26,813 $525,517 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐1‐0622 $388,763 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐2‐0061 $47,471 $113,381 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0257 $180,831 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0304 $312,904 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0308 $141,276 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0309 $155,280 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0328 $129,815 $326,988 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0442 $507,586 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0503 $625,696 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐2‐0003 $80,676 $461,953 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐2‐0055 $68,394 $446,336 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐C‐0252 $250,483 $761,821 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0029 $240,622 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0301 $16,137 $164,230 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0149 $767,671 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0536 $58,061 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0683 $88,241 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0719 $37,739 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0810 $96,640 $155,298 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0814 $51,572 $165,582 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐19‐1‐0090 $4,343 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐1‐0714 BAYLOR COLLEGE W81XWH‐15‐1‐0714 $16,419 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0631 CALIFORNIA UCSF W81XWH‐17‐1‐0631 $77,743 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0597 COLORADO W81XWH‐17‐1‐0597 $16,900 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐2‐0046 DUKE W81XWH‐15‐2‐0046 $101,311 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐2‐0003 FLORIDA STATE W81XWH‐16‐2‐0003 $234,641 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐10‐2‐0090 JOHNS HOPKINS W81XWH‐10‐2‐0090 $16,085 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐2‐0074 JOHNS HOPKINS W81XWH‐15‐2‐0074 $513 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐2‐0060 JOHNS HOPKINS W81XWH‐16‐2‐0060 $393,225 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐11‐2‐0161 NAVREF W81XWH‐11‐2‐0161 ‐$1,077 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐D‐0024 PITTSBURGH W81XWH‐16‐D‐0024 $73,155 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐17‐1‐0610 PITTSBURGH W81XWH‐17‐1‐0610 $461,755 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0790 ROCHESTER W81XWH‐18‐1‐0790 $172,216 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐15‐2‐0068 VANDERBILT UNIVERSITY W81XWH‐15‐2‐0068 $21,457 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐1‐0063 VANDERBILT UNIVERSITY W81XWH‐16‐1‐0063 $8,527 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐1‐0063 VANDERBILT UNIVERSITY W81XWH‐16‐1‐0063 ‐$1,155 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐1‐0559 VANDERBILT UNIVERSITY W81XWH‐16‐1‐0559 $20,020 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐16‐2‐0052 VANDERBILT UNIVERSITY W81XWH‐16‐2‐0052 $8,750 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0234 VANDERBILT UNIVERSITY W81XWH‐18‐1‐0234 $55,301 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MILITARY MEDICAL RESEARCH AND DEVELOPMENT 12.420 W81XWH‐18‐1‐0412 VANDERBILT UNIVERSITY W81XWH‐18‐1‐0412 $5,557 $9,588,058 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BASIC SCIENTIFIC RESEARCH 12.431 W911NF‐14‐2‐0022 VANDERBILT UNIVERSITY W911NF‐14‐2‐0022 $5,142 $367,161 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

Vanderbilt University Medical CenterSchedule of Expenditures of Federal Awards and State Financial AssistanceFor the Year Ended June 30, 2019

Accompanying notes follow this Schedule.

40




BASIC SCIENTIFIC RESEARCH 12.431 W911NF‐14‐3‐0022 VANDERBILT UNIVERSITY W911NF‐14‐3‐0022 $362,019 $367,161 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AIR FORCE DEFENSE RESEARCH SCIENCES PROGRAM 12.800 FA8650‐16‐2‐6G02 CINCINNATI FA8650‐16‐2‐6G02 $38,436 $38,436 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 HR0011‐18‐2‐0001 $4,083,148 $5,996,421 $6,431,996 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 HR0011‐17‐2‐0023 PASTEUR HR0011‐17‐2‐0023 $410,141 $6,431,996 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH AND TECHNOLOGY DEVELOPMENT 12.910 2017‐1708150003 VANDERBILT UNIVERSITY 2017‐1708150003 $25,434 $6,431,996 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

TOTAL DEPARTMENT OF DEFENSE $5,620,430 $16,621,906

INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES

PROMOTION OF THE ARTS_GRANTS TO ORGANIZATIONS AND INDIVIDUALS 45.024 1884433‐38‐C‐18 $74,286 $74,286 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TOTAL INSTITUTE OF MUSEUM AND LIBRARY SERVICES OR NATIONAL ENDOWMENT FOR THE ARTS OR NATIONAL ENDOWMENT FOR THE HUMANITIES $74,286

NATIONAL SCIENCE FOUNDATIONENGINEERING GRANTS 47.041 IIP‐1912903 $44,733 $69,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

ENGINEERING GRANTS 47.041 1537659 VANDERBILT UNIVERSITY 1537659 $10,077 $69,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENGINEERING GRANTS 47.041 CBET‐1604426 VANDERBILT UNIVERSITY CBET‐1604426 $2,935 $69,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENGINEERING GRANTS 47.041 CBET‐1605200 VANDERBILT UNIVERSITY CBET‐1605200 $10,783 $69,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENGINEERING GRANTS 47.041 CBET‐1705714 VANDERBILT UNIVERSITY CBET‐1705714 $266 $69,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENGINEERING GRANTS 47.041 IIP‐1819996 VENOSTENT, INC IIP‐1819996 $401 $69,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

COMPUTER AND INFORMATION SCIENCE AND ENGINEERING 47.070 NSF CNS‐1526014 $24,317 $322,535 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315COMPUTER AND INFORMATION SCIENCE AND ENGINEERING 47.070 NSF CNS‐1536871 $17,846 $36,579 $322,535 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315COMPUTER AND INFORMATION SCIENCE AND ENGINEERING 47.070 NSF CNS‐1757644 $170,360 $322,535 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315COMPUTER AND INFORMATION SCIENCE AND ENGINEERING 47.070 NSF IIS‐1418504 $88,339 $322,535 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

COMPUTER AND INFORMATION SCIENCE AND ENGINEERING 47.070 1329737 JOHNS HOPKINS 1329737 ‐$3,170 $322,535 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315COMPUTER AND INFORMATION SCIENCE AND ENGINEERING 47.070 1327566 VANDERBILT UNIVERSITY 1327566 $2,516 $322,535 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315COMPUTER AND INFORMATION SCIENCE AND ENGINEERING 47.070 1750994 VANDERBILT UNIVERSITY 1750994 $3,594 $322,535 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

BIOLOGICAL SCIENCES 47.074 NSF IOS‐1557634 $171,756 $277,582 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOLOGICAL SCIENCES 47.074 1649443 PITTSBURGH 1649443 $8,356 $277,582 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOLOGICAL SCIENCES 47.074 1814520 TENNESSEE 1814520 $97,470 $277,582 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315OFFICE OF INTERNATIONAL SCIENCE AND ENGINEERING 47.079 OISE‐9531011 CRDF OISE‐9531011 $21,052 $21,052 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

TOTAL NATIONAL SCIENCE FOUNDATION $17,846 $690,364

ENVIRONMENTAL PROTECTION AGENCYSCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM 66.509 83927501 MEHARRY 83927501 $39,838 $244,609 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM 66.509 83927501 MEHARRY 83927501 $22,857 $244,609 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM 66.509 83573601 VANDERBILT UNIVERSITY 83573601 $173,291 $244,609 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM 66.509 83573601 VANDERBILT UNIVERSITY 83573601 $5,505 $244,609 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315SCIENCE TO ACHIEVE RESULTS (STAR) RESEARCH PROGRAM 66.509 83573601 VANDERBILT UNIVERSITY 83573601 $3,118 $244,609 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

TOTAL ENVIRONMENTAL PROTECTION AGENCY $244,609

DEPARTMENT OF ENERGYEPIDEMIOLOGY AND OTHER HEALTH STUDIES FINANCIAL ASSISTANCE PROGRAM 81.108 DE‐AU000042 NCRPM DE‐AU000042 $10,416 $10,416 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NUCLEAR ENERGY RESEARCH, DEVELOPMENT AND DEMONSTRATION 81.121 DE‐NE0008664 VIRGINIA TECH DE‐NE0008664 $59,659 $59,659 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL NUCLEAR SECURITY ADMINISTRATION (NNSA) MINORITY SERVING INSTITUTIONS (MSI) PROGRAM 81.123 DE‐NA0003525 SANDIA DE‐NA0003525 $305,556 $305,556 OTHER AWARDS $40,431,607

TOTAL DEPARTMENT OF ENERGY $375,631

DEPARTMENT OF EDUCATIONSPECIAL EDUCATION_GRANTS TO STATES 84.027 45026:ST TN TN EDUCATION 45026:ST TN $325,786 $2,902,786 SPECIAL EDUCATION CLUSTER (IDEA) $3,090,600SPECIAL EDUCATION_GRANTS TO STATES 84.027 45237:ST TN TN EDUCATION 45237:ST TN $5,325 $2,517,681 $2,902,786 SPECIAL EDUCATION CLUSTER (IDEA) $3,090,600SPECIAL EDUCATION_GRANTS TO STATES 84.027 33136‐00718 VANDERBILT UNIVERSITY 33136‐00718 $4,462 $2,902,786 SPECIAL EDUCATION CLUSTER (IDEA) $3,090,600SPECIAL EDUCATION_GRANTS TO STATES 84.027 H027A140052‐14A VANDERBILT UNIVERSITY H027A140052‐14A $54,857 $2,902,786 SPECIAL EDUCATION CLUSTER (IDEA) $3,090,600REHABILITATION SERVICES_VOCATIONAL REHABILITATION GRANTS TO STATES 84.126 49497:ST TN TN HUMAN SERVICES 49497:ST TN ‐$945 $34,465 OTHER AWARDS $40,431,607REHABILITATION SERVICES_VOCATIONAL REHABILITATION GRANTS TO STATES 84.126 57672:ST TN VANDERBILT UNIVERSITY 57672:ST TN $35,410 $34,465 OTHER AWARDS $40,431,607SPECIAL EDUCATION_PRESCHOOL GRANTS 84.173 49454:ST TN TN EDUCATION 49454:ST TN $188,155 $187,814 SPECIAL EDUCATION CLUSTER (IDEA) $3,090,600SPECIAL EDUCATION_PRESCHOOL GRANTS 84.173 49454:ST TN TN EDUCATION 49454:ST TN ‐$341 $187,814 SPECIAL EDUCATION CLUSTER (IDEA) $3,090,600SPECIAL EDUCATION‐GRANTS FOR INFANTS AND FAMILIES 84.181 49965:ST TN TN EDUCATION 49965:ST TN $547,320 $895,250 OTHER AWARDS $40,431,607


41




SPECIAL EDUCATION‐GRANTS FOR INFANTS AND FAMILIES 84.181 49965:ST TN TN EDUCATION 49965:ST TN $712 $895,250 OTHER AWARDS $40,431,607SPECIAL EDUCATION‐GRANTS FOR INFANTS AND FAMILIES 84.181 54078:ST TN TN EDUCATION 54078:ST TN ‐$271 $895,250 OTHER AWARDS $40,431,607SPECIAL EDUCATION‐GRANTS FOR INFANTS AND FAMILIES 84.181 54078:ST TN TN EDUCATION 54078:ST TN $347,489 $895,250 OTHER AWARDS $40,431,607

RESEARCH IN SPECIAL EDUCATION 84.324 R 324 A160300 $283,520 $318,866 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH IN SPECIAL EDUCATION 84.324 R 324 A180171 VANDERBILT UNIVERSITY R 324 A180171 $35,346 $318,866 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

SPECIAL EDUCATION ‐ PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES 84.325 H 325 K160370 $314 $223,657 OTHER AWARDS $40,431,607SPECIAL EDUCATION ‐ PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES 84.325 H 325 K160371 $214,013 $223,657 OTHER AWARDS $40,431,607

SPECIAL EDUCATION ‐ PERSONNEL DEVELOPMENT TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES 84.325 H 325 D140087‐17 VANDERBILT UNIVERSITY H 325 D140087‐17 $9,330 $223,657 OTHER AWARDS $40,431,607

SPECIAL EDUCATION_TECHNICAL ASSISTANCE AND DISSEMINATION TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES 84.326 H 326 T150002 $240,836 $293,898 OTHER AWARDS $40,431,607SPECIAL EDUCATION_TECHNICAL ASSISTANCE AND DISSEMINATION TO IMPROVE SERVICES AND RESULTS FOR CHILDREN WITH DISABILITIES 84.326 H 326 T180048 $53,062 $293,898 OTHER AWARDS $40,431,607

TRANSITION PROGRAMS FOR STUDENTS WITH INTELLECTUAL DISABILITIES INTO HIGHER EDUCATION 84.407 P407A150058‐18 VANDERBILT UNIVERSITY P407A150058‐18 $21,473 $21,473 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

TOTAL DEPARTMENT OF EDUCATION $5,325 $4,878,209

DEPARTMENT OF HEALTH AND HUMAN SERVICESGLOBAL AIDS 93.067 6 NU2GGH001943‐02‐05 $820,402 $9,654,528 $31,174,753 OTHER AWARDS $40,431,607GLOBAL AIDS 93.067 6 NU2GGH001943‐03‐10 $513,034 $21,526,675 $31,174,753 OTHER AWARDS $40,431,607GLOBAL AIDS 93.067 6 NU2GGH002071‐01‐03 ‐$6,450 $31,174,753 OTHER AWARDS $40,431,607BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES ‐ PREVENTION AND SURVEILLANCE 93.073 5 NU53 DD000001‐03‐03 $215,258 $215,258 OTHER AWARDS $40,431,607

HOSPITAL PREPAREDNESS PROGRAM (HPP) AND PUBLIC HEALTH EMERGENCY PREPAREDNESS (PHEP) ALIGNED COOPERATIVE AGREEMENTS 93.074 54788:ST TN TN HEALTH 54788:ST TN $249,976 $249,976 OTHER AWARDS $40,431,607BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH 93.080 5 NU27 DD001155‐03‐00 NORTH CAROLINA 5 NU27 DD001155‐03‐00 $19,194 $34,054 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISORDER PROGRAM: PREVENTION, SURVEILLANCE, AND RESEARCH 93.080 6 NU27 DD001155‐04‐02 NORTH CAROLINA 6 NU27 DD001155‐04‐02 $14,860 $34,054 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES 93.083 3 U01 IP000979‐03S1 ‐$3,957 $623,924 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES 93.083 5 U01 IP000979‐04 $37,471 $64,060 $623,924 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

PREVENTION OF DISEASE, DISABILITY, AND DEATH THROUGH IMMUNIZATION AND CONTROL OF RESPIRATORY AND RELATED DISEASES 93.083 5 U01 IP000979‐05 $42,179 $563,821 $623,924 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

PREVENTION OF DISEASE, DISABILITY, AND DEATH BY INFECTIOUS DISEASES 93.084 1 U01 CK000512‐01 TEXAS 1 U01 CK000512‐01 $24,534 $24,534 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 7 R01 FD004117‐05 $5,824 $24,106 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 5 R01 FD004778‐03 $17,758 $17,758 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 5 R01 FD004778‐04 $161,707 $387,760 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF22301610046C COLORADO HHSF22301610046C $2,167 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF223201400042I HARVARD PILGRIM HHSF223201400042I $65,884 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF223201400042I HARVARD PILGRIM HHSF223201400042I $6,132 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF223201400042I HARVARD PILGRIM HHSF223201400042I $25,650 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF22320140030I HARVARD PILGRIM HHSF22320140030I $179,149 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF22320140030I HARVARD PILGRIM HHSF22320140030I $55,491 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF22320140030I HARVARD PILGRIM HHSF22320140030I $15,454 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF22320140030I HARVARD PILGRIM HHSF22320140030I $1,563 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF22320140030I HARVARD PILGRIM HHSF22320140030I $5,370 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF22320140030I HARVARD PILGRIM HHSF22320140030I $12,542 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF223201710132C HARVARD PILGRIM HHSF223201710132C $36,845 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315FOOD AND DRUG ADMINISTRATION_RESEARCH 93.103 HHSF2230160100C ICON CLINICAL RESEARCH HHSF2230160100C ‐$8,218 $827,653 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315COMPREHENSIVE COMMUNITY MENTAL HEALTH SERVICES FOR CHILDREN WITH SERIOUS EMOTIONAL DISTURBANCES (SED) 93.104 60896:ST TN

TN MENTAL HEALTH DEVELOPMENTAL 60896:ST TN $68,395 $68,395 OTHER AWARDS $40,431,607

MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 4 R40 MC30769‐01‐02 $1,476 $3,266,533 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 5 H30 MC24046‐04‐00 HOG 5 H30 MC24046‐04‐00 $2,481,893 $3,266,533 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 6 H30 MC24046‐07‐01 HOG 6 H30 MC24046‐07‐01 $14,997 $3,266,533 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


42




MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 5 H30 MC24046‐08‐00 HOG 5 H30 MC24046‐08‐00 $1,351 $3,266,533 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 5 UA3 MC11054‐08‐00 MASSACHUSETTS 5 UA3 MC11054‐08‐00 $12,617 $3,266,533 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 6 UA3 MC11054‐10‐00 MASSACHUSETTS 6 UA3 MC11054‐10‐00 $5,382 $3,266,533 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 7 T73 MC30767‐01‐00 $25,683 $33,634 $3,266,533 OTHER AWARDS $40,431,607MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 5 T73 MC30767‐02‐00 $115,201 $125,420 $3,266,533 OTHER AWARDS $40,431,607MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 7 T73 MC30767‐03‐01 $3,220 $556,866 $3,266,533 OTHER AWARDS $40,431,607

MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 6 UA3 MC11054‐09‐00 MASSACHUSETTS 6 UA3 MC11054‐09‐00 $8,525 $3,266,533 OTHER AWARDS $40,431,607MATERNAL AND CHILD HEALTH FEDERAL CONSOLIDATED PROGRAMS 93.110 6 UA3 MC11054‐10‐00 MASSACHUSETTS 6 UA3 MC11054‐10‐00 $24,372 $3,266,533 OTHER AWARDS $40,431,607

ENVIRONMENTAL HEALTH 93.113 5 R01 ES014942‐11 ‐$5,700 $53,043 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENVIRONMENTAL HEALTH 93.113 5 R01 ES016931‐11 $3,141 $10,679 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENVIRONMENTAL HEALTH 93.113 6 R01 ES022936‐06 $120,457 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

ENVIRONMENTAL HEALTH 93.113 5 R01 ES007331‐23 AECOM 5 R01 ES007331‐23 $7,773 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENVIRONMENTAL HEALTH 93.113 5 R01 ES007331‐24 AECOM 5 R01 ES007331‐24 $56,579 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENVIRONMENTAL HEALTH 93.113 2 R01 ES010563‐17 AECOM 2 R01 ES010563‐17 $78,702 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENVIRONMENTAL HEALTH 93.113 1 R01 ES027845‐01A1 COLUMBIA 1 R01 ES027845‐01A1 $23,862 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENVIRONMENTAL HEALTH 93.113 6 R01 ES010563‐18 PURDUE 6 R01 ES010563‐18 $32,443 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENVIRONMENTAL HEALTH 93.113 7 R01 ES016931‐12 PURDUE 7 R01 ES016931‐12 $132,002 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ENVIRONMENTAL HEALTH 93.113 5 T32 ES007028‐44 VANDERBILT UNIVERSITY 5 T32 ES007028‐44 $1,398 $516,938 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315PROJECT GRANTS AND COOPERATIVE AGREEMENTS FOR TUBERCULOSIS CONTROL PROGRAMS 93.116 200‐2011‐41276 DUKE 200‐2011‐41276 $36,504 $106,265 $144,965 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315PROJECT GRANTS AND COOPERATIVE AGREEMENTS FOR TUBERCULOSIS CONTROL PROGRAMS 93.116 200‐2011‐41276 DUKE 200‐2011‐41276 $21,006 $38,700 $144,965 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

ORAL DISEASES AND DISORDERS RESEARCH 93.121 1 K23 DE028010‐01A1 $26,542 $640,100 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ORAL DISEASES AND DISORDERS RESEARCH 93.121 1 R01 DE027749‐01 $69,941 $535,894 $640,100 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

ORAL DISEASES AND DISORDERS RESEARCH 93.121 7 R01 DE024982‐04 PENNSYLVANIA 7 R01 DE024982‐04 $63,267 $640,100 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ORAL DISEASES AND DISORDERS RESEARCH 93.121 1 R03 DE027494‐01 TEXAS HEALTH SCIENCE HOUSTON 1 R03 DE027494‐01 $14,397 $640,100 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

EMERGENCY MEDICAL SERVICES FOR CHILDREN 93.127 2 H33 MC31540‐02‐00 $103,390 $132,934 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EMERGENCY MEDICAL SERVICES FOR CHILDREN 93.127 5 H33MC31540‐03‐00 $29,544 $132,934 OTHER AWARDS $40,431,607

INJURY PREVENTION AND CONTROL RESEARCH AND STATE AND COMMUNITY BASED PROGRAMS 93.136 1 R01 CE003009‐01‐00 NORTH CAROLINA 1 R01 CE003009‐01‐00 $14,571 $14,571 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM 93.137 1 CPI MP171157‐01‐00 MEHARRY 1 CPI MP171157‐01‐00 $15,026 $62,485 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315COMMUNITY PROGRAMS TO IMPROVE MINORITY HEALTH GRANT PROGRAM 93.137 5 CPI MP171157‐02‐00 MEHARRY 5 CPI MP171157‐02‐00 $47,459 $62,485 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

AIDS EDUCATION AND TRAINING CENTERS 93.145 5 U1O HA30535‐02‐00 $1,012,205 $1,042,144 $4,598,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AIDS EDUCATION AND TRAINING CENTERS 93.145 5 U1O HA30535‐03‐00 $2,453,794 $3,530,120 $4,598,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

AIDS EDUCATION AND TRAINING CENTERS 93.145 5 U1O HA28686‐03‐00 RUTGERS NEW JERSEY 5 U1O HA28686‐03‐00 $6,054 $6,538 $4,598,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AIDS EDUCATION AND TRAINING CENTERS 93.145 5 U1O HA28686‐04‐00 RUTGERS NEW JERSEY 5 U1O HA28686‐04‐00 $19,393 $4,598,195 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH 93.153 2 H12 HA030750‐02 $28,853 $500,743 OTHER AWARDS $40,431,607COORDINATED SERVICES AND ACCESS TO RESEARCH FOR WOMEN, INFANTS, CHILDREN, AND YOUTH 93.153 5 H12 HA030750‐03 $471,890 $500,743 OTHER AWARDS $40,431,607HUMAN GENOME RESEARCH 93.172 HHSN268201600002P $626 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 R01 HG006844‐08 $100,488 $436,599 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 7 R01 HG007733‐04 $37,766 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 RM1 HG009034‐02 $295,218 $295,218 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 RM1 HG009034‐03 $275,640 $848,361 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 RM1 HG009034‐04 $120,202 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 3 R01 HG009694‐02S1 $58,065 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 R01 HG009694‐03 $444,727 $712,915 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 T32 HG008341‐02 $259 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 T32 HG008341‐03 $205,607 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 U01 HG007253‐04 $270,406 $1,104,236 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 U01 HG008672‐03 ‐$16,365 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 U01 HG008672‐04 $253,104 $1,237,743 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 U01 HG008701‐03 $61,239 $61,239 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 U01 HG008701‐04 $775,891 $1,521,523 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 1 U01 HG010232‐01 $39,932 $193,577 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

HUMAN GENOME RESEARCH 93.172 1 U24 HG010262‐01 BIMH 1 U24 HG010262‐01 $51,447 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 1 R01 HG010004‐01A1 BOSTON CHILDREN'S 1 R01 HG010004‐01A1 $53,722 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


43




HUMAN GENOME RESEARCH 93.172 5 R01 HG010004‐02 BOSTON CHILDREN'S 5 R01 HG010004‐02 $25,295 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 1 R01 HG010365‐01 COLUMBIA 1 R01 HG010365‐01 $25,193 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 R01 HG008605‐03 MINNESOTA 5 R01 HG008605‐03 $126,552 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 1 R01 HG009914‐01 UNIV OF LOUISVILLE 1 R01 HG009914‐01 $108,457 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 R01 HG009914‐02 UNIV OF LOUISVILLE 5 R01 HG009914‐02 $40,283 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 U01 HG009086‐03 VANDERBILT UNIVERSITY 5 U01 HG009086‐03 $75,412 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 U01 HG009086‐03 VANDERBILT UNIVERSITY 5 U01 HG009086‐03 $344,235 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HUMAN GENOME RESEARCH 93.172 5 R01 HG007879‐03 WASHINGTON 5 R01 HG007879‐03 $70,122 $7,738,289 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 F32 DC015726‐02 $4,255 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 F32 DC015726‐03 $13,479 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 F32 DC016580‐01 $9,389 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 F32 DC016580‐02 $48,878 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 K18 DC017383‐01 $134,089 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC008408‐12 $346,234 $511,331 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 7 R01 DC011755‐06 $15,942 $53,903 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC011777‐06 $209,209 $514,375 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC013117‐06 $196,142 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC013270‐04 $620,754 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R03 DC014802‐04 $2,996 $41,736 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R03 DC014809‐04 $3,936 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R03 DC015075‐03 $108,595 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC015388‐03 $315,071 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC015405‐03 $25,558 $34,958 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R01 DC015988‐02 $94,662 $457,319 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 U01 DC016033‐01A1 $554,644 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R21 DC016080‐02 $87,865 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R21 DC016144‐03 $226,314 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R01 DC016236‐01A1 $49,878 $61,025 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R01 DC016643‐01 $159,460 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R21 DC016710‐02 $234,358 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R01 DC016977‐01A1 $91,999 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R01 DC017175‐01 $515,281 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R01 DC017683‐01A1 $52,573 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC09404‐10 $11,166 $436,711 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R21 DC16723‐01A1 $150,360 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 T35 DC008763‐13 $16,133 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 2 T35 DC08763‐12A1 $7,149 $20,213 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R01 DC016643‐01 BTNRH 1 R01 DC016643‐01 $32,242 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 4 R24 DC122707‐05 CHILDRENS PHILADELPHIA 4 R24 DC122707‐05 $25,203 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 P50 DC015857‐01A1 HARVARD 1 P50 DC015857‐01A1 $7,099 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R44 DC015920‐02 INTELLIGENT HEARING 5 R44 DC015920‐02 $190,128 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R01 DC015997‐01A1 IOWA 1 R01 DC015997‐01A1 $90,616 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 P50 DC015857‐02 MASSACHUSETTS EYE EAR 1 P50 DC015857‐02 $71,992 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R01 DC017078‐01 MASSACHUSETTS EYE EAR 1 R01 DC017078‐01 $58,025 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC017078‐02 MASSACHUSETTS EYE EAR 5 R01 DC017078‐02 $30,359 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R43 DC016780‐01 MIMOSA 1 R43 DC016780‐01 $68,148 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC015780‐02 NATHAN KLINE INSTITUTE 5 R01 DC015780‐02 $5,611 $27,942 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC015780‐03 NATHAN KLINE INSTITUTE 5 R01 DC015780‐03 $1,053 $40,132 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC003937‐19 NEW YORK 5 R01 DC003937‐19 $25,083 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 7 R01 DC015405‐04 PITTSBURGH 7 R01 DC015405‐04 $72,377 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 U01 DC014706‐02 UTAH 5 U01 DC014706‐02 $1,019 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


44




RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC013767‐04 VANDERBILT UNIVERSITY 5 R01 DC013767‐04 $12,109 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC013767‐04 VANDERBILT UNIVERSITY 5 R01 DC013767‐04 ‐$94 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC013767‐04 VANDERBILT UNIVERSITY 5 R01 DC013767‐04 $6,325 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC013767‐05 VANDERBILT UNIVERSITY 5 R01 DC013767‐05 $8,024 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC014037‐05 VANDERBILT UNIVERSITY 5 R01 DC014037‐05 $25,550 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R01 DC014462‐03 VANDERBILT UNIVERSITY 5 R01 DC014462‐03 $228,647 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R21 DC016153‐01A1 VANDERBILT UNIVERSITY 1 R21 DC016153‐01A1 $33,887 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R41 DC016578‐01 VISISONICS 1 R41 DC016578‐01 $18,029 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 5 R03 DC015329‐02 WAYNE STATE 5 R03 DC015329‐02 $11,152 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH RELATED TO DEAFNESS AND COMMUNICATION DISORDERS 93.173 1 R21 DC016724‐01A1 WISCONSIN 1 R21 DC016724‐01A1 $9,078 $6,768,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS 93.185 5 U01 IP001063‐02 $200,892 $1,806,809 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

IMMUNIZATION RESEARCH, DEMONSTRATION, PUBLIC INFORMATION AND EDUCATION_TRAINING AND CLINICAL SKILLS IMPROVEMENT PROJECTS 93.185 5 U01 IP001063‐03 $1,112,982 $1,806,809 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315



RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 5 R01 AT004821‐10 $222 $66,699 $275,928 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 5 R61 AT009340‐02 $27,799 $275,928 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 5 UH2 AT009145‐03 BROWN 5 UH2 AT009145‐03 $2,099 $275,928 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 5 UH3 AT009145‐04 BROWN 5 UH3 AT009145‐04 $10,684 $275,928 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 3 U54 AT007748‐05S1 DUKE 3 U54 AT007748‐05S1 $95,282 $275,928 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 1 R01 AT009680‐01A1 RUSH MEDICAL CENTER 1 R01 AT009680‐01A1 $73,988 $275,928 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH AND TRAINING IN COMPLEMENTARY AND INTEGRATIVE HEALTH 93.213 4 R01 AT007830‐04 VANDERBILT UNIVERSITY 4 R01 AT007830‐04 ‐$623 $275,928 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

NATIONAL RESEARCH SERVICE AWARDS_HEALTH SERVICES RESEARCH TRAINING 93.225 1 T32 HS026122‐01 $191,034 $191,034 OTHER AWARDS $40,431,607RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 1 R18 HS025931‐01A1 $11,073 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 5 K12 HS022990‐04 $12,328 $56,791 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 5 K12 HS022990‐05 $255,512 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 1 K12 HS026395‐01 $185,398 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 6 R01 HS021496‐04 $102,178 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 6 R01 HS022093‐02 ‐$1 ‐$1 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 6 R01 HS022093‐02 $15,977 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 6 R01 HS022640‐02 $135,131 $135,131 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 6 R01 HS022640‐02 ‐$40,890 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 7 R03 HS024637‐02 $26,028 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 1 R01 HS025976‐01A1 $186,953 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 5 R03 HS026069‐02 $48,307 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 1 R18 HS026158‐01 $38,739 $203,714 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 1 R18 HS026616‐01 $219,255 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 1 R18 HS223757‐01A1 BWH 1 R18 HS223757‐01A1 $6,260 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 1 R01 HS025979‐01A1 CAROLINAS 1 R01 HS025979‐01A1 $2,492 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 5 R01 HS023306‐04 INDIANA 5 R01 HS023306‐04 $27,013 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


45




RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 5 R01 HS025411‐02 INDIANA 5 R01 HS025411‐02 $4,346 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 5 U18 HS025291‐02 SEATTLE CHILDREN'S HOSP 5 U18 HS025291‐02 $4,104 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH ON HEALTHCARE COSTS, QUALITY AND OUTCOMES 93.226 5 U18 HS025291‐03 SEATTLE CHILDREN'S HOSP 5 U18 HS025291‐03 $35,985 $1,485,626 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

POLICY RESEARCH AND EVALUATION GRANTS 93.239 HHSP223201700050C $3,442 $5,438 $200,310 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315POLICY RESEARCH AND EVALUATION GRANTS 93.239 HHSP233201700036C $72,575 $94,775 $200,310 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315POLICY RESEARCH AND EVALUATION GRANTS 93.239 HHSP233201700051C $100,097 $200,310 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 F32 MH112263‐01A1 $6,282 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 F32 MH112263‐02 $54,959 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 K01 MH103500‐05 $83,010 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 K01 MH107255‐04 $121,664 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 K01 MH107256‐04 $28,546 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 K24 MH110598‐03 $176,514 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 K23 MH116339‐03 $149,708 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH070560‐11 $187,718 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH100096‐07 $672 $371,418 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH102246‐06 $8,721 $496,676 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH102266‐05 $118,644 $460,460 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH102272‐05 $293,259 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 6 R34 MH104428‐03 $45,186 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 7 R01 MH106511‐03 $80,185 $256,305 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH107435‐04 $60,485 $379,661 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R24 MH109105‐04 $31,636 $160,825 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R21 MH109225‐03 $27,288 $91,244 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R21 MH111567‐02 $77,944 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH111599‐03 $469,182 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH111776‐03 $189,415 $513,923 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH111877‐03 $86,348 $446,910 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R03 MH112783‐02 $19,782 $59,795 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R21 MH113262‐03 $189,632 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH113362‐03 $98,504 $1,264,579 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH113438‐02 $125,270 $295,683 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R01 MH113478‐01 $74,859 $487,462 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH113576‐02 $25,934 $398,142 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R01 MH114906‐01 $356,414 $613,576 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH115000‐02 $206,394 $318,984 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R01 MH116058‐01A1 $21,791 $94,253 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R01 MH116269‐01A1 $33,791 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R21 MH118539‐01 $17,417 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH100030‐05 CALIFORNIA DAVIS 5 R01 MH100030‐05 $14,177 $22,037 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R01 MH107467‐02 CALIFORNIA UCSF 1 R01 MH107467‐02 $20,754 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R01 MH107666‐01 CHICAGO 1 R01 MH107666‐01 ‐$1,444 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 3 U19 MH113136‐02S3 JOHNS HOPKINS 3 U19 MH113136‐02S3 $31,172 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R01 MH118223‐01 MASSACHUSETTS 1 R01 MH118223‐01 $5,690 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 U01 MH110925‐02 NORTH CAROLINA 5 U01 MH110925‐02 $8,166 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 U01 MH110925‐03 NORTH CAROLINA 5 U01 MH110925‐03 $4,781 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 U01 MH110925‐03 NORTH CAROLINA 5 U01 MH110925‐03 $41,977 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R01 MH098260‐05 PENNSYLVANIA 5 R01 MH098260‐05 $45,934 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 R33 MH103518‐05 VANDERBILT UNIVERSITY 5 R33 MH103518‐05 $41,402 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R21 MH111548‐01 VANDERBILT UNIVERSITY 1 R21 MH111548‐01 $38,106 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 T32 MH018921‐28 VANDERBILT UNIVERSITY 5 T32 MH018921‐28 $60,366 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 1 R01 MH112913‐01A1 WISCONSIN 1 R01 MH112913‐01A1 $127,021 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MENTAL HEALTH RESEARCH GRANTS 93.242 5 U01 MH112913‐02 WISCONSIN 5 U01 MH112913‐02 $16,402 $9,107,072 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES_PROJECTS OF REGIONAL AND NATIONAL SIGNIFICANCE 93.243 1 H79 SP021359‐03 MEHARRY 1 H79 SP021359‐03 $4,501 $4,501 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

POISON CENTER SUPPORT AND ENHANCEMENT GRANT PROGRAM 93.253 5 H4B HS30752‐02‐00 $66,767 $377,230 OTHER AWARDS $40,431,607POISON CENTER SUPPORT AND ENHANCEMENT GRANT PROGRAM 93.253 5 H4B HS30752‐03‐00 $310,463 $377,230 OTHER AWARDS $40,431,607OCCUPATIONAL SAFETY AND HEALTH PROGRAM 93.262 200‐2015‐63553 $737,093 $764,485 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

OCCUPATIONAL SAFETY AND HEALTH PROGRAM 93.262 1 R21 OH011452‐01‐00 CALIFORNIA UCSF 1 R21 OH011452‐01‐00 $27,392 $764,485 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HEALTH SYSTEMS STRENGTHENING AND HIV/AIDS PREVENTION, CARE AND TREATMENT UNDER THE PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF 93.266 1 R01 HS025411‐01 INDIANA 1 R01 HS025411‐01 ‐$3,438 ‐$3,438 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

IMMUNIZATION COOPERATIVE AGREEMENTS 93.268 200‐2012‐50430 $279,720 $509,003 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315IMMUNIZATION COOPERATIVE AGREEMENTS 93.268 200‐2012‐50430 $98,008 $509,003 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315IMMUNIZATION COOPERATIVE AGREEMENTS 93.268 200‐2012‐50430 $100,847 $509,003 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315IMMUNIZATION COOPERATIVE AGREEMENTS 93.268 200‐2012‐50430 $14,407 $509,003 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


46




IMMUNIZATION COOPERATIVE AGREEMENTS 93.268 200‐2017‐M‐94349 $8,468 $15,881 $509,003 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315IMMUNIZATION COOPERATIVE AGREEMENTS 93.268 200‐2013‐F‐57544 ABT ASSOCIATES 200‐2013‐F‐57544 $140 $509,003 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

ALCOHOL RESEARCH PROGRAMS 93.273 1 R21 AA025385‐02 $8,372 $109,299 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 5 R01 AA026186‐03 $22,034 $344,089 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 1 U01 AA026222‐01 $181,050 $201,282 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 5 U01 AA026222‐02 $129,567 $213,679 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

ALCOHOL RESEARCH PROGRAMS 93.273 1 R01 AA025859‐01 BOSTON MEDICAL 1 R01 AA025859‐01 $4,115 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 1 R01 AA025859‐02 BOSTON MEDICAL 1 R01 AA025859‐02 $24,031 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 5 U01 AA020780‐07 BOSTON MEDICAL 5 U01 AA020780‐07 $17,763 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 5 U01 AA020780‐08 BOSTON MEDICAL 5 U01 AA020780‐08 $78,083 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 5 U01 AA021989‐05 BOSTON MEDICAL 5 U01 AA021989‐05 $2,750 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 1 U01 AA026209‐01 BRISTOL 1 U01 AA026209‐01 $19,669 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 7 R03 AA026099‐02 OCF 7 R03 AA026099‐02 $8,507 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 1 U01 AA026224‐01 YALE 1 U01 AA026224‐01 $29,647 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALCOHOL RESEARCH PROGRAMS 93.273 5 U01 AA026224‐02 YALE 5 U01 AA026224‐02 $27,809 $1,080,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 5 K23 DA038720‐05 $147,928 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 5 R01 DA037891‐05 $142,351 $521,328 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 5 R01 DA040630‐04 $590,429 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 1 R01 DA045729‐01 $21,626 $514,804 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 1 R21 DA043960‐01A1 ALABAMA 1 R21 DA043960‐01A1 $32,486 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 5 UG1 DA040317‐04 DUKE 5 UG1 DA040317‐04 $14,070 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 5 UG1 DA040317‐05 DUKE 5 UG1 DA040317‐05 $1,509 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 5 R01 DA034629‐05 PITTSBURGH 5 R01 DA034629‐05 $28,833 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 5 R01 DA039522‐04 RUSH MEDICAL CENTER 5 R01 DA039522‐04 $36,517 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DRUG ABUSE AND ADDICTION RESEARCH PROGRAMS 93.279 1 R21 DA020149‐01A2 VANDERBILT UNIVERSITY 1 R21 DA020149‐01A2 ‐$2,569 $1,885,335 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CENTERS FOR DISEASE CONTROL AND PREVENTION_INVESTIGATIONS AND TECHNICAL ASSISTANCE 93.283 52614:ST TN TN HEALTH 52614:ST TN ‐$6,718 ‐$6,718 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 F32 EB021840‐03 $10 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB017767‐05 $156,101 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 6 R21 EB018033‐03 $7 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB018992‐04 $282,219 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB020666‐04 $257,451 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R21 EB021012‐02 $51,599 $159,843 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB024525‐02 $416,609 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R21 EB025258‐02 $80,593 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB026991‐02 $10,701 $115,928 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 T32 EB001628‐15 $4,234 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 2 T32 EB001628‐16 $254,690 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 U01 EB021214‐04 CALIFORNIA UCSF 5 U01 EB021214‐04 $607,191 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB014308‐04 VANDERBILT UNIVERSITY 5 R01 EB014308‐04 $160,394 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 2 R01 EB016695‐05 VANDERBILT UNIVERSITY 2 R01 EB016695‐05 $115,742 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB017230‐04 VANDERBILT UNIVERSITY 5 R01 EB017230‐04 $88,411 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 1 R01 EB019409‐03 VANDERBILT UNIVERSITY 1 R01 EB019409‐03 $30,531 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB019409‐05 VANDERBILT UNIVERSITY 5 R01 EB019409‐05 $9,163 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB019409‐05 VANDERBILT UNIVERSITY 5 R01 EB019409‐05 $7,326 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB019980‐04 VANDERBILT UNIVERSITY 5 R01 EB019980‐04 $37,225 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


47




DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 5 R01 EB023717‐02 VANDERBILT UNIVERSITY 5 R01 EB023717‐02 $74,314 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 1 R21 EB024199‐02 VANDERBILT UNIVERSITY 1 R21 EB024199‐02 $30,835 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 1 R01 EB024864‐01 VANDERBILT UNIVERSITY 1 R01 EB024864‐01 $11,539 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DISCOVERY AND APPLIED RESEARCH FOR TECHNOLOGICAL INNOVATIONS TO IMPROVE HUMAN HEALTH 93.286 1 R01 EB026901‐01A1 VANDERBILT UNIVERSITY 1 R01 EB026901‐01A1 $16,420 $2,916,776 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 5 U54 MD010722‐02 $107,202 $107,202 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 5 U54 MD010722‐03 $1,449,687 $2,204,360 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 5 U54 MD010722‐04 $241,158 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 1 R01 MD013493‐01 DUKE 1 R01 MD013493‐01 $16,311 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 5 R01 MD013493‐02 DUKE 5 R01 MD013493‐02 $10,026 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 5 U54 MD007586‐32 MEHARRY 5 U54 MD007586‐32 $18,229 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 5 U54 MD007586‐32 MEHARRY 5 U54 MD007586‐32 $35,680 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 5 U54 MD007586‐32 MEHARRY 5 U54 MD007586‐32 $16,045 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 2 U54 MD007593‐07 MEHARRY 2 U54 MD007593‐07 $10,685 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 5 U54 MD007593‐10 MEHARRY 5 U54 MD007593‐10 $43,844 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 5 U54 MD008173‐04 MSM 5 U54 MD008173‐04 $9,420 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MINORITY HEALTH AND HEALTH DISPARITIES RESEARCH 93.307 1 U54 MD012397‐01A1 SAN DIEGO 1 U54 MD012397‐01A1 $8,763 $2,721,723 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

TRANS‐NIH RESEARCH SUPPORT 93.310 1 DP2 HD098859‐01 $192,732 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 6 OT2 OD023132‐02 $8,211 $615,798 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 3 OT2 OD023850‐01 $92,935 $546,178 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 1 R21 GM118944‐01 ‐$18,588 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 5 UH2 CA203708‐02 $104,966 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 5 U01 HG007674‐05 $325,431 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 2 U01 HG007674‐06 $1,322,655 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 5 U2C OD023196‐02 $3,835,110 $16,400,424 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

TRANS‐NIH RESEARCH SUPPORT 93.310 5 UG3 OD023320‐02 AECOM 5 UG3 OD023320‐02 $22,647 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 4 UH3 OD023320‐03 AECOM 4 UH3 OD023320‐03 $162,550 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 5 U54 GM119023‐01 BOSTON COLLEGE 5 U54 GM119023‐01 $11,070 $12,064 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 5 U54 GM119023‐05 BOSTON COLLEGE 5 U54 GM119023‐05 $219,059 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 5 U2C OD023375‐02 DUKE 5 U2C OD023375‐02 $6,308 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 8 U54 GM119023‐03 FISK 8 U54 GM119023‐03 ‐$15,704 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 1 U24 OD023319‐01 NORTHWESTERN 1 U24 OD023319‐01 $28,705 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 1 U24 OD023319‐03 NORTHWESTERN 1 U24 OD023319‐03 $144,829 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 1 OT3 OD025460‐01 SANTA CRUZ 1 OT3 OD025460‐01 $13,980 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 1 U54 DK120058‐01 VANDERBILT UNIVERSITY 1 U54 DK120058‐01 $83,243 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 5 UG3 OD023271‐02 WASHINGTON 5 UG3 OD023271‐02 $14,549 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 4 UH3 OD023271‐03 WASHINGTON 4 UH3 OD023271‐03 $86,279 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 5 UG3 OD023282‐02 WISCONSIN 5 UG3 OD023282‐02 $147,429 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 5 UG3 OD023282‐02 WISCONSIN 5 UG3 OD023282‐02 $53,460 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315TRANS‐NIH RESEARCH SUPPORT 93.310 4 UH3 OD023282‐03 WISCONSIN 4 UH3 OD023282‐03 $1,103,919 $21,572,913 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION 93.315 5 U01 DD001073‐05 $23,250 $90,515 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION 93.315 5 U01 DD001073‐06 $44,789 $90,515 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION 93.315 5 U01 DD001075‐05 $5,728 $90,515 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RARE DISORDERS: RESEARCH, SURVEILLANCE, HEALTH PROMOTION, AND EDUCATION 93.315 5 U01 DD001075‐06 $16,748 $90,515 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

EMERGING INFECTIONS PROGRAMS 93.317 59293:ST TN TN HEALTH 59293:ST TN $2,570,315 $2,570,315 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC) 93.323 56372:ST TN TN HEALTH 56372:ST TN $33,736 $41,891 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EPIDEMIOLOGY AND LABORATORY CAPACITY FOR INFECTIOUS DISEASES (ELC) 93.323 61814:ST TN TN HEALTH 61814:ST TN $8,155 $41,891 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 KL2 TR002245‐02 $101,710 $599,843 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 1 R13 TR001694‐01A1 $6,788 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 R21 TR001723‐02 $83,346 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 U24 TR001579‐04 $249 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 KL2 TR002245‐03 $255,806 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 1 TL1 TR002244‐01 ‐$219 $0 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 TL1 TR002244‐02 ‐$837 $274,596 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 TL1 TR002244‐03 $80,979 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 6 UL1 TR000445‐11 ‐$580 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


48




NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 U24 TR001579‐02 $148,058 $225,781 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 U24 TR001579‐03 $361,613 $5,117,596 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 UL1 TR002243‐02 $484,801 $6,206,956 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 UL1 TR002243‐03 $1,234 $1,100,043 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 1 U01 TR002398‐01 $173,690 $717,602 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 U01 TR002398‐02 $36,484 $345,755 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 3 UL1 TR001881‐03S2 CALIFORNIA UCLA 3 UL1 TR001881‐03S2 $79,986 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 3 UL1 TR001425‐04S1 CCHMC 3 UL1 TR001425‐04S1 $41,805 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 1 UL1 TR002366‐01 CHILDREN'S MERCY 1 UL1 TR002366‐01 $17,579 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 1 U24 TR001608‐02 DUKE 1 U24 TR001608‐02 $115,462 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 U24 TR001608‐04 DUKE 5 U24 TR001608‐04 $1,746,688 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 U01 TR001803‐02 DUKE 5 U01 TR001803‐02 $27,300 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 U01 TR001803‐03 DUKE 5 U01 TR001803‐03 $133,665 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 3 UL1 TR002553‐01S1 DUKE 3 UL1 TR002553‐01S1 $2,718 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 3 UL1 TR002553‐02S1 DUKE 3 UL1 TR002553‐02S1 $4,873 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 1 U01 TR001812‐02 MASSACHUSETTS 1 U01 TR001812‐02 $12,658 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 U01 TR001812‐03 MASSACHUSETTS 5 U01 TR001812‐03 $217,144 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 3 UL1 TR001412‐04S1 NEW YORK (SUNY) 3 UL1 TR001412‐04S1 $28,821 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 1 UG3 TR002097‐01 VANDERBILT UNIVERSITY 1 UG3 TR002097‐01 $1,764 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 5 UG3 TR002097‐02 VANDERBILT UNIVERSITY 5 UG3 TR002097‐02 $359,934 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 3 UG3 TR002097‐02S1 VANDERBILT UNIVERSITY 3 UG3 TR002097‐02S1 $2,343 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCES 93.350 1 U01 TR002383‐01 VANDERBILT UNIVERSITY 1 U01 TR002383‐01 $96,270 $17,903,770 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

RESEARCH INFRASTRUCTURE PROGRAMS 93.351 1 S10 OD021771‐01 $1,997,848 $2,466,630 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH INFRASTRUCTURE PROGRAMS 93.351 1 S10 OD023475‐01A1 $212,722 $2,466,630 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315RESEARCH INFRASTRUCTURE PROGRAMS 93.351 1 S10 OD023543‐01 $215,000 $2,466,630 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

RESEARCH INFRASTRUCTURE PROGRAMS 93.351 1 R43 OD023257‐01A1 RECOMBINETICS 1 R43 OD023257‐01A1 $41,060 $2,466,630 RESEARCH AND DEVELOPMENT CLUSTER $337,364,31521ST CENTURY CURES ACT ‐ BEAU BIDEN CANCER MOONSHOT 93.353 1 U2C CA233291‐01 $185,473 $1,215,260 $1,215,260 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

PUBLIC HEALTH EMERGENCY RESPONSE: COOPERATIVE AGREEMENT FOR EMERGENCY RESPONSE: PUBLIC HEALTH CRISIS RESPONSE 93.354 61319:ST TN TN HEALTH 61319:ST TN $169,406 $169,406 OTHER AWARDS $40,431,607

NURSE EDUCATION, PRACTICE QUALITY AND RETENTION GRANTS 93.359 6 UD7 HP30932‐02‐01 VANDERBILT UNIVERSITY 6 UD7 HP30932‐02‐01 $265,870 $265,870 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NURSING RESEARCH 93.361 5 R01 NR015079‐04 $17,399 $295,491 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315NURSING RESEARCH 93.361 5 R01 NR015079‐06 $278,092 $295,491 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

SICKLE CELL TREATMENT DEMONSTRATION PROGRAM 93.365 1 U1E MC31108‐01‐00 CAROLINAS 1 U1E MC31108‐01‐00 $8,297 $10,200 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315SICKLE CELL TREATMENT DEMONSTRATION PROGRAM 93.365 6 U1E MC31108‐02‐01 CAROLINAS 6 U1E MC31108‐02‐01 $1,903 $10,200 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER CAUSE AND PREVENTION RESEARCH 93.393 HHSN261201600027I $18,976 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 P01 CA028842‐31 ‐$6,900 ‐$6,900 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 P01 CA028842‐32 $21,041 $22,087 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 P01 CA028842‐33 $254,706 $893,042 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 P01 CA116087‐11 $117,974 $890,001 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 2 P01 CA116087‐12 $2,006 $427,019 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA077955‐23 $557,218 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 2 R01 CA138833‐07 ‐$714 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 6 R01 CA158473‐06 $548,279 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R03 CA182063‐03 $40,071 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA188214‐06 $23,224 $647,736 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA189152‐05 $366,202 $631,283 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 6 R01 CA190428‐02 ‐$1,552 $0 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA190612‐06 $109,797 $427,139 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R03 CA195660‐03 ‐$1 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R21 CA197344‐03 $933 $32,916 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA198482‐05 $295,183 $343,702 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA200999‐05 $55,937 $208,132 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R21 CA201856‐03 $1,748 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA202936‐05 $227,650 $441,419 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA202981‐02 $418,347 $2,542,310 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA203012‐03 $41,575 $399,289 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA204819‐02 $114,571 $498,408 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA206564‐04 ‐$593 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA207401‐03 $285,868 $518,106 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA207466‐03 $102,639 $516,236 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 4 R00 CA207848‐03 $3,805 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA227130‐01A1 $7,310 $216,076 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA230352‐01A1 $79,131 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


49




CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA232516‐01A1 $4,059 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 U01 CA161045‐06 $332,158 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 UM1 CA173640‐06 $232,367 $705,284 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 UM1 CA182910‐05 $266,367 $555,995 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 UM1 CA182910‐06 $9,801 $518,758 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 U01 CA202979‐02 $10,472 $233,558 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 U01 CA202979‐03 $42,174 $2,963,523 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER CAUSE AND PREVENTION RESEARCH 93.393 2 R01 CA172253‐06 BH1 2 R01 CA172253‐06 $5,267 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 U01 CA187508‐03 BOSTON MEDICAL 5 U01 CA187508‐03 $84,402 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 U01 CA187508‐04 BOSTON MEDICAL 5 U01 CA187508‐04 $43,459 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA197422‐04 CALIFORNIA SYSTEMWIDE 5 R01 CA197422‐04 $13,806 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA192156‐03 CALIFORNIA UCSF 5 R01 CA192156‐03 $109,302 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA197422‐03 CALIFORNIA UCSF 1 R01 CA197422‐03 $12,998 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 2 P01 CA138338‐07 CALIFORNIA 2 P01 CA138338‐07 $12,078 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 P01 CA138338‐08 CALIFORNIA 5 P01 CA138338‐08 $9,114 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA209798‐01‐A1 CALIFORNIA 1 R01 CA209798‐01‐A1 $35,257 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA209798‐02 CALIFORNIA 1 R01 CA209798‐02 $34,310 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA209798‐03 CALIFORNIA 5 R01 CA209798‐03 $22,822 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA220581‐01A1 CASE WESTERN RESERVE 1 R01 CA220581‐01A1 $34,864 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA190428‐04 DUKE 5 R01 CA190428‐04 $29,240 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA183750‐05 FHCRC 5 R01 CA183750‐05 $23,313 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 7 U19 CA203654‐02 IARC 7 U19 CA203654‐02 $33,656 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA157823‐06 INDIANA 5 R01 CA157823‐06 $1,700 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA207538‐03 KENTUCKY 5 R01 CA207538‐03 $31,755 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 HHSN261200800001E LEIDOS HHSN261200800001E $40,003 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 7 R01 CA206564‐05 MIAMI 7 R01 CA206564‐05 $7,675 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA206564‐06 MIAMI 5 R01 CA206564‐06 $10,349 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA204113‐03 NEW YORK 5 R01 CA204113‐03 $199,455 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA204113‐04 NEW YORK 5 R01 CA204113‐04 $29,621 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA226086‐01A1 NORTH CAROLINA 1 R01 CA226086‐01A1 $3,982 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 HHSN261201200035I NORTHWESTERN HHSN261201200035I $25,542 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 HHSN261201200035I NORTHWESTERN HHSN261201200035I $146,606 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA228156‐01A1 ROSWELL PARK CANCER 1 R01 CA228156‐01A1 $26,276 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA215520‐02 THOMAS JEFFERSON 5 R01 CA215520‐02 $32,347 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R01 CA207538‐02 UNIV OF LOUISVILLE 5 R01 CA207538‐02 $227,103 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA232743‐01A1 UPPR 1 R01 CA232743‐01A1 $12,083 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 HHSN216200800001E VANDERBILT UNIVERSITY HHSN216200800001E $6,408 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 HHSN216200800001E VANDERBILT UNIVERSITY HHSN216200800001E $14,012 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 2 R01 CA164605‐06 VANDERBILT UNIVERSITY 2 R01 CA164605‐06 $23,468 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 R01 CA200709‐01 VANDERBILT UNIVERSITY 1 R01 CA200709‐01 $90,295 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 1 U01 CA224276‐01A1 VANDERBILT UNIVERSITY 1 U01 CA224276‐01A1 $68,616 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CAUSE AND PREVENTION RESEARCH 93.393 5 R00 CA207848‐05 WISCONSIN 5 R00 CA207848‐05 $49,537 $17,759,977 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA152662‐09 $184,807 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 R01 CA109106‐13 $1,827 $380,034 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 R01 CA163806‐06 ‐$1 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 R01 CA184693‐06 $26,807 $162,322 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 7 R01 CA194024‐03 $87,505 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 1 R01 CA227133‐01A1 $96,009 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA142565‐09 $218,804 $249,364 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA142565‐10 $25,354 $151,558 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA152662‐07 $5,364 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA152662‐08 $52,838 $597,236 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA182364‐05 $10,881 $445,636 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA182364‐06 $10,946 $204,010 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 UM1 CA183727‐06 $885,439 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 2 UM1 CA183727‐07 $312,094 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA186145‐03 $2,651 $2,651 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA186145‐04 $47,143 $95,418 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA186145‐05 $72,993 $312,940 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 1 U24 CA220325‐01A1 $13,683 $425,201 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 1 U01 CA231840‐01 $163,890 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U24 CA184407‐06 BOSTON CHILDREN'S 5 U24 CA184407‐06 $108,609 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA214182‐02 BOSTON 5 U01 CA214182‐02 $6,466 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA214182‐03 BOSTON 5 U01 CA214182‐03 $20,363 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 1 R01 CA227466‐01 CALIFORNIA UCSF 1 R01 CA227466‐01 $27,869 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


50




CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 1 R01 CA218526‐01 CSMC 1 R01 CA218526‐01 $144,091 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 U01 CA195603‐01 IARC 5 U01 CA195603‐01 ‐$2,784 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 1 U01 CA195603‐04 IARC 1 U01 CA195603‐04 $12,524 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 7 R01 CA158472‐05 MIAMI 7 R01 CA158472‐05 $106,021 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 1 R01 CA200987‐02 MIAMI 1 R01 CA200987‐02 $1,935 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 1 R01 CA200987‐03 MIAMI 1 R01 CA200987‐03 $128,899 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 5 R01 CA163772‐05 MSSM 5 R01 CA163772‐05 $7,962 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER DETECTION AND DIAGNOSIS RESEARCH 93.394 1 R01 CA212147‐01A1 VANDERBILT UNIVERSITY 1 R01 CA212147‐01A1 $39,771 $5,363,203 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER TREATMENT RESEARCH 93.395 1 UG1 CA233270‐01 $64,422 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 6 R01 CA121210‐10 $192,939 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 R01 CA166492‐06 $44,711 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 7 R01 CA178613‐05 $204,021 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 R00 CA181491‐04 $8,678 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 6 R21 CA184387‐03 $1,596 $1,596 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 6 R21 CA184387‐03 ‐$206 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 R21 CA208631‐02 $3,152 $55,489 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 R01 CA213201‐01A1 $12,581 $186,476 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 R21 CA226562‐01A1 $4,964 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 R01 CA227481‐01A1 $62,470 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 U10 CA180847‐06 $337,132 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER TREATMENT RESEARCH 93.395 4 R42 CA171552‐02 AADI 4 R42 CA171552‐02 $50,549 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 R01 CA181050‐02 CHILDREN'S HOSP LA 5 R01 CA181050‐02 ‐$4,093 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 R01 CA196854‐04 CHILDRENS PHILADELPHIA 5 R01 CA196854‐04 ‐$1,560 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 2 U10 CA180886‐06 CHILDRENS PHILADELPHIA 2 U10 CA180886‐06 $16 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 U01 CA180886‐01 CHILDRENS PHILADELPHIA 1 U01 CA180886‐01 $36,487 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 U10 CA180886‐01 CHILDRENS PHILADELPHIA 1 U10 CA180886‐01 $17,056 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 U10 CA180886‐02S7 CHILDRENS PHILADELPHIA 1 U10 CA180886‐02S7 $805 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 U10 CA180886‐05 CHILDRENS PHILADELPHIA 5 U10 CA180886‐05 $1,000 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 U10 CA180886‐05 CHILDRENS PHILADELPHIA 5 U10 CA180886‐05 $15,000 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 UG1 CA189955‐01 CHILDRENS PHILADELPHIA 1 UG1 CA189955‐01 $2,789 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 UG1 CA189955‐05 CHILDRENS PHILADELPHIA 5 UG1 CA189955‐05 $12,628 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 9 R44 CA228756‐02 CUMBERLAND 9 R44 CA228756‐02 $226,246 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 R01 CA184173‐01A1 DUKE 1 R01 CA184173‐01A1 ‐$77 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 U10 CA180820‐05 ECOG 5 U10 CA180820‐05 $1,765 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 U10 CA180820‐05 ECOG 5 U10 CA180820‐05 $69,912 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 U10 CA180820‐05 ECOG 1 U10 CA180820‐05 $12,559 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 U10 CA180820‐05 ECOG 5 U10 CA180820‐05 $17,085 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 2 U10 CA180820‐06 ECOG 2 U10 CA180820‐06 $6,664 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 U01 CA180950‐05 EMORY 5 U01 CA180950‐05 $114,102 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 4 R01 CA118953‐09 FHCRC 4 R01 CA118953‐09 $3,112 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 HHSN261201100100C MOFFITT CANCER CENTER HHSN261201100100C $808 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 4 P01 CA129243‐10 MSKCC 4 P01 CA129243‐10 $9,110 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 2 P01 CA129243‐11 MSKCC 2 P01 CA129243‐11 $71,140 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 UG1 CA189867‐04 NRG FDN 5 UG1 CA189867‐04 $50,255 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 U10 CA180888‐05 OHSU 5 U10 CA180888‐05 $63,309 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 U10 CA180888‐06 OHSU 5 U10 CA180888‐06 $24,657 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 4 R00 CA181491‐02 VANDERBILT UNIVERSITY 4 R00 CA181491‐02 ‐$115 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 R01 CA116021‐14 VANDERBILT UNIVERSITY 5 R01 CA116021‐14 $39,615 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 R01 CA214043‐03 VANDERBILT UNIVERSITY 5 R01 CA214043‐03 $65,705 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 R37 CA223770‐01 VANDERBILT UNIVERSITY 1 R37 CA223770‐01 $15,435 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 R01 CA224241‐01A1 VANDERBILT UNIVERSITY 1 R01 CA224241‐01A1 $52,980 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 1 R01 CA238553‐01 VANDERBILT UNIVERSITY 1 R01 CA238553‐01 $7,490 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 UM1 CA186689‐04 YALE 5 UM1 CA186689‐04 $2 $155,600 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER TREATMENT RESEARCH 93.395 5 UM1 CA186689‐05 YALE 5 UM1 CA186689‐05 $31,410 $2,332,136 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER BIOLOGY RESEARCH 93.396 5 R01 CA200681‐04 $401,870 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 1 R01 CA227833‐01A1 $21,486 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 R01 CA095004‐15 $301,252 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 R01 CA162433‐06 $146 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 R01 CA177681‐06 $1,719 $351,416 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 6 R21 CA187307‐03 ‐$1,019 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 R01 CA193219‐05 $412,347 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 R00 CA194198‐04 $193,549 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 1 R35 CA197570‐01A1 ‐$3,570 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 R35 CA197570‐02 $692,544 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 R35 CA197570‐03 $260,921 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


51




CANCER BIOLOGY RESEARCH 93.396 5 R01 CA217987‐02 $49,720 $438,640 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 1 R01 CA222594‐01A1 $269,511 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U24 CA163056‐08 $295,172 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U24 CA163056‐09 $120,518 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U19 CA179514‐06 $126,985 $473,479 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U01 CA196405‐04 $35,814 $166,832 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U01 CA196405‐05 $206,764 $827,747 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER BIOLOGY RESEARCH 93.396 1 R21 CA210210‐02 KANSAS 1 R21 CA210210‐02 $68,277 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 HHSN261200800001E LEIDOS HHSN261200800001E $109,170 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 HHSN261200800001E LEIDOS HHSN261200800001E $96,203 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U24 CA213274‐02 MSKCC 5 U24 CA213274‐02 $43,677 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U24 CA213274‐03 MSKCC 5 U24 CA213274‐03 $22,642 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U24 CA194215‐02 TEXAS HEALTH SCIENCE HOUSTON 5 U24 CA194215‐02 $34,044 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U24 CA194215‐03 TEXAS HEALTH SCIENCE HOUSTON 5 U24 CA194215‐03 $128,901 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 R01 CA064140‐25 VANDERBILT UNIVERSITY 5 R01 CA064140‐25 $20,446 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 1 R01 CA163499‐01A1 VANDERBILT UNIVERSITY 1 R01 CA163499‐01A1 ‐$3,387 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 R01 CA178030‐03 VANDERBILT UNIVERSITY 5 R01 CA178030‐03 $61,580 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER BIOLOGY RESEARCH 93.396 5 U01 CA202229‐03 VANDERBILT UNIVERSITY 5 U01 CA202229‐03 $1,731 $5,806,125 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER CENTERS SUPPORT GRANTS 93.397 1 P50 CA236733‐01 $51,564 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 5 P30 CA068485‐22 $1,322,510 $2,369,580 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 6 P50 CA095103‐15 ‐$3,519 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 5 P50 CA098131‐16 $371,627 $1,569,963 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 5 P20 CA210300‐02 $9,244 $28,822 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 6 P30 CA68485‐20 ‐$23,140 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 5 P30 CA68485‐23 $549,857 $4,937,578 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 5 U54 CA163072‐08 $51,794 $290,646 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 5 U54 CA163072‐09 $804,417 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER CENTERS SUPPORT GRANTS 93.397 2 P50 CA150964‐06A1 CASE WESTERN RESERVE 2 P50 CA150964‐06A1 $8,256 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 2 P50 CA150964‐07 CASE WESTERN RESERVE 2 P50 CA150964‐07 $30,825 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 1 U54 CA217450‐01A1 VANDERBILT UNIVERSITY 1 U54 CA217450‐01A1 $323,455 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER CENTERS SUPPORT GRANTS 93.397 5 U54 CA217450‐02 VANDERBILT UNIVERSITY 5 U54 CA217450‐02 $68,632 $10,457,079 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER RESEARCH MANPOWER 93.398 5 F32 CA216942‐02 $18,221 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 1 F32 CA224962‐01 $47,395 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 F32 CA224962‐02 $19,212 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 1 F32 CA236309‐01 $32,441 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K12 CA090625‐18 ‐$2,108 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K12 CA090625‐19 $942,428 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K25 CA168936‐06 $46,093 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K07 CA172294‐06 $60,093 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K24 CA172355‐07 $5,317 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K25 CA176219‐06 $146,909 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K23 CA204726‐03 $162,509 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K99 CA215360‐02 $91,253 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K07 CA218247‐02 $124,179 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 1 K99 CA218892‐01A1 $99,475 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 K07 CA225404‐02 $148,100 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 1 K99 CA230205‐01A1 $24,048 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 T32 CA106183‐14 ‐$229 $8,704 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 T32 CA106183‐15 $265,328 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 2 T32 CA160056‐07 $59,512 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 5 T32 CA160056‐08 $326,217 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 1 T32 CA217834‐01A1 $112,852 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CANCER RESEARCH MANPOWER 93.398 2 T32 CA009582‐31 VANDERBILT UNIVERSITY 2 T32 CA009582‐31 $3,521 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 2 T32 CA119925‐11 VANDERBILT UNIVERSITY 2 T32 CA119925‐11 $31,692 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 2 T32 CA119925‐11 VANDERBILT UNIVERSITY 2 T32 CA119925‐11 $28,252 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER RESEARCH MANPOWER 93.398 2 T32 CA119925‐11 VANDERBILT UNIVERSITY 2 T32 CA119925‐11 $47,187 $2,848,830 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ACL NATIONAL INSTITUTE ON DISABILITY, INDEPENDENT LIVING, AND REHABILITATION RESEARCH 93.433 90IFRE0001‐1‐01‐00 VANDERBILT UNIVERSITY 90IFRE0001‐1‐01‐00 $1,610 $1,610 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ACA ‐ STATE INNOVATION MODELS: FUNDING FOR MODEL DESIGN AND MODEL TESTING ASSISTANCE 93.624 60138:ST TN TN HEALTH 60138:ST TN $71,594 $71,594 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS 93.630 58369:ST TN TN ECONOMIC COMMUNITY 58369:ST TN $172,908 $203,379 OTHER AWARDS $40,431,607DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS 93.630 54634:ST TN

TN MENTAL HEALTH DEVELOPMENTAL 54634:ST TN ‐$5,021 $203,379 OTHER AWARDS $40,431,607


52




DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS 93.630 60173:ST TN


DEVELOPMENTAL DISABILITIES BASIC SUPPORT AND ADVOCACY GRANTS 93.630 60176:ST TN


UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE 93.632 90 DD 00825‐02‐01 $2,831 $3,161 $540,669 OTHER AWARDS $40,431,607UNIVERSITY CENTERS FOR EXCELLENCE IN DEVELOPMENTAL DISABILITIES EDUCATION, RESEARCH, AND SERVICE 93.632 90 DD 00825‐03‐00 $124,261 $537,508 $540,669 OTHER AWARDS $40,431,607ACA‐TRANSFORMING CLINICAL PRACTICE INITIATIVE: PRACTICE TRANSFORMATION NETWORKS (PTNS) 93.638 1 L1 CMS331549‐02‐00 $846,487 $3,186,389 $6,739,121 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ACA‐TRANSFORMING CLINICAL PRACTICE INITIATIVE: PRACTICE TRANSFORMATION NETWORKS (PTNS) 93.638 1 L1 CMS331549‐03‐00 $558,862 $3,552,732 $6,739,121 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

FOSTER CARE_TITLE IV‐E 93.658 42852:ST TN TN CHILDRENS SERVICES 42852:ST TN $1,741 $1,741 $115,465 OTHER AWARDS $40,431,607FOSTER CARE_TITLE IV‐E 93.658 42852:ST TN TN CHILDRENS SERVICES 42852:ST TN ‐$5,764 $115,465 OTHER AWARDS $40,431,607FOSTER CARE_TITLE IV‐E 93.658 56787:ST TN TN CHILDRENS SERVICES 56787:ST TN $6,985 $119,488 $115,465 OTHER AWARDS $40,431,607STATE PUBLIC HEALTH ACTIONS TO PREVENT AND CONTROL DIABETES, HEART DISEASE, OBESITY AND ASSOCIATED RISK FACTORS AND PROMOTE SCHOOL HEALTH FINANCED IN PART BY PREVENTION AND PUBLIC HEALTH FUNDING (PPHF) 93.757 54724:ST TN TN HEALTH 54724:ST TN $111 $5,309 OTHER AWARDS $40,431,607STATE PUBLIC HEALTH ACTIONS TO PREVENT AND CONTROL DIABETES, HEART DISEASE, OBESITY AND ASSOCIATED RISK FACTORS AND PROMOTE SCHOOL HEALTH FINANCED IN PART BY PREVENTION AND PUBLIC HEALTH FUNDING (PPHF) 93.757 54724:ST TN TN HEALTH 54724:ST TN $5,198 $5,309 OTHER AWARDS $40,431,607

PREVENTIVE HEALTH AND HEALTH SERVICES BLOCK GRANT FUNDED SOLELY WITH PREVENTION AND PUBLIC HEALTH FUNDS (PPHF) 93.758 59366:ST TN TN HEALTH 59366:ST TN $379,624 $379,624 OTHER AWARDS $40,431,607MEDICAL ASSISTANCE PROGRAM 93.778 05 U05 M15ADM‐17 MICHIGAN 05 U05 M15ADM‐17 $7,600 $5,600,805 MEDICAID CLUSTER $5,600,805MEDICAL ASSISTANCE PROGRAM 93.778 53068:ST TN TN CHILDRENS SERVICES 53068:ST TN ‐$25,743 $35,704 $5,600,805 MEDICAID CLUSTER $5,600,805MEDICAL ASSISTANCE PROGRAM 93.778 52379:ST TN TN FINANCE ADMINISTRATION 52379:ST TN ‐$15,956 $6,123 $5,600,805 MEDICAID CLUSTER $5,600,805MEDICAL ASSISTANCE PROGRAM 93.778 54867:ST TN TN HEALTH 54867:ST TN $14,443 $56,187 $5,600,805 MEDICAID CLUSTER $5,600,805MEDICAL ASSISTANCE PROGRAM 93.778 54867:ST TN TN HEALTH 54867:ST TN $36,141 $503,478 $5,600,805 MEDICAID CLUSTER $5,600,805

MEDICAL ASSISTANCE PROGRAM 93.778 52379:ST TNTN MENTAL HEALTH DEVELOPMENTAL 52379:ST TN $1,042,561 $5,600,805 MEDICAID CLUSTER $5,600,805

MEDICAL ASSISTANCE PROGRAM 93.778 53068:ST TNTN MENTAL HEALTH DEVELOPMENTAL 53068:ST TN $2,877 $2,804,875 $5,600,805 MEDICAID CLUSTER $5,600,805

MEDICAL ASSISTANCE PROGRAM 93.778 46264:ST TN TN TENNCARE 46264:ST TN ‐$1,220 $5,600,805 MEDICAID CLUSTER $5,600,805MEDICAL ASSISTANCE PROGRAM 93.778 46264:ST TN TN TENNCARE 46264:ST TN $1,138,805 $5,600,805 MEDICAID CLUSTER $5,600,805MEDICAL ASSISTANCE PROGRAM 93.778 61290:ST TN TN TENNCARE 61290:ST TN $6,692 $5,600,805 MEDICAID CLUSTER $5,600,805

OPIOID STR 93.788 62292:ST TNTN MENTAL HEALTH DEVELOPMENTAL 62292:ST TN $27,183 $27,183 OTHER AWARDS $40,431,607

CARDIOVASCULAR DISEASES RESEARCH 93.837 1 DP2 HL137166‐01 $11,992 $523,768 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 F32 HL144081‐01 $50,965 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 F32 HL137385‐01 $11,592 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 F32 HL137385‐02 $50,953 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 F32 HL137394‐01 $14,100 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 F32 HL137394‐02 $50,273 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 F32 HL140849‐01 $69,482 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 F32 HL140874‐01A1 $59,028 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 F32 HL144048‐01 $48,530 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 T32 HL105334‐09 $9,296 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL125032‐05 $31,122 $94,315 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL138519‐02 $400,394 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 7 K23 HL141539‐02 $2,570 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 F32 HL143927‐01A1 $8,445 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K08 HL116803‐06 $13,794 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K01 HL121045‐05 $54,602 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K08 HL121671‐05 $93,710 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K23 HL123938‐05 $223,574 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K23 HL127104‐04 $189,551 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K23 HL127130‐04 $184,122 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K23 HL127704‐05 $154,180 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K23 HL128928‐03 $172,397 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K01 HL130497‐05 $156,309 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K12 HL133117‐03 $414,688 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K23 HL133477‐02 $159,308 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


53




CARDIOVASCULAR DISEASES RESEARCH 93.837 1 K99 HL135442‐01 $14,386 $80,356 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 K01 HL135461‐03 $144,735 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 K01 HL140278‐02 $111,821 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 6 P01 HL056693‐20 $148,860 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 P01 HL116263‐04 $228,256 $228,256 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 P01 HL116263‐05 $406,718 $2,283,625 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 P01 HL128203‐02 $306,189 $306,189 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 P01 HL128203‐03 $1,717,670 $2,360,942 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 P01 HL129941‐02 $435,954 $563,174 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 P01 HL129941‐03 $1,098,212 $2,206,342 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 2 R01 HL070715‐14A1 $747,405 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL071670‐14 $5,338 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 2 R56 HL081707‐12A1 $264,780 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL094786‐07 $301,691 $613,742 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R25 HL096223‐10 ‐$507 $66,096 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 6 R01 HL109388‐06 $902 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL111516‐06 $117 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL118386‐05 $126 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL118392‐05 $40,226 $40,354 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL121139‐05 $135,798 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL122847‐05 $470,090 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL124116‐04 $209,883 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL124935‐06 $382,280 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL125426‐06 $27,000 $356,278 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL125865‐04 $790 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL127173‐05 $499,791 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL127442‐02 $96,582 $116,811 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL128386‐03 $631,396 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL128983‐02 $7,318 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL128983‐03 $668,953 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL128983‐04 $47,515 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL128996‐05 $569,883 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL131977‐02 $3,155 $3,155 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL131977‐03 $154,057 $428,047 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL131977‐04 $17,526 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL132338‐02 $497,821 $751,996 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R21 HL132805‐02 $114,260 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL133127‐02 $6,991 $408,365 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL133290‐03 $376,076 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL133786‐02 $5,023 $301,029 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL133860‐02 $68,758 $80,228 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL133860‐03 $325,492 $662,330 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL134895‐02 $7,150 $443,697 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL135011‐02 $437,258 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL135129‐01A1 $37 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R00 HL135442‐03 $138,408 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R03 HL135453‐02 $5,079 $22,517 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL136824‐02 $95,221 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R35 HL140016‐01 $64,523 $434,174 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R35 HL140016‐02 $6,031 $483,594 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL140074‐01 $439,223 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL140145‐01 $27,125 $348,527 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R03 HL140264‐02 $79,007 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R21 HL140375‐02 $90,989 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R56 HL141248‐01 $260,273 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R56 HL141466‐01 $229,756 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL142583‐01 $258,307 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL142856‐01A1 $83,164 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R35 HL144980‐01 $240,986 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL146401‐01 $75,808 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL146524‐01 $37,514 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL149386‐01 $67,558 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R25 HL096223‐09 $6,119 $36,493 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL131911‐05 $194,612 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 2 T32 HL105334‐07 ‐$957 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


54




CARDIOVASCULAR DISEASES RESEARCH 93.837 5 T32 HL105334‐08 $479,439 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 6 U01 HL103620‐07 ‐$1,858 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 6 U01 HL122904‐04 ‐$1,396 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL131911‐04 $774,917 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL128044‐04 ALABAMA 5 R01 HL128044‐04 $85,161 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL128563‐04 ALABAMA 5 R01 HL128563‐04 $16,238 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL120338‐04 ALABAMA 5 U01 HL120338‐04 ‐$20,329 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL120338‐05 ALABAMA 5 U01 HL120338‐05 $2,434 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R21 HL140443‐01A1 BOSTON CHILDREN'S 1 R21 HL140443‐01A1 $30,465 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL146134‐01 BOSTON CHILDREN'S 1 R01 HL146134‐01 $17,261 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL126136‐03 BOSTON 5 R01 HL126136‐03 $1,866 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL126136‐04 BOSTON 5 R01 HL126136‐04 $4,421 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 P50 HL112349‐05 BWH 5 P50 HL112349‐05 $17,872 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R21 HL145420‐01 BWH 1 R21 HL145420‐01 $7,065 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 U01 HL123336‐01 BWH 1 U01 HL123336‐01 $54,544 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL130163‐02 BWH 5 U01 HL130163‐02 $50,225 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL130163‐03 BWH 5 U01 HL130163‐03 $8,984 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL130163‐04 BWH 5 U01 HL130163‐04 $6,522 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 2 K24 HL112827‐06 CALIFORNIA UCSF 2 K24 HL112827‐06 $50,009 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL126555‐04 CALIFORNIA UCSF 5 R01 HL126555‐04 $24,950 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL129856‐03 CALIFORNIA UCSF 5 R01 HL129856‐03 $133,359 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 4 R24 HL105333‐05 CCHMC 4 R24 HL105333‐05 $25,358 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U54 HL127672‐03 CCHMC 5 U54 HL127672‐03 $16,741 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U54 HL127672‐04 CCHMC 5 U54 HL127672‐04 $80,988 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL131755‐02 CCHMC 5 U01 HL131755‐02 $1,210 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL130828‐02 DARTMOUTH 5 R01 HL130828‐02 $11,578 $11,578 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL130828‐03 DARTMOUTH 5 R01 HL130828‐03 $222,338 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U10 HL084904‐11 DUKE 5 U10 HL084904‐11 $24,048 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL105462‐06 DUKE 5 U01 HL105462‐06 $44,685 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U01 HL105462‐07 DUKE 5 U01 HL105462‐07 $70,551 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 4 U01 HL117904‐05 DUKE 4 U01 HL117904‐05 $14,130 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 4 U01 HL117904‐06 DUKE 4 U01 HL117904‐06 $11,029 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL132320‐03 HARVARD 1 R01 HL132320‐03 $33,903 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL132320‐04 HARVARD 5 R01 HL132320‐04 $5,520 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R34 HL136986‐02 INDIANA 5 R34 HL136986‐02 $52,088 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL126557‐02 IUPUI 5 R01 HL126557‐02 ‐$484 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL126557‐04 IUPUI 5 R01 HL126557‐04 $23,934 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL132153‐01A1 JOHNS HOPKINS 1 R01 HL132153‐01A1 $7,450 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL135114‐02 JOHNS HOPKINS 1 R01 HL135114‐02 $29,389 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 3 R01 HL135114‐02S1 JOHNS HOPKINS 3 R01 HL135114‐02S1 $26,458 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL134731‐02 KENTUCKY 1 R01 HL134731‐02 $49,610 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL134731‐03 KENTUCKY 5 R01 HL134731‐03 $40,155 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R44 HL132746‐01A1 KNOLL 1 R44 HL132746‐01A1 $1,124 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL018646‐39 MASSACHUSETTS 5 R01 HL018646‐39 $18,421 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 4 R01 HL111821‐05 MASSACHUSETTS 4 R01 HL111821‐05 $157,874 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 4 R01 HL111821‐06 MASSACHUSETTS 4 R01 HL111821‐06 $37,428 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL127215‐03 MICHIGAN 5 R01 HL127215‐03 $17,168 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U10 HL069330‐15 MICHIGAN 5 U10 HL069330‐15 $305 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R21 HL135300‐01 MINNESOTA 1 R21 HL135300‐01 $20,370 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL136679‐02 MINNESOTA 5 R01 HL136679‐02 $10,273 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL123227‐02 MINNESOTA 5 R01 HL123227‐02 $15,926 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 4 U10 HL068270‐15 NEW ENGLAND RESEARCH 4 U10 HL068270‐15 $26,319 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 4 U10 HL068270‐15 NEW ENGLAND RESEARCH 4 U10 HL068270‐15 $64,787 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 U24 HL135691‐02 NEW ENGLAND RESEARCH 5 U24 HL135691‐02 $7,216 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 7 R01 HL139968‐02 NEW YORK (SUNY) 7 R01 HL139968‐02 $6,628 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 U01 HL105907‐01 NEW YORK 1 U01 HL105907‐01 $17,931 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL142302‐01 NORTH CAROLINA 1 R01 HL142302‐01 $356,165 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL130502‐03 NORTHWESTERN 5 R01 HL130502‐03 $41,570 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL134905‐01 PENNSYLVANIA 1 R01 HL134905‐01 $12,971 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL134905‐03 PENNSYLVANIA 5 R01 HL134905‐03 $16,445 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R56 HL136517‐01 PITTSBURGH 1 R56 HL136517‐01 $16,563 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R21 HL129066‐02 PITTSBURGH 1 R21 HL129066‐02 ‐$145 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R03 HL144668‐01 PITTSBURGH 1 R03 HL144668‐01 $34,434 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 OT3 HL142481‐01 SANTA CRUZ 1 OT3 HL142481‐01 $131,394 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL117913‐03 STANFORD 1 R01 HL117913‐03 $23,751 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


55




CARDIOVASCULAR DISEASES RESEARCH 93.837 2 R01 HL123968‐05 STANFORD 2 R01 HL123968‐05 $9,822 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL141851‐01A1 STANFORD 1 R01 HL141851‐01A1 $9,270 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL133790‐02 TULANE 1 R01 HL133790‐02 $2,850 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL133790‐03 TULANE 5 R01 HL133790‐03 $164 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL133870‐02 UMC 1 R01 HL133870‐02 $21,091 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL133870‐03 UMC 5 R01 HL133870‐03 $8,944 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL128393‐02 UNIVERSITY OF OKLAHOMA 5 R01 HL128393‐02 $63,314 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL128393‐03 UNIVERSITY OF OKLAHOMA 5 R01 HL128393‐03 $112,465 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R21 HL127368‐01 VANDERBILT UNIVERSITY 1 R21 HL127368‐01 ‐$27 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 R01 HL122347‐04 VANDERBILT UNIVERSITY 5 R01 HL122347‐04 $36,108 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 T32 HL007411‐38 VANDERBILT UNIVERSITY 5 T32 HL007411‐38 $63,234 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 T32 HL007411‐38 VANDERBILT UNIVERSITY 5 T32 HL007411‐38 $57,855 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 T32 HL007411‐38 VANDERBILT UNIVERSITY 5 T32 HL007411‐38 $18,459 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 T32 HL007411‐38 VANDERBILT UNIVERSITY 5 T32 HL007411‐38 $58,789 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 5 T32 HL007411‐38 VANDERBILT UNIVERSITY 5 T32 HL007411‐38 $9,218 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 2 R01 HL090586‐05 VIRGINIA COMMONWEALTH 2 R01 HL090586‐05 $279 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 4 R44 HL140669‐02 VOLUMETRIX 4 R44 HL140669‐02 $21,338 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CARDIOVASCULAR DISEASES RESEARCH 93.837 1 R01 HL139968‐01 WAYNE STATE 1 R01 HL139968‐01 $17,738 $29,197,727 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

LUNG DISEASES RESEARCH 93.838 2 K24 HL103836‐06 $215,635 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 K08 HL121174‐05 $39,624 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 K08 HL127102‐05 $145,301 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 K24 HL127301‐05 $129,592 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 K08 HL130595‐05 $164,910 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 K08 HL133484‐02 $143,263 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 K08 HL136888‐03 $200,515 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 K08 HL138088‐02 $93,839 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 K23 HL143053‐01 $173,241 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 K24 HL143281‐01 $67,214 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 K12 HL143956‐01 $50,701 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 K01 HL145338‐01 $25,892 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 P01 HL092870‐07 $10,839 $10,839 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 P01 HL092870‐08 $628,791 $1,787,158 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 P01 HL092870‐09 $186,631 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 2 P01 HL108800‐07 $36,300 $69,567 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 P01 HL108800‐08 $139,184 $1,822,214 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R34 HL136989‐02 $70,321 $251,763 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 6 R01 HL095797‐09 $21,666 $74,863 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 2 R01 HL095797‐10 $291,162 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 6 R01 HL111111‐05 $686 $686 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL111111‐06 $137,662 $322,034 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 6 R01 HL116597‐04 $2 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 2 R01 HL116597‐05A1 $27,028 $203,945 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL117074‐06 $105,756 $385,068 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL119503‐05 $7,142 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 2 R01 HL119503‐06 $258,354 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL122417‐05 $7,520 $485,557 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL122554‐06 $628,700 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 6 R01 HL126176‐03 $126,238 $397,372 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL126492‐04 $25,533 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL126671‐06 $417,732 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R21 HL129020‐03 $1,796 $2,837 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL131906‐04 $20,150 $459,910 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R21 HL133742‐02 $33,581 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL134802‐02 $389,558 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL134802‐02 $359,468 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL135849‐03 $27,233 $758,719 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL136449‐01A1 $42,921 $178,302 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL136664‐03 $70,251 $166,205 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL136748‐03 $536,146 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R34 HL136989‐02 $16,050 $16,050 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R34 HL136989‐03 $1,906 $12,430 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL140231‐01A1 $108,749 $399,725 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL141567‐01A1 $142,091 $305,045 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL142720‐01A1 $87,840 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R38 HL143619‐01 $166,721 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


56




LUNG DISEASES RESEARCH 93.838 1 R01 HL146588‐01 $19,536 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 2 T32 HL087738‐12 ‐$25,081 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 T32 HL087738‐13 $290,853 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 T32 HL087738‐14 $58,921 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 2 T32 HL094296‐11 $309,374 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123033‐04 $337 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123033‐05 $66,971 $306,378 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123033‐06 $35,892 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL125212‐05 ‐$843 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL125212‐06 $244,839 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

LUNG DISEASES RESEARCH 93.838 2 R01 HL116473‐06A1 BWH 2 R01 HL116473‐06A1 $8,270 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R35 HL140026‐01 CALIFORNIA UCSF 1 R35 HL140026‐01 $27,417 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R35 HL140026‐02 CALIFORNIA UCSF 5 R35 HL140026‐02 $53,936 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL131755‐03 CCHMC 5 U01 HL131755‐03 $7,514 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL125177‐04 CLEVELAND CLINIC 5 U01 HL125177‐04 ‐$89,721 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL125177‐05 CLEVELAND CLINIC 5 U01 HL125177‐05 $236,015 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL121518‐04 COLORADO 5 U01 HL121518‐04 $2,813 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL132153‐03 JOHNS HOPKINS 5 R01 HL132153‐03 $8,197 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123009‐02 MASSACHUSETTS 5 U01 HL123009‐02 $2,874 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123009‐04 MASSACHUSETTS 5 U01 HL123009‐04 $18,625 $194,970 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123009‐05 MASSACHUSETTS 5 U01 HL123009‐05 $99,939 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123009‐05 MASSACHUSETTS 5 U01 HL123009‐05 $49,833 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123009‐05 MASSACHUSETTS 5 U01 HL123009‐05 $25,500 $46,714 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123009‐05 MASSACHUSETTS 5 U01 HL123009‐05 $7,559 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123009‐06 MASSACHUSETTS 5 U01 HL123009‐06 $29,821 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123009‐06 MASSACHUSETTS 5 U01 HL123009‐06 $53,167 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL123009‐06 MASSACHUSETTS 5 U01 HL123009‐06 $6,129 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL122477‐03 NORTHWESTERN 5 R01 HL122477‐03 $1,406 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL122477‐05 NORTHWESTERN 5 R01 HL122477‐05 $7,676 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 2 R01 HL087115‐06A1 PENNSYLVANIA 2 R01 HL087115‐06A1 $20,251 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL134015‐01 PENNSYLVANIA 1 R01 HL134015‐01 $38,918 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL135144‐02 PITTSBURGH 1 R01 HL135144‐02 $104,950 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 U01 HL128954‐04 PITTSBURGH 5 U01 HL128954‐04 $6,700 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL121067‐04 SEATTLE CHILDREN'S HOSP 1 R01 HL121067‐04 $26,004 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R41 HL140709‐01 SQUIBB 1 R41 HL140709‐01 $5,135 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 5 R01 HL138510‐02 TEXAS HEALTH SCIENCE HOUSTON 5 R01 HL138510‐02 $6,092 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 1 R01 HL145372‐01 TRANSLATIONAL GENOMICS 1 R01 HL145372‐01 $121,958 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 15FED1511233‐0004 VA 15FED1511233‐0004 $240,230 $293,300 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 15FED1511233‐0005 VA 15FED1511233‐0005 $53,336 $228,204 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315LUNG DISEASES RESEARCH 93.838 17FED1708489 VA 17FED1708489 $24,961 $15,819,794 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

BLOOD DISEASES AND RESOURCES RESEARCH 93.839 2 R01 HL124159‐06 $15,199 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 K23 HL138291‐02 $165,575 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 1 K23 HL141447‐01 $137,644 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 1 OT3 HL147810‐01 $160,337 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 R01 HL106812‐09 $306,104 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 6 R01 HL114518‐04 $104,248 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 R01 HL124159‐04 $14,583 $380,951 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 R01 HL130018‐03 $55,251 $404,471 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 R01 HL133559‐02 $375,444 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 1 R35 HL140025‐01 $426,452 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 R35 HL140025‐02 $414,492 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 R01 HL141943‐02 $284,562 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 R01 HL133896‐02 ALABAMA 5 R01 HL133896‐02 $6,916 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 U01 HL117721‐05 EMORY 5 U01 HL117721‐05 $85,830 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 2 R01 HL118979‐05 MINNESOTA 2 R01 HL118979‐05 $33,674 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 1 UG1 HL138645‐01 MSSM 1 UG1 HL138645‐01 $2,468 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 UG1 HL138645‐02 MSSM 5 UG1 HL138645‐02 $20,099 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 R01 HL133896‐02 MUSC 5 R01 HL133896‐02 $13,123 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 1 U01 HL069294‐01 NMDP 1 U01 HL069294‐01 $1,396 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 1 U24 HL138660‐01 NMDP 1 U24 HL138660‐01 $28,485 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 1 R01 HL144113‐01 OHSU 1 R01 HL144113‐01 $78,358 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 5 U01 HL133996‐03 ST. JUDE HOSPTIAL 5 U01 HL133996‐03 $56,914 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOOD DISEASES AND RESOURCES RESEARCH 93.839 HHSN26201300046C UMC HHSN26201300046C $23,405 $3,526,147 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

TRANSLATION AND IMPLEMENTATION SCIENCE RESEARCH FOR HEART, LUNG, BLOOD DISEASES, AND SLEEP DISORDERS 93.840 5 K12 HL137943‐02 $87,483 $290,782 $290,782 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


57




ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 K08 AR072757‐02 $145,286 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 6 R01 AR063157‐05 $48,631 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 R21 AR067871‐02 $16,659 $16,659 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 R21 AR067871‐02 ‐$8,021 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 R21 AR067938‐02 $85,238 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 1 R21 AR072483‐01A1 $76,151 $175,249 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 R01 AR073001‐02 $118,924 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 1 R21 AR073133‐01A1 $112,378 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 1 R01 AR073764‐01A1 $61,062 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 1 R01 AR073831‐01A1 $27,504 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 1 R01 AR073874‐01 $222,874 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 R21 AR074261‐02 $159,961 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 1 R13 AR074889‐01 $39,000 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 U34 AR69201‐02 $34,717 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 1 R01 AR074131‐01 CASE WESTERN RESERVE 1 R01 AR074131‐01 $43,703 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 2 R01 AR053684‐13 CLEVELAND CLINIC 2 R01 AR053684‐10 $433,487 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 UM1 AR063381‐05 IOWA 5 UM1 AR063381‐05 $37,962 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 UM1 AR063381‐05 IOWA 5 UM1 AR063381‐05 ‐$17 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 1 R21 AR070620‐01 KENTUCKY 1 R21 AR070620‐01 $22,991 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 R01 AR064772‐05 VANDERBILT UNIVERSITY 5 R01 AR064772‐05 $15,609 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 T32 AR059039‐07 VANDERBILT UNIVERSITY 5 T32 AR059039‐07 ‐$976 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 T32 AR059039‐07 VANDERBILT UNIVERSITY 5 T32 AR059039‐07 $57,856 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 T32 AR059039‐08 VANDERBILT UNIVERSITY 5 T32 AR059039‐08 $55,687 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 T32 AR059039‐08 VANDERBILT UNIVERSITY 5 T32 AR059039‐08 $4,167 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 T32 AR059039‐08 VANDERBILT UNIVERSITY 5 T32 AR059039‐08 $4,036 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 T32 AR059039‐08 VANDERBILT UNIVERSITY 5 T32 AR059039‐08 $12,406 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 5 T32 AR059039‐09 VANDERBILT UNIVERSITY 5 T32 AR059039‐09 $1,053 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ARTHRITIS, MUSCULOSKELETAL AND SKIN DISEASES RESEARCH 93.846 2 R01 AR060846‐05 WASHINGTON ST. LOUIS 2 R01 AR060846‐05 $131,553 $2,058,979 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 P30 DK058404‐18 $53,512 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK101332‐04 $31,044 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 7 U01 DK105556‐05 $46,705 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK110804‐05 $12,328 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK115545‐01A1 $281,403 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 F32 DK116520‐03 $4,963 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 F32 DK108492‐03 ‐$467 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 F32 DK108492‐04 $54,123 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 F32 DK111101‐02 $30,196 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 F32 DK113710‐01 $717 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 7 F32 DK116520‐02 $45,419 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 K01 DK099473‐05 $21,341 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 K23 DK100533‐06 $2,137 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 K23 DK101689‐04 $181,242 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 K23 DK103910‐05 $139,637 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 K01 DK106306‐05 $132,693 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 K01 DK106311‐04 $169,263 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 K08 DK106472‐05 $151,076 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 K23 DK106511‐04 $200,882 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 K01 DK109019‐03 $125,265 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 K23 DK114566‐01A1 $153,950 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 K01 DK117969‐01 $101,311 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 K23 DK118118‐01A1 $14,550 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 K23 DK118192‐01 $125,733 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 P30 DK020593‐41 $580,749 $2,317,531 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 P30 DK020593‐42 $481,106 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 P30 DK058404‐17 $182,293 $1,204,761 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 P30 DK092986‐08 $33,446 $79,271 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 P30 DK092986‐09 $86,455 $587,616 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 P20 DK112080‐01 ‐$937 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 P30 DK114809‐01 $25,735 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 P30 DK114809‐02 $1,168,644 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK0113423‐02 $258,581 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK018381‐45 $830,890 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 6 R01 DK048370‐22 ‐$2,713 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK048370‐24 $261,715 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK051265‐23 $144,478 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


58




DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 7 R01 DK051610‐24 $253,877 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 6 R01 DK056942‐14 $23 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK058587‐18 $289,069 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK061470‐15 $119,275 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK062794‐15 $39,999 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 R01 DK062794‐16A1 $57,611 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 R01 DK065138‐17 $488,116 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 7 R01 DK066358‐12 $279,601 $552,581 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK069921‐14 $472,283 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK078158‐08 $109,590 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK081134‐09 $256,013 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 6 R01 DK081646‐09 $30 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK081646‐11 $574,829 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK084246‐10 $39,832 $342,131 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK093501‐08 $213,484 $552,161 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK093660‐07 $19 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK095785‐06 $38 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 R01 DK095785‐07 $255,438 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK096994‐06 $14,985 $14,985 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK096994‐06 ‐$14,985 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK097332‐06 $1,196 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK099204‐06 $231,329 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 R01 DK099467‐07 $70,731 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK100431‐04 $133,097 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 6 R01 DK100694‐05 $10,468 $485,695 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK101332‐06 $8,197 $427,281 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 6 R21 DK101342‐03 $50,489 $51,570 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK101791‐05 $300,204 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R24 DK103067‐06 $109,008 $1,203,249 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK103935‐06 $94,886 $222,733 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK104817‐05 $199,722 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK105371‐06 $30,997 $449,940 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK105550‐06 $32,433 $178,695 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 R01 DK105550‐07 $71,893 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK105847‐05 $321,490 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R24 DK106755‐06 $533,076 $1,025,834 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK108159‐05 $291,737 $441,461 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 6 R56 DK108352‐02 $4,086 $104,890 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK108968‐05 $15,630 $348,507 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK109102‐04 $13,067 $299,156 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK110166‐02 $464,519 $728,469 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R03 DK110399‐03 $48,299 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R21 DK110657‐02 ‐$5,801 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK111554‐03 $8,790 $339,130 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK111671‐02 $354,067 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 6 R01 DK112262‐02 $24,386 $1,158,070 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK112688‐03 $409,944 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R03 DK113329‐01 $59,820 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK116625‐01 $365,662 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK116957‐01A1 $256,038 $360,396 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK116964‐02 $414,578 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK117144‐01A1 $236,600 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK117875‐01 $467,258 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK119212‐01 $9,278 $200,400 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK119282‐01A1 $23,709 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R03 DK119733‐01 $494 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R03 DK119735‐01 $6,038 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK120025‐01 $163,044 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK121101‐01 $82,113 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK121316‐01 $29,268 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R25 DK096999‐08 $123,876 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK099467‐06 $27,393 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 T35 DK007383‐40 $78,279 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 T32 DK007569‐29 $16,117 $16,117 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 T32 DK007569‐30 $35,247 $246,493 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


59




DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 T32 DK007673‐25 ‐$5,849 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 T32 DK007673‐26 $331,441 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 T32 DK007061‐44 $23,327 $25,582 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 T32 DK007061‐45 $341,552 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 T35 DK007383‐39 $105,665 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK082192‐11 $231,303 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK085465‐09 ‐$26,773 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK085465‐10 $456,153 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK099923‐06 $311,777 $516,476 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 6 UC4 DK104211‐02 $741,669 $1,035,514 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK110804‐03 $11,830 $11,830 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK110804‐04 $44,699 $278,263 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 3 U01 DK110804‐04S1 $18,890 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 UC4 DK112232‐01 $1,542,978 $2,112,528 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 U01 DK112271‐01 $70,265 $131,582 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK112271‐02 $207,504 $444,208 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 U01 DK116093‐01 ‐$2,730 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK116093‐02 $186,851 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK116093‐03 $20,042 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R18 DK118471‐01 AECOM 1 R18 DK118471‐01 $22,046 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK113980‐01A1 ALABAMA 1 R01 DK113980‐01A1 $35,143 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK113980‐02 ALABAMA 5 R01 DK113980‐02 $17,552 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U24 DK076169‐12 AUGUSTA 5 U24 DK076169‐12 $42,664 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U24 DK076169‐12 AUGUSTA 5 U24 DK076169‐12 $48,805 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U24 DK115255‐02 AUGUSTA 5 U24 DK115255‐02 $20,258 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK105554‐04 BIMH 5 U01 DK105554‐04 $35,737 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK115392‐01 BWH 1 R01 DK115392‐01 $47,069 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK115392‐02 BWH 5 R01 DK115392‐02 $14,967 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 U01 DK120429‐01 CALIFORNIA UCSD 1 U01 DK120429‐01 $5,713 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 DP3 DK114812‐01 CASE WESTERN RESERVE 1 DP3 DK114812‐01 $28,305 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 U01 DK094157‐07 CASE WESTERN RESERVE 2 U01 DK094157‐07 $18 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK094157‐07 CASE WESTERN RESERVE 5 U01 DK094157‐07 ‐$11 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 U01 DK094157‐07 CASE WESTERN RESERVE 2 U01 DK094157‐07 $2,851 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 U01 DK094157‐08 CASE WESTERN RESERVE 2 U01 DK094157‐08 $16,207 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK094157‐08 CASE WESTERN RESERVE 5 U01 DK094157‐08 $221,562 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 U54 DK118612‐01 CHICAGO 1 U54 DK118612‐01 $26,100 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 UC4 DK098085‐02 CITY OF HOPE 2 UC4 DK098085‐02 $258,623 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R24 DK090964‐09 COLORADO 5 R24 DK090964‐09 $232,040 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK113201‐01A1 DARTMOUTH 1 R01 DK113201‐01A1 $225,516 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 U01 DK098246‐06 GEORGE WASHINGTON DC 2 U01 DK098246‐06 $41,183 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK098246‐07 GEORGE WASHINGTON DC 5 U01 DK098246‐07 $424,245 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 U24 DK076169‐11 GRU 2 U24 DK076169‐11 $39 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


60




DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 R01 DK081572‐09 HARVARD 2 R01 DK081572‐09 $37,201 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK081572‐10 HARVARD 5 R01 DK081572‐10 $93,259 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 R56 DK084045‐05A1 KENTUCKY 2 R56 DK084045‐05A1 $30,053 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK110375‐02 MARYLAND 1 R01 DK110375‐02 $248,355 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK051610‐23 MDIBL 5 R01 DK051610‐23 $3,356 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 U01 DK120456‐01 MIAMI 1 U01 DK120456‐01 $47,461 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 3 U01 DK104833‐04S1 MUSC 3 U01 DK104833‐04S1 $32,736 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 UM1 DK100866‐03 NATIONWIDE 5 UM1 DK100866‐03 $1,689 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 UM1 DK100866‐04 NATIONWIDE 5 UM1 DK100866‐04 $11,135 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK114485‐01A1 NEW YORK (SUNY) 1 R01 DK114485‐01A1 $6,377 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 UM1 DK100867‐05 NORTH CAROLINA 5 UM1 DK100867‐05 $1,254 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 UM1 DK100867‐05 NORTH CAROLINA 5 UM1 DK100867‐05 ‐$16,707 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 UM1 DK100867‐06 NORTH CAROLINA 5 UM1 DK100867‐06 $8,430 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 UM1 DK100867‐06 NORTH CAROLINA 5 UM1 DK100867‐06 $56,981 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 UM1 DK100867‐06 NORTH CAROLINA 5 UM1 DK100867‐06 $55,393 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 R01 DK092217‐05A1 NORTHWESTERN 2 R01 DK092217‐05A1 $16,893 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK105689‐03 PENNSYLVANIA 1 R01 DK105689‐03 $17,993 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK105689‐04 PENNSYLVANIA 5 R01 DK105689‐04 $89,334 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R18 DK118460‐01 PITTSBURGH 1 R18 DK118460‐01 $8,764 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK097829‐01 PNDRI 1 R01 DK097829‐01 $11,240 $11,416 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK102934‐05 RUTGERS NEW JERSEY 5 R01 DK102934‐05 $27,531 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK104936‐04 SEATTLE CHILDREN'S HOSP 5 R01 DK104936‐04 $72,351 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U01 DK085465‐07 SOUTH FLORIDA 5 U01 DK085465‐07 $161,873 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK038217‐25 TEXAS 5 R01 DK038217‐25 $8,443 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R24 DK090964‐10 UNIVERSITY OF OKLAHOMA 5 R24 DK090964‐10 $79,755 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 R01 DK054902‐16A1 VANDERBILT UNIVERSITY 2 R01 DK054902‐16A1 $38,183 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK054902‐19 VANDERBILT UNIVERSITY 5 R01 DK054902‐19 $11,508 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DL103831‐01A1 VANDERBILT UNIVERSITY 1 R01 DL103831‐01A1 $3,371 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK106228‐04 VANDERBILT UNIVERSITY 5 R01 DK106228‐04 $4,676 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK117147‐01A1 VANDERBILT UNIVERSITY 1 R01 DK117147‐01A1 $131,179 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 T32 DK007563‐31 VANDERBILT UNIVERSITY 2 T32 DK007563‐31 $4,863 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 2 U24 DK059637‐17 VANDERBILT UNIVERSITY 2 U24 DK059637‐17 ‐$1 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


61




DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 U2C DK059637‐18 VANDERBILT UNIVERSITY 5 U2C DK059637‐18 $256,298 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 UC4 DK108120‐01 VANDERBILT UNIVERSITY 1 UC4 DK108120‐01 $244,842 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 1 R01 DK111175‐03 WASHINGTON ST. LOUIS 1 R01 DK111175‐03 $172,185 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315DIABETES, DIGESTIVE, AND KIDNEY DISEASES EXTRAMURAL RESEARCH 93.847 5 R01 DK099165‐02 WASHINGTON 5 R01 DK099165‐02 $4,318 $36,263,081 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 F32 NS101788‐02 $29,519 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 K23 NS080988‐06 $74,831 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS066927‐10 $1,022 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 6 R01 NS075270‐06 $61,992 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 6 R01 NS078289‐05 ‐$1,051 ‐$1,051 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 6 R01 NS078289‐05 ‐$610 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 6 R01 NS078680‐06 ‐$5,832 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS078680‐08 $447,925 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 6 R01 NS078828‐05 $109,149 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS082635‐05 $47,320 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS092961‐05 $4,036 $454,783 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS093669‐05 $210,716 $498,984 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS094041‐03 $50,963 $89,649 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS094041‐04 $388,360 $933,301 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS096127‐05 $343,330 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R21 NS096483‐02 $82,501 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R00 NS097618‐04 $200,060 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS097763‐04 $212,061 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS097783‐04 $8,841 $619,495 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS097821‐04 $14,520 $382,069 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 3 R01 NS100980‐01 $534,196 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS104149‐02 $343,610 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R01 NS107424‐01 $243,934 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R21 NS107877‐01 $118,418 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R01 NS108445‐01A1 $75,522 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS109114‐02 $203,561 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS110130‐02 $7,677 $203,664 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 T32 NS007491‐17 $14,348 $14,348 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


62




EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 T32 NS007491‐18 $127,361 $138,711 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 T32 NS007491‐18S1 $755 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 U54 NS65736‐09 $230,993 $234,342 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 U54 NS065736‐10 $676,209 $1,283,021 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 U10 NS077318‐07 ‐$3,877 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 U10 NS086492‐05 $133,476 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U24 NS107128‐01 $278,491 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS107666‐01 $136,552 $358,681 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R01 NS104339‐01 ALABAMA 1 R01 NS104339‐01 $18,686 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS104339‐02 ALABAMA 5 R01 NS104339‐02 $14,754 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R01 NS104094‐01 CALIFORNIA UCSF 1 R01 NS104094‐01 $5,517 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R01 NS096173‐01A1 CALIFORNIA UCSF 1 R01 NS096173‐01A1 $81,065 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS026835‐01A1 CALIFORNIA UCSF 1 U01 NS026835‐01A1 $1,393 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS092764‐01A1 CALIFORNIA UCSF 1 U01 NS092764‐01A1 $4,942 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 U01 NS092764‐03 CALIFORNIA UCSF 5 U01 NS092764‐03 $26,903 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 U01 NS086090‐05 CINCINNATI 5 U01 NS086090‐05 $10,048 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS092076‐01A1 CINCINNATI 1 U01 NS092076‐01A1 ‐$6,156 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS095869‐01A1 CINCINNATI 1 U01 NS095869‐01A1 $1,480 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS082244‐05 FLORIDA 5 R01 NS082244‐05 $5,567 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R01 NS102371‐01A1 MASSACHUSETTS 1 R01 NS102371‐01A1 $14,854 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS102371‐02 MASSACHUSETTS 5 R01 NS102371‐02 $7,482 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS088312‐01 MASSACHUSETTS 1 U01 NS088312‐01 $3,974 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS088312‐01 MASSACHUSETTS 1 U01 NS088312‐01 $4,279 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS88312‐01 MASSACHUSETTS 1 U01 NS88312‐01 $257 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS088312‐01 MASSACHUSETTS 1 U01 NS088312‐01 $18,143 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS090259‐02 MASSACHUSETTS 1 U01 NS090259‐02 $30,474 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 U01 NS096767‐01 MASSACHUSETTS 1 U01 NS096767‐01 $47,469 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 U01 NS080168‐05 MAYO CLINIC 5 U01 NS080168‐05 $12,086 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS097512‐02 MCLEAN 5 R01 NS097512‐02 $17,566 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 2 R44 NS064647‐07 OPTIMA 2 R44 NS064647‐07 $7,439 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 2 U01 NS061799‐07 ROCHESTER 2 U01 NS061799‐07 $3,160 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS094595‐03 TENNESSEE 5 R01 NS094595‐03 $26,599 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


63




EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R01 NS100996‐02 UNIV OF LOUISVILLE 1 R01 NS100996‐02 $55,049 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 2 R01 NS32387‐18A1 VANDERBILT UNIVERSITY 2 R01 NS32387‐18A1 ‐$43 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS049251‐11 VANDERBILT UNIVERSITY 5 R01 NS049251‐11 $75,756 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS095291‐12 VANDERBILT UNIVERSITY 5 R01 NS095291‐12 $73,784 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS096238‐03 VANDERBILT UNIVERSITY 5 R01 NS096238‐03 $12,350 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 5 R01 NS096238‐04 VANDERBILT UNIVERSITY 5 R01 NS096238‐04 $4,605 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R01 NS104497‐01 VANDERBILT UNIVERSITY 1 R01 NS104497‐01 $8,775 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R21 NS106510‐01 VANDERBILT UNIVERSITY 1 R21 NS106510‐01 $13,815 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315EXTRAMURAL RESEARCH PROGRAMS IN THE NEUROSCIENCES AND NEUROLOGICAL DISORDERS 93.853 1 R21 NS109521‐01 VANDERBILT UNIVERSITY 1 R21 NS109521‐01 $12,809 $9,356,232 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 K08 AI106420‐06 $98,422 $233,306 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 K23 AI120875‐04 $159,033 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI131722‐03 $55,081 $698,424 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R21 AI145397‐01 $28,113 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R21 AI146698‐01 $579 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 F32 AI143005‐01 $24,413 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $150,233 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $66,405 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $256,199 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $1,324,085 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $693,000 $748,580 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $334,351 $452,242 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $172,098 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $124,620 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $39,074 $543,233 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $853,008 $1,264,860 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $72,916 $198,559 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $72,563 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201300023I $369,239 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201400018C $10,039 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201700071C $134,151 $314,782 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201700071C $113,950 $120,591 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201700071C $543,286 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201700071C $115,023 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201700071C $518,128 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 K24 AI077930‐10 $40,213 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 K08 AI103038‐06 ‐$177 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 7 K23 AI106406‐05 $2,160 $118,530 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 K08 AI113107‐05 $152,887 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 K23 AI113150‐06 $164,680 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 K08 AI116949‐06 $210,703 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 K23 AI118804‐06 $179,293 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 K01 AI131895‐02 $108,425 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 K23 AI141621‐01 $77,107 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 P30 AI110527‐03 $965 $965 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 P30 AI110527‐04 $557,630 $1,347,601 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 P30 AI110527‐05 $307,349 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI039657‐22 $169,105 $562,128 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI044924‐19 $14,005 $371,771 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 2 R01 AI051448‐16 $313,366 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 6 R01 AI069233‐12 $307,591 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI073843‐11 $403,089 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI077505‐10 $413,849 $537,030 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 6 R01 AI093234‐06 ‐$4,396 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 2 R01 AI093234‐07 $36,403 $124,725 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI095755‐08 $14,695 $522,408 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI101171‐05 $258,606 $449,365 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


64




ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI107052‐06 $417,849 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 2 R01 AI108197‐06 $235,670 $546,602 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI111820‐06 $118,001 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI113292‐06 $449,085 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 6 R01 AI114339‐03 $269 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI114816‐05 $474,431 $602,964 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R56 AI118361‐01A1 $19,803 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 6 R01 AI118932‐02 $171,215 $692,078 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI120790‐03 $298,951 $504,982 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R21 AI121549‐02 $70,681 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R21 AI121796‐02 $82,395 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R21 AI123307‐02 $72,798 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R03 AI124190‐02 $29,605 $51,342 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI124456‐02 $46,216 $644,136 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R24 AI124872‐05 $51,516 $581,389 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI125642‐01A1 $168,214 $608,104 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R21 AI127129‐02 $48,570 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 7 R01 AI127205‐02 $61,241 $126,074 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI127828‐02 $314,897 $928,243 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R21 AI128281‐02 $132,123 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R21 AI129950‐02 $259,930 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI130459‐03 $558,660 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI131771‐01A1 $191,395 $468,043 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI132560‐03 $484,046 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI134036‐02 $168,207 $447,728 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI136526‐01A1 $95,510 $432,606 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R34 AI136815‐01 $96,685 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI138581‐01A1 $77,083 $148,706 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R21 AI139012‐01 $164,029 $230,933 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R21 AI139021‐02 $234,784 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI139172‐01A1 $62,806 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI142095‐01 $55,621 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI143710‐01 $72,239 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R21 AI144193‐01 $62,144 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI145265‐01 $155,665 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 T32 AI007474‐24 $16,784 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 T32 AI007474‐25 $264,341 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 T32 AI095202‐08 $19,745 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 T32 AI095202‐09 $270,208 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI069439‐13 $226,970 $689,815 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI069439‐14 $267,159 $1,354,889 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI069923‐13 $396,463 $399,363 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI069923‐14 $1,202,294 $1,901,903 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U19 AI095227‐08 ‐$17,301 $64,069 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U19 AI095227‐09 $295,851 $1,172,262 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI104336‐06 $296,871 $376,115 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U19 AI117905‐03 $325,814 $325,814 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U19 AI117905‐04 $1,632,029 $2,217,334 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U19 AI117905‐05 $65,335 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI125135‐02 $278,441 $421,393 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI125135‐03 $346,861 $1,225,441 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 U01 AI132004‐01 $30,415 $30,415 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI132004‐02 $124,131 $848,978 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSD20002013M53890B ABT ASSOCIATES HHSD20002013M53890B $7,448 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI096299‐09 AECOM 5 U01 AI096299‐09 $88,945 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI134648‐01 ALABAMA 1 R01 AI134648‐01 ‐$4,770 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI134648‐02 ALABAMA 1 R01 AI134648‐02 $227,741 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 U19 AI109680‐05 ALABAMA 1 U19 AI109680‐05 $298,952 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 U19 AI142759‐01 ALABAMA 1 U19 AI142759‐01 $112,707 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 R43 AI118087 AVATAR R43 AI118087 $263 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI109565‐05 BENAROYA RESEARCH 5 UM1 AI109565‐05 $112,613 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI134430‐01 BOSTON 1 R01 AI134430‐01 $3,790 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI134430‐02 BOSTON 5 R01 AI134430‐02 $57,579 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R41 AI141302‐01 BRB 1 R41 AI141302‐01 $78,703 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI123001‐02 BWH 5 R01 AI123001‐02 $887 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


65




ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068636‐12 BWH 5 UM1 AI068636‐12 $63,292 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068636‐12 BWH 5 UM1 AI068636‐12 $153,180 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068636‐12 BWH 5 UM1 AI068636‐12 $4,413 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI106701‐05 BWH 5 UM1 AI106701‐05 $163,135 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 P01 AI106695‐04 CALIFORNIA UC BERKELEY 5 P01 AI106695‐04 $288,261 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 7 UM1 AI068636‐13 CALIFORNIA UCLA 7 UM1 AI068636‐13 $8,095 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068636‐13 CALIFORNIA UCLA 5 UM1 AI068636‐13 $3,953 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068636‐13 CALIFORNIA UCLA 5 UM1 AI068636‐13 $53,207 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI106701‐06 CALIFORNIA UCLA 5 UM1 AI106701‐06 $78,359 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI117211‐04 CALIFORNIA 5 R01 AI117211‐04 $72,302 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 U54 AI117804‐01 CEGIR 1 U54 AI117804‐01 $6,519 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 U01 AI126612‐01A1 CHILDREN'S HOSP LA 1 U01 AI126612‐01A1 $1,220 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI104681‐06 DUKE 5 UM1 AI104681‐06 $27,982 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN27220150008C EMORY HHSN27220150008C $78,037 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068619‐12 FAMILY HEALTH INTERNATIONAL 5 UM1 AI068619‐12 ‐$206 ‐$206 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068619‐12 FAMILY HEALTH INTERNATIONAL 5 UM1 AI068619‐12 $41,976 $41,976 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068614‐12 FHCRC 5 UM1 AI068614‐12 $230,897 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068614‐13 FHCRC 5 UM1 AI068614‐13 $27,310 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068614‐13 FHCRC 5 UM1 AI068614‐13 $5,663 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 UM1 AI068614‐13 FHCRC 5 UM1 AI068614‐13 $11,900 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI089999‐08 HAWAII 5 R01 AI089999‐08 $8,444 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI069911‐12 INDIANA 5 U01 AI069911‐12 $7,118 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201400058C INTEGRAL HHSN272201400058C $1,115 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201400058C INTEGRAL HHSN272201400058C $47,742 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 2 R44 AI124766‐02A1 IQUITY 2 R44 AI124766‐02A1 $49,438 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 2 R44 AI129147‐02 IQUITY 2 R44 AI129147‐02 $30,870 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 U19 AI142764‐01 JACKSON 1 U19 AI142764‐01 $16,379 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI127469‐02 JOHNS HOPKINS 5 R01 AI127469‐02 $27,573 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI127469‐03 JOHNS HOPKINS 5 R01 AI127469‐03 $2,069 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 2 UM1 AI068632‐12 JOHNS HOPKINS 2 UM1 AI068632‐12 $3,410 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 2 UM1 AI068632‐13 JOHNS HOPKINS 2 UM1 AI068632‐13 $4,943 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI069918‐12 JOHNS HOPKINS 5 U01 AI069918‐12 $14 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U01 AI069918‐13 JOHNS HOPKINS 5 U01 AI069918‐13 $90,056 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 U19 AI142790‐01 LA JOLLA PHARMA 1 U19 AI142790‐01 $4,300 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN268201100026C MICHIGAN HHSN268201100026C $11,849 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI105129‐05 NEW YORK 5 R01 AI105129‐05 $4,915 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI132178‐02 NORTH CAROLINA 5 R01 AI132178‐02 $267,170 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R21 AI128418‐01A1 OHIO STATE 1 R21 AI128418‐01A1 $95,029 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 2 R01 AI085062‐07A1 PITTSBURGH 2 R01 AI085062‐07A1 $13,901 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI137523‐01 STANFORD 1 R01 AI137523‐01 $88,658 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R56 AI132682‐01A1 TEXAS 1 R56 AI132682‐01A1 $7,508 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R01 AI141661‐01 TEXAS 1 R01 AI141661‐01 $173,848 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 U19 AI109711‐05 TEXAS 5 U19 AI109711‐05 $160,475 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 U19 AI142785‐01 TEXAS 1 U19 AI142785‐01 $113,140 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI112295‐05 U OF EDUARDO 5 R01 AI112295‐05 $59,404 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 2 R01 AI044924‐09A1 VANDERBILT UNIVERSITY 2 R01 AI044924‐09A1 ‐$1,112 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 1 R21 AI121626‐01A1 VANDERBILT UNIVERSITY 1 R21 AI121626‐01A1 $1,427 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 T32 AI112541‐04 VANDERBILT UNIVERSITY 5 T32 AI112541‐04 $8,751 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 HHSN272201400018C WASHINGTON ST. LOUIS HHSN272201400018C $125,020 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 3 R01 AI073755‐08S1 WASHINGTON ST. LOUIS 3 R01 AI073755‐08S1 $181 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI073755‐11 WASHINGTON ST. LOUIS 5 R01 AI073755‐11 $120,585 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315ALLERGY, IMMUNOLOGY AND TRANSPLANTATION RESEARCH 93.855 5 R01 AI125363‐03 WASHINGTON ST. LOUIS 5 R01 AI125363‐03 $28,599 $40,812,746 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MICROBIOLOGY AND INFECTIOUS DISEASES RESEARCH 93.856 5 R01 AG046116‐05 KENTUCKY 5 R01 AG046116‐05 $11,815 $11,815 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM120523‐03 $348,613 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R01 GM132204‐01 $5,877 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 K23 GM110469‐04 $131,443 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 K08 GM117367‐05 $144,829 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 K23 GM117395‐05 $101,034 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 K08 GM123445‐02 $153,295 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 K23 GM129662‐01 $123,655 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 P50 GM115305‐04 $10,734 $43,546 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 P50 GM115305‐05 $43,459 $2,312,101 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM099924‐07 $76,843 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM103859‐04 $10,054 $284,268 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM109145‐05 $164,499 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


66




BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM112871‐05 $316,936 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM115353‐04 $5,887 $166,423 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM118300‐04 $222,572 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM118557‐03 $17,854 $20,380 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM120484‐03 $38,997 $568,480 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R01 GM121711‐01 $258,673 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM124109‐03 $329,963 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R35 GM124685‐02 $329,076 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R01 GM126062‐01A1 $26,261 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R01 GM126535‐01A1 $457,111 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R35 GM131770‐01 $19,797 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 2 T32 GM007569‐42 ‐$837 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 T32 GM007569‐43 $521,225 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 T32 GM108554‐05 $1,703 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 T32 GM108554‐06 $255,517 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM118361‐03 ALABAMA 5 R01 GM118361‐03 ‐$16,290 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM108025‐04 CCHMC 5 R01 GM108025‐04 ‐$7,730 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R35 GM126943‐01 CCHMC 1 R35 GM126943‐01 $27,495 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R35 GM126943‐02 CCHMC 5 R35 GM126943‐02 $1,362 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R01 GM129783‐01A1 CHILDREN'S MERCY 1 R01 GM129783‐01A1 $8,480 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM108807‐04 CHILDRENS PHILADELPHIA 5 R01 GM108807‐04 ‐$6,578 $76,345 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM114640‐04 CINCINNATI 5 R01 GM114640‐04 $61,921 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM117473‐02 DUKE 5 R01 GM117473‐02 $34,085 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM116184‐04 OHSU 5 R01 GM116184‐04 $23,048 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R01 GM105247‐01 PENNSYLVANIA 1 R01 GM105247‐01 ‐$192 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 P50 GM082251‐12 PITTSBURGH 5 P50 GM082251‐12 $324,917 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R01 GM119197‐01 TENNESSEE 1 R01 GM119197‐01 $341,741 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM118412‐02 VANDERBILT UNIVERSITY 5 R01 GM118412‐02 $54,914 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 2 R01 GM076592‐10 VANDERBILT UNIVERSITY 2 R01 GM076592‐10 $15,211 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM076592‐11 VANDERBILT UNIVERSITY 5 R01 GM076592‐11 $7,350 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 5 R01 GM117916‐03 VANDERBILT UNIVERSITY 5 R01 GM117916‐03 $7,215 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R01 GM118412‐01A1 VANDERBILT UNIVERSITY 1 R01 GM118412‐01A1 $5,328 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BIOMEDICAL RESEARCH AND RESEARCH TRAINING 93.859 1 R35 GM125028‐01 VANDERBILT UNIVERSITY 1 R35 GM125028‐01 $3,688 $8,352,171 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 U54 HD083211‐06 $97,059 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 2 K12 HD043483‐17 $31,682 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 K12 HD043483‐18 $398,410 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 K12 HD087023‐04 $144,827 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 K12 HD087023‐05 $236,973 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD059794‐11 $450,611 $579,377 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD074584‐06 $286,190 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD074711‐05 $250,007 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD076983‐06 $119,443 $396,364 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R21 HD080148‐03 $125,266 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD081121‐05 ‐$26,222 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD081121‐06 $127,059 $430,744 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD084461‐05 $513,168 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD084500‐05 $32,123 $262,695 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD086792‐04 $91,560 $500,305 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD088662‐02 $41,123 $296,645 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R21 HD088830‐02 $139,089 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD090061‐03 $127,145 $494,611 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD093671‐02 $131,302 $471,666 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 1 R01 HD094946‐01 $190,311 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 1 R01 HD097344‐01 $86,504 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 T32 HD060554‐08 $2,762 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 T32 HD060554‐09 $375,955 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 T32 HD060554‐10 $7,320 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 U01 HD076733‐04 $8,729 $8,729 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 U01 HD076733‐05 $124,514 $327,258 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 U54 HD083211‐05 $406,723 $1,324,649 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 U54 HD083211‐04 $113,872 $113,872 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 U54 HD061222‐13 ALABAMA 5 U54 HD061222‐13 $29,135 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 U54 HD061222‐14 ALABAMA 5 U54 HD061222‐14 $76,055 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


67




CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 U54 HS061222‐13 ALABAMA 5 U54 HS061222‐13 $6,025 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD083181‐02 BAYLOR COLLEGE 5 R01 HD083181‐02 $218,650 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 2 R01 HD024356‐24 CALIFORNIA DAVIS 2 R01 HD024356‐24 $76,369 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 2 R01 HD024356‐25 CALIFORNIA DAVIS 2 R01 HD024356‐25 $5,464 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 1 R01 HD093661‐01A1 CASE WESTERN RESERVE 1 R01 HD093661‐01A1 $21,094 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 HHSN27520120000031 DUKE HHSN27520120000031 $6,061 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD081044‐02 DUKE 5 R01 HD081044‐02 $666 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 U01 HD073984‐06 DUKE 5 U01 HD073984‐06 $6,123 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 7 R01 HD082127‐05 KANSAS 7 R01 HD082127‐05 $400 $139,735 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD067126‐05 MARYLAND 5 R01 HD067126‐05 $7,664 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 2 R01 HD067126‐07 MARYLAND 2 R01 HD067126‐07 $13,027 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD081120‐04 NATIONWIDE 5 R01 HD081120‐04 $21,925 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD081120‐05 NATIONWIDE 5 R01 HD081120‐05 $4,316 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD082187‐04 NORTH CAROLINA 5 R01 HD082187‐04 ‐$400 ‐$400 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD082187‐04 NORTH CAROLINA 5 R01 HD082187‐04 ‐$7,850 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD82127‐02 NORTH CAROLINA 5 R01 HD82127‐02 ‐$4,237 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 1 R01 HD096332‐01 NORTHSHORE 1 R01 HD096332‐01 $15,461 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 1 R43 HD095351‐01 PRAGMADX 1 R43 HD095351‐01 $10,245 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 1 R43 HD093501‐01 RXREVU 1 R43 HD093501‐01 $34,995 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD084679‐03 STANFORD 5 R01 HD084679‐03 $3 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD084679‐04 STANFORD 5 R01 HD084679‐04 $9,984 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD079625‐04 TEXAS 5 R01 HD079625‐04 $15,566 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 1 R01 HD093665‐01 TULANE 1 R01 HD093665‐01 $15,369 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD044073‐13 VANDERBILT UNIVERSITY 5 R01 HD044073‐13 $2,533 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD053714‐09 VANDERBILT UNIVERSITY 5 R01 HD053714‐09 $2,085 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD089474‐02 VANDERBILT UNIVERSITY 5 R01 HD089474‐02 $184 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 5 R01 HD084606‐03 WAKE FOREST 5 R01 HD084606‐03 $25,561 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CHILD HEALTH AND HUMAN DEVELOPMENT EXTRAMURAL RESEARCH 93.865 1 R01 HD095628‐01 WASHINGTON ST. LOUIS 1 R01 HD095628‐01 $70,377 $8,888,401 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

AGING RESEARCH 93.866 5 R01 AG047992‐06 $18,366 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG061518‐01 $68,633 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 F32 AG058395‐01 $23,623 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 F32 AG058395‐02 $28,873 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 HHSN271201700397P $7,433 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 HHSN271201800393P $17,102 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 K23 AG045966‐05 $157,631 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 K24 AG046373‐06 $86,962 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 2 K24 AG046373‐07 $87,158 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


68




AGING RESEARCH 93.866 5 K01 AG049164‐04 $110,921 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 K76 AG054864‐03 $208,880 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 K01 AG058700‐02 $108,205 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 6 R01 AG034962‐07 $323,407 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 6 R01 AG035117‐06 ‐$352 $350,957 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R21 AG059941‐01 $162,899 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R03 AG060085‐01 $62,395 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 7 R01 AG041177‐06 ‐$788 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R01 AG043471‐06 $137,917 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R01 AG047992‐04 $239,704 $239,704 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R01 AG047992‐05 $1,687,546 $1,876,277 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R01 AG048915‐02 $419,630 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 7 R21 AG049332‐02 $26,605 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R01 AG053264‐05 $63,761 $815,066 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R01 AG056534‐03 $4,282 $622,991 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG058639‐01A1 $46,470 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R01 AG058856‐02 $415,580 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG059716‐01 $146,681 $349,762 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG061351‐01 $36,596 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

AGING RESEARCH 93.866 9 R44 AG059371‐02 AVATAR 9 R44 AG059371‐02 $48,406 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 P01 AG027296‐09 BROWN 5 P01 AG027296‐09 $8,423 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 RO1 AG54366‐01A1 BWH 1 RO1 AG54366‐01A1 $4 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG056368‐01A1 BWH 1 R01 AG056368‐01A1 $16,301 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG062563‐01 CALIFORNIA UCSF 1 R01 AG062563‐01 $7,649 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 6 R01 AG047992‐02 CALIFORNIA 6 R01 AG047992‐02 $157,185 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 2 U19 AG024904‐11 CALIFORNIA 2 U19 AG024904‐11 $91,723 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R24 AG054259‐02 HARVARD 1 R24 AG054259‐02 $12,169 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R24 AG052459‐03 HARVARD 5 R24 AG052459‐03 $15,993 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 RF1 AG059869‐01 JOHNS HOPKINS 1 RF1 AG059869‐01 $2,309 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R01 AG037120‐05 MARYLAND 5 R01 AG037120‐05 $19,130 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 2 R01 AG041794‐04 NBER ECONOMIC 2 R01 AG041794‐04 $80,853 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG059861‐01 OHIO STATE 1 R01 AG059861‐01 $37,393 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG050716‐01A1 UNIVERSITY OF VERMONT 1 R01 AG050716‐01A1 $14,462 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG055606‐01 UTAH 1 R01 AG055606‐01 $7,855 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R01 AG043458‐03 VANDERBILT UNIVERSITY 1 R01 AG043458‐03 $51,519 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R01 AG054622‐02 VANDERBILT UNIVERSITY 5 R01 AG054622‐02 $6,791 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 R44 AG055184‐02 VANDERBILT UNIVERSITY 5 R44 AG055184‐02 $174,672 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 T32 AG058524‐01 VANDERBILT UNIVERSITY 1 T32 AG058524‐01 $1,230 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 T32 AG058524‐01 VANDERBILT UNIVERSITY 1 T32 AG058524‐01 $46,499 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 3 T32 AG058524‐01S1 VANDERBILT UNIVERSITY 3 T32 AG058524‐01S1 $1,159 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 3 T32 AG058524‐01S1 VANDERBILT UNIVERSITY 3 T32 AG058524‐01S1 $48,075 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 5 T32 AG058524‐02 VANDERBILT UNIVERSITY 5 T32 AG058524‐02 $512 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 1 R44 AG058268‐01A1 XYKEN 1 R44 AG058268‐01A1 $5,651 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315AGING RESEARCH 93.866 4 R44 AG058268‐02 XYKEN 4 R44 AG058268‐02 $865 $7,666,083 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

VISION RESEARCH 93.867 5 K08 EY027464‐02 $178,273 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 1 K08 EY029006‐01 $174,106 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 P30 EY008126‐30 $83,796 $84,024 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 P30 EY008126‐31 $370,264 $719,198 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY007533‐30 $494,820 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY013760‐13 $203,412 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY017427‐10 $295,624 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 2 R01 EY020496‐06A1 $399,923 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY020894‐09 $472,594 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY022349‐09 $16,947 $276,373 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY022618‐06 $156,211 $327,509 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY023240‐05 $44,729 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY023397‐06 $331 $236,910 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 2 R01 EY023397‐07 $13,753 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY023639‐05 $52,624 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 7 R01 EY024063‐04 $419,959 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY024373‐05 $288,624 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY024997‐06 $387,122 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY027746‐03 $21,612 $423,097 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 1 R01 EY028133‐01A1 $28,421 $168,969 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 1 R01 EY029693‐01 $56,686 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


69




VISION RESEARCH 93.867 5 U01 EY027265‐02 $84,645 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 U01 EY027265‐03 $378,042 $624,873 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 1 U24 EY029893‐01 $159,101 $315,765 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

VISION RESEARCH 93.867 1 R21 EY028671‐01 AUGUSTA 1 R21 EY028671‐01 $2,700 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R21 EY028671‐02 AUGUSTA 5 R21 EY028671‐02 $2,168 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 4 R01 EY021137‐05 CHILDRENS PHILADELPHIA 4 R01 EY021137‐05 $46 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 UG1 EY025553‐03 EMORY 5 UG1 EY025553‐03 $9,295 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 UG1 EY025553‐04 EMORY 5 UG1 EY025553‐04 $7,708 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 U10 EY011751‐03 JCHR 5 U10 EY011751‐03 $18,244 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 U01 EY011751‐20 JCHR 5 U01 EY011751‐20 $16,879 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 U10 EY011751‐22 JCHR 5 U10 EY011751‐22 $80,999 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 U10 EY011751‐22 JCHR 5 U10 EY011751‐22 $15,852 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 U10 EY024527‐04 JOHNS HOPKINS 5 U10 EY024527‐04 $6,467 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 U10 EY025990‐02 MSSM 5 U10 EY025990‐02 $3,696 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 1 U10 EY026869‐01 NEW YORK 1 U10 EY026869‐01 $2,084 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 U01 EY023533‐05 PENNSYLVANIA 5 U01 EY023533‐05 $5,762 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 1 U24 EY029903‐01 STANFORD 1 U24 EY029903‐01 $123,661 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 1 R21 EY026176‐01 VANDERBILT UNIVERSITY 1 R21 EY026176‐01 ‐$6,544 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 R01 EY027729‐02 VANDERBILT UNIVERSITY 5 R01 EY027729‐02 $130,650 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 T32 EY007135‐24 VANDERBILT UNIVERSITY 5 T32 EY007135‐24 $46,091 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 T32 EY021453‐08 VANDERBILT UNIVERSITY 5 T32 EY021453‐08 $50,479 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315VISION RESEARCH 93.867 5 T32 EY021453‐08 VANDERBILT UNIVERSITY 5 T32 EY021453‐08 $10,726 $7,270,575 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

MEDICAL LIBRARY ASSISTANCE 93.879 7 R01 LM012178‐04 $77,052 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 7 R21 LM012448‐03 $8,174 $61,173 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 5 R01 LM10207‐09 $147,023 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 5 R01 LM10685‐08 $52,173 $122,158 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 2 R01 LM10685‐09 $415,502 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 5 R00 LM11933‐04 $186,551 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

MEDICAL LIBRARY ASSISTANCE 93.879 5 R01 LM012806‐02 TEXAS HEALTH SCIENCE HOUSTON 5 R01 LM012806‐02 $50,474 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 1 R01 LM012806‐01 TEXAS HEALTH SCIENCE HOUSTON 1 R01 LM012806‐01 $15,581 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 5 T15 LM007450‐17 VANDERBILT UNIVERSITY 5 T15 LM007450‐17 $51,627 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 3 T15 LM007450‐17S2 VANDERBILT UNIVERSITY 3 T15 LM007450‐17S2 $12,903 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 5 T32 LM012412‐02 VANDERBILT UNIVERSITY 5 T32 LM012412‐02 $19,790 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MEDICAL LIBRARY ASSISTANCE 93.879 5 T32 LM012412‐03 VANDERBILT UNIVERSITY 5 T32 LM012412‐03 $2,661 $1,162,495 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315CANCER PREVENTION AND CONTROL PROGRAMS FOR STATE, TERRITORIAL AND TRIBAL ORGANIZATIONS 93.898 59823:ST TN TN HEALTH 59823:ST TN $90,082 $90,082 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315HIV EMERGENCY RELIEF PROJECT GRANTS 93.914 354532:METRO NASHVILLE 354532:METRO $545,500 $629,740 OTHER AWARDS $40,431,607HIV EMERGENCY RELIEF PROJECT GRANTS 93.914 379959:METRO NASHVILLE 379959:METRO $84,240 $629,740 OTHER AWARDS $40,431,607HIV CARE FORMULA GRANTS 93.917 34349‐48619:ST TN TN HEALTH 34349‐48619:ST TN $239,006 $1,008,366 OTHER AWARDS $40,431,607HIV CARE FORMULA GRANTS 93.917 58112:ST TN TN HEALTH 58112:ST TN $769,360 $1,008,366 OTHER AWARDS $40,431,607

GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE 93.918 5 H76 HA30761‐04‐00 $108,366 $677,891 OTHER AWARDS $40,431,607GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE 93.918 6 H76 HA30761‐02 $6,294 $677,891 OTHER AWARDS $40,431,607GRANTS TO PROVIDE OUTPATIENT EARLY INTERVENTION SERVICES WITH RESPECT TO HIV DISEASE 93.918 6 H76 HA30761‐03 $563,231 $677,891 OTHER AWARDS $40,431,607

HIV PREVENTION ACTIVITIES_NON‐GOVERNMENTAL ORGANIZATION BASED 93.939 1 R01 CA225005‐01A1 $114,523 $400,218 $400,218 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315BLOCK GRANTS FOR COMMUNITY MENTAL HEALTH SERVICES 93.958 60895:ST TN TN MENTAL HEALTH 60895:ST TN $8,500 $65,902 $65,902 OTHER AWARDS $40,431,607

INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 2 D43 TW09337‐07 $194,108 $203,803 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 D43 TW09337‐08 $680,628 $1,107,274 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 D43 TW09744‐04 $14,148 $15,475 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 D43 TW09744‐05 $213,016 $367,043 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 D43 TW09745‐04 ‐$3,276 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 D43 TW09745‐05 $34,374 $277,987 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 R25 TW09337‐06 $1,283 $1,815 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 R25 TW09722‐06 $59,986 $173,867 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 R21 TW10899‐02 $30,137 $168,164 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 D43 TW009337‐09 $17,531 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 D43 TW009744‐06 $13,610 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 D43 TW009745‐06 $1,302 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 5 D43 TW010559‐02 CAPE TOWN 5 D43 TW010559‐02 $28,386 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 1 R21 TW010620‐01 PURDUE 1 R21 TW010620‐01 $14,934 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 3 R21 TW010620‐02S1 PURDUE 3 R21 TW010620‐02S1 $59,146 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 1 R21 TW010471‐01 UNIVERSITY OF ZAMBIA 1 R21 TW010471‐01 ‐$609 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315


70




INTERNATIONAL RESEARCH AND RESEARCH TRAINING 93.989 1 R21 TW010635‐01 VANDERBILT UNIVERSITY 1 R21 TW010635‐01 $10,372 $2,456,824 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES 93.994 54083:ST TN TN HEALTH 54083:ST TN $236,998 $272,389 OTHER AWARDS $40,431,607MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES 93.994 49293:ST TN

TN MENTAL HEALTH DEVELOPMENTAL 49293:ST TN ‐$3,180 $272,389 OTHER AWARDS $40,431,607

MATERNAL AND CHILD HEALTH SERVICES BLOCK GRANT TO THE STATES 93.994 57826:ST TN


AUTISM AND OTHER DEVELOPMENTAL DISABILITIES, SURVEILLANCE, RESEARCH, AND PREVENTION 93.998 1 NU53 DD000010‐01‐00 $142,412 $142,412 OTHER AWARDS $40,431,607TOTAL DEPARTMENT OF HEALTH AND HUMAN SERVICES $60,879,911 $362,194,139

SOCIAL SECURITY ADMINISTRATIONSOCIAL SECURITY_RESEARCH AND DEMONSTRATION 96.007 5 RRC08098401‐10‐00 MICHIGAN 5 RRC08098401‐10‐00 $10,000 $10,000 RESEARCH AND DEVELOPMENT CLUSTER $337,364,315

TOTAL SOCIAL SECURITY ADMINISTRATION $10,000

U.S. AGENCY FOR INTERNATIONAL DEVELOPMENTUSAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS 98.001 7200AA18CA00019 $3,813 $201,754 $885,296 OTHER AWARDS $40,431,607

USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS 98.001 AID‐OAA‐A‐14‐00029 AINPC AID‐OAA‐A‐14‐00029 $8,870 $885,296 OTHER AWARDS $40,431,607USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS 98.001 720‐656‐18‐C‐00001 CHEMONICS 720‐656‐18‐C‐00001 $560,332 $885,296 OTHER AWARDS $40,431,607USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS 98.001 AID‐OAA‐A‐11‐00012 NAS AID‐OAA‐A‐11‐00012 $436 $885,296 OTHER AWARDS $40,431,607USAID FOREIGN ASSISTANCE FOR PROGRAMS OVERSEAS 98.001 AID‐OAA‐A‐11‐00012 VANDERBILT UNIVERSITY AID‐OAA‐A‐11‐00012 $113,904 $885,296 OTHER AWARDS $40,431,607

TOTAL U.S. AGENCY FOR INTERNATIONAL DEVELOPMENT $3,813 $885,296

TOTAL EXPENDITURE OF FEDERAL AWARDS $66,621,864 $386,487,327

Please Note:Italicized award lines indicate pass‐through funding

The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.


71



TOTAL EXPENDITURE OF FEDERAL AWARDS 66,621,864 386,487,327STATE FINANCIAL ASSISTANCE

42139:COMPREHENSIVE CARE CLINIC FOR STATE APPROVED CLIENTS 42139:ST TN $94,74849293:CHILDREN AND YOUTH WITH SPECIAL HEALTH CARE NEEDS‐FED 49293:ST TN ‐$4,88053384:COMMUNITY FORENSIC ‐ JUV CT EVALUATIONS 53384:ST TN CFJCE $270,02953384:DOC (BOP) RISK ASSESSMENTS 53384:ST TN BOP $69,50854083:GENETIC SCREENING TESTING COUNSELING‐FED FUNDS 54083:ST TN ‐$554083:GENETIC SCREENING, TESTING, COUNSELING‐FED FUNDS 54083:ST TN $751,90054854:MITIGATING ACES IN PEDIATRIC PRIMARY CARE 54854:ST TN $4,038 $20,72454955:COMMUNITY SUPPORTS THROUGH INFORMATION AND REFERRAL 54955:ST TN ‐$56456787:CPS ASSESSMENT TRACK TRAINING ACADEMY 56787:ST TN $293,81557826:CHILDREN AND YOUTH WITH SPECIAL HEALTH CARE CYSHCN 57826:ST TN $29,04158710:TENNESSEE INTEGRATED COURT SCREENING AND REFERRAL PROJ 58710:ST TN $57,33058794:HEALTHIER FAMILIES FOR A HEALTHIER TN: PREVENTING COM 58794:ST TN $98,01158795:MITIGATING ACES IN PEDIATRIC PRIMARY CARE AND A HOME V 58795:ST TN $4,285 $91,41059045:COMMUNITY SUPPORTS THROUGH INFORMATION AND REFER 59045:ST TN $74,83759263:CLOVER BOTTOM NEUROLOGY SPASTICITY CLINICS 59263:ST TN $11,57259366:POISON CONTROL SERVICES 59366:ST TN $374,67461290:NETWORK OF OPIOID USE DISORDERS (OUD) STUDIES 61290:ST TN $731INTERNAL CAR SEAT PROGRAM STATE OF TENNESSEE $7,043

TOTAL STATE FINANCIAL ASSISTANCE $8,323 $2,239,924

TOTAL EXPENDITURE OF FEDERAL AWARDS AND STATE FINANCIAL ASSISTANCE $66,630,187 $388,727,251

Please Note:The accompanying Notes to the Schedule of Expenditures of Federal Awards are an integral part of the schedule.



72

Vanderbilt University Medical Center Notes to the Schedule of Expenditures of Federal Awards and State Financial Assistance For the Year Ended June 30, 2019

73

1. Basis of Presentation

The accompanying Schedule of Expenditures of Federal Awards and State Financial Assistance (the "Schedule") includes the activity of Vanderbilt University Medical Center ("VUMC") under programs of the federal government and of the State of Tennessee for the year ended June 30, 2019. The information in the Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards ("Uniform Guidance") and State of Tennessee Audit Manual.

For purposes of the Schedule, federal and state awards include all grants, contracts and similar agreements entered into directly between VUMC and agencies and departments of the federal government and all sub-awards to VUMC by organizations pursuant to federal grants, contracts and similar agreements, and agencies and departments of the Tennessee state government, including federal awards passed through by the State of Tennessee.

2. Summary of Significant Accounting Policies for the Schedule

For purposes of the Schedule, expenditures for federal and state programs are recognized on the accrual basis, which is consistent with generally accepted accounting principles.

Expenditures for federal and state awards of VUMC are determined using the cost accounting principles and procedures set forth in the Uniform Guidance and State of Tennessee Audit Manual. Under these cost principles, certain expenditures are not allowable or are limited as to reimbursement.

Negative amounts represent adjustments or credits made in the normal course of business to amounts reported as expenditures in prior years.

3. Facilities and Administrative Costs

VUMC has elected not to use the 10% de minimis indirect cost rate allowed under the Uniform Guidance.

Expenditures for certain federal and state awards of VUMC include facilities and administrative costs (indirect costs). Facilities and administrative costs allocated to such awards were based on predetermined fixed rates negotiated with VUMC's cognizant federal agency, the U.S. Department of Health and Human Services.


74


Tel: +1 615 252 2000 ey.com

Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in

Accordance with Government Auditing Standards

Senior Management and the Board of Directors Vanderbilt University Medical Center

We have audited, in accordance with auditing standards generally accepted in the United States and the standards applicable to financial audits contained in Government Auditing Standards, issued by the Comptroller General of the United States, the financial statements of Vanderbilt University Medical Center, which comprise the consolidated balance sheet as of June 30, 2019, and the related consolidated statements of operations and changes in net assets, and cash flows for the year then ended and the related notes to the consolidated financial statements, and have issued our report thereon dated November 12, 2019.

Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered Vanderbilt University Medical Center’s internal control over financial reporting “internal control” to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of Vanderbilt University Medical Center’s internal control. Accordingly, we do not express an opinion on the effectiveness of Vanderbilt University Medical Center’s internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity’s financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit, we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.


75

Compliance and Other Matters

As part of obtaining reasonable assurance about whether Vanderbilt University Medical Center’s consolidated financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under Government Auditing Standards.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the result of that testing, and not to provide an opinion on the effectiveness of the entity’s internal control or on compliance. This report is an integral part of an audit performed in accordance with Government Auditing Standards in considering the entity’s internal control and compliance. Accordingly, this communication is not suitable for any other purpose.



76


Tel: +1 615 252 2000 ey.com

Report of Independent Auditors on Compliance for Each Major Federal Program and Report on Internal Control Over

Compliance Required by the Uniform Guidance

Senior Management and the Board of Directors Vanderbilt University Medical Center

Report on Compliance for Each Major Federal Program

We have audited Vanderbilt University Medical Center’s compliance with the types of compliance requirements described in the U.S. Office of Management and Budget (OMB) Compliance Supplement that could have a direct and material effect on each of Vanderbilt University Medical Center’s major federal programs for the year ended June 30, 2019. Vanderbilt University Medical Center’s major federal programs are identified in the summary of auditor’s results section of the accompanying schedule of findings and questioned costs.

Management’s Responsibility

Management is responsible for compliance with the requirements of federal statutes, regulations and the terms and conditions of its federal awards applicable to its federal programs.

Auditor’s Responsibility

Our responsibility is to express an opinion on compliance for each of Vanderbilt University Medical Center’s major federal programs based on our audit of the types of compliance requirements referred to above. We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States; the standards applicable to financial audits contained in Government Auditing Standards issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance). Those standards and the Uniform Guidance require that we plan and perform the audit to obtain reasonable assurance about whether noncompliance with the types of compliance requirements referred to above that could have a direct and material effect on a major federal program occurred. An audit includes examining, on a test basis, evidence about Vanderbilt University Medical Center’s compliance with those requirements and performing such other procedures as we considered necessary in the circumstances.

We believe that our audit provides a reasonable basis for our opinion on compliance for each major federal program. However, our audit does not provide a legal determination of Vanderbilt University Medical Center’s compliance.


77

Opinion on Each Major Federal Program

In our opinion, Vanderbilt University Medical Center complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2019.

Other Matters

The results of our auditing procedures disclosed an instance of noncompliance which is required to be reported in accordance with the Uniform Guidance, and which is described in the accompanying schedule of findings and questioned costs as item 2019-001 related to the Research and Development Cluster over Procurement and Suspension and Debarment. Our opinion on each major federal program is not modified with respect to this matter.

Vanderbilt University Medical Center’s response to the noncompliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. Vanderbilt University Medical Center’s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

Report on Internal Control Over Compliance

Management of Vanderbilt University Medical Center is responsible for establishing and maintaining effective internal control over compliance with the types of compliance requirements referred to above. In planning and performing our audit of compliance, we considered Vanderbilt University Medical Center’s internal control over compliance with the types of requirements that could have a direct and material effect on each major federal program to determine the auditing procedures that are appropriate in the circumstances for the purpose of expressing an opinion on compliance for each major federal program and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, we do not express an opinion on the effectiveness of Vanderbilt University Medical Center’s internal control over compliance.

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance yet important enough to merit attention by those charged with governance.


78

Our consideration of internal control over compliance was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies and therefore, material weaknesses or significant deficiencies may exist that have not been identified. We did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses. However, we did identify a certain deficiency in internal control over compliance, as described in the accompanying schedule of findings and questioned costs as item 2019-001 related to the Research and Development Cluster and the Special Education Cluster (IDEA) over Procurement and Suspension and Debarment, that we consider to be a significant deficiency.

Vanderbilt University Medical Center’s response to the internal control over compliance finding identified in our audit is described in the accompanying schedule of findings and questioned costs. Vanderbilt University Medical Center’s response was not subjected to the auditing procedures applied in the audit of compliance and, accordingly, we express no opinion on the response.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.


Vanderbilt University Medical Center Schedule of Findings and Questioned Costs For the Year Ended June 30, 2019

79

Section I—Summary of Auditor’s Results

Financial Statements Type of report the auditor issued on whether the financial statements audited were prepared in accordance with GAAP: Unmodified Internal control over financial reporting:

Material weakness(es) identified? yes X no

Significant deficiency(ies) identified? yes X none reported

Noncompliance material to financial statements noted? yes X no

Federal Awards

Internal control over major federal programs:

Material weakness(es) identified? yes X no

Significant deficiency(ies) identified? X yes none reported

Type of auditor’s report issued on compliance for major federal programs: Unmodified Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)? X yes no

Identification of major federal programs:

CFDA number(s) Name of federal program or cluster Various Research and Development Cluster 84.027/84.173 Special Education Cluster (IDEA) Dollar threshold used to distinguish between Type A and Type B programs:

$3,000,000

Auditee qualified as low-risk auditee? X yes no


80

Section II—Financial Statement Findings

None noted.

Vanderbilt University Medical CenterSchedule of Findings and Questioned CostsFor the Year Ended June 30, 2019

81

Section III—Federal Award Findings and Questioned Costs

2019–001 SUSPENSION AND DEBARMENT

Federal Program Information: Federal Agency and Program Name CFDA #Research and Development ClusterSpecial Education Cluster (IDEA)

Various84.027/84.173

Criteria: 2 CFR 200.303 requires that a non-federal entity must “(a) establish and maintaineffective internal control over the Federal award that provides reasonableassurance that the non-Federal entity is managing the Federal award incompliance with Federal statutes, regulations, and the terms and conditions of theFederal award. These internal controls should be in compliance with guidance in“Standards for Internal Control in the Federal Government” issued by theComptroller General of the United States and the “Internal Control IntegratedFramework”, issued by the Committee of Sponsoring Organizations of theTreadway Commission (COSO).

2 CFR 200.213 states that “Non-federal entities are subject to the non-procurementdebarment and suspension regulations implementing Executive Orders 12549 and12689, 2 CFR part 180. These regulations restrict awards, subawards, andcontracts with certain parties that are debarred, suspended, or otherwise excludedfrom or ineligible for participation in Federal assistance programs or activities.”

Condition: During our testing of 37 transactions for suspension and debarment of theResearch and Development Cluster, we noted that for one transaction, for $41, ofthe 37 transactions tested for $2,061,516, there was a lack of supportingdocumentation demonstrating that management was monitoring the contractors toensure they were not suspended or debarred when the purchase was made; thiswas determined to be a systemic issue.

Further, management has internal controls to assess potential suspension anddebarment matches it receives from its a third-party servicer who performssuspension and debarment searches for them. However, the internal controls arenot precise enough to ensure a resolution has been completed for each matchidentified.

Questioned Costs: N/A

Context: Total federal expenditures for Research and Development Cluster were$337,364,315 of which approximately $25.1 million were expenditures subject tosuspension and debarment requirements for the year ended June 30, 2019. Totalfederal expenditures for IDEA Cluster were $3,090,600 of which approximately$0.2 million were subject to suspension and debarment requirements for the yearended June 30, 2019. Management performed an assessment of 100% of thecontractors and identified 65 contractors that were not monitored for suspensionand debarment at the time of purchase for the year ended June 30, 2019.

Cause: Vanderbilt University Medical Center does not have adequately designed internalcontrols and policies and procedures in place to ensure that contractors are beingproperly monitored for suspension and debarment.


82

2019–001 SUSPENSION AND DEBARMENT (continued)

Effect: Vanderbilt University Medical Center is not in compliance with federal statutes, regulations, and the terms of the conditions of the federal award. Federal monies may be expended to contractors who are suspended or debarred.

Recommendation: We recommend that Vanderbilt University Medical Center implement adequate internal controls and policies and procedures to ensure that all contractors are not suspended or debarred. In addition, adequate internal controls should be put in place to document the resolution of all suspension and debarment matches identified.

Views of Responsible Officials:

Management concurs with the finding and has developed a plan to correct the finding.

EY | Assurance | Tax | Transactions | Advisory

About EYEY is a global leader in assurance, tax, transaction and advisory services. The insights and quality services we deliver help build trust and confidence in the capital markets and in economies the world over. We develop outstanding leaders who team to deliver on our promises to all of our stakeholders. In so doing, we play a critical role in building a better working world for our people, for our clients and for our communities.

EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients. Information about how EY collects and uses personal data and a description of the rights individuals have under data protection legislation is available via ey.com/privacy. For more information about our organization, please visit ey.com.

© 2019 Ernst & Young LLP. All Rights Reserved.

ey.com

VANDERBILT U N I V E R S I TY MEDICAL C E N T E R

VUMC Finance

CORRECTIVE ACTION PLAN for the Year Ended June 30, 2019

2019-001

The Vanderbilt University Medical Center (VUMC) has controls to monitor vendors to ensure that contractors are not suspended or debarred. However, VUMC determined that certain vendors were not included in the file sent to the third party engaged to monitor for suspension or debarment. We identified these vendors and determined that none of the vendors were suspended or debarred at any time during fiscal year 20 19.

We will reassess the reconciliation performed between the debarment file submitted to our vendors and the accounts payable subledger to ensure that we do not omit any vendors in the future. The Controller's office will obtain a quarterly reconciliation from the sourcing department to provide a secondary level of review.

VUMC will also improve the documentation to evidence the resolution of suspended or debarred vendors.

The Controller's office will be responsible for implementation of the planned corrective action by fiscal year end 2020.

3319 West End Avenue Suite 700 Nashville, TN 37203-6840

tel 615.322.2381 fax 615.343.4052 finance.mc.vanderbilt.edu

VANDERBILT U N I V E R S I TY MEDICAL CENTER

VUMC Finance

Summary Schedule of Prior Audit Findings

Federal Award Findings and Questioned Costs - Fourteen Months Ended June 30, 2017

Finding 2017-01 - Fixed Asset identification

Finding: Four (4) of the forty (40) assets that the auditor selected to be observed were not properly tagged in accordance with VUMC's internal controls over the Equipment and Real Property Management Compliance Requirement.

Current Year Status: During the prior year, Management agreed that there were limited instances of missing fixed asset tags on equipment acquired under a Federal award. Management acknowledged that missing tags may lead to instances of noncompliance in the nature of use, condition, safeguarding, or disposition of assets acquired under Federal awards, as those assets may not be identifiable as being acquired with Federal funding.

To strengthen this control, during Fiscal 2018, VUMC conducted a physical inventory of materially all fixed assets acquired under a Federal award, replacing any identified missing fixed asset tags. In addition, VUMC documented communication protocols between fixed asset physical inventory dates to ensure that, in the future, any missing or destroyed tags are replaced.

Financial Statement Findings - Year Ended June 30, 2017

None identified.

3319 West End Avenue Suite 700 Nashville, TN 37203-6840

tel 615.322.2381 fax 615.343.4052 finance.mc.vanderbilt.edL1

vanderbilt university medical center years ended june 30

Documents